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A NETWORK VIEW ON NEURODEGENERATIVE DISORDERS
By Sreedevi Chandrasekaran, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Advisor: Danail G. Bonchev, Ph.D., D. Sc.
Professor, School of Life Sciences
Neurodegeneration is a chronic, progressive and debilitating condition that af-
fects majority of the World’s elderly population who are at greater risk. Numerous
scientific studies suggest that there could be a common underlying molecular mech-
anism that promotes the degeneration and the subsequent neuronal loss, however
so far the progress in this direction is rather limited. Abnormal protein misfoldings,
as well as protein plaque formations in the brain, are some of the hallmark charac-
teristic features of neurodegenerative disorders (NDDs). Genetic and environmental
factors, oxidative stress, excessive reactive oxygen species formation, mitochondrial
dysfunction, energy depletion and autophagy disruption etc. are some of the widely
suspected mechanisms that manifest the cognitive, motor and emotional symptoms
ABSTRACT xvi
of these NDDs. Motivated by some molecular traits found in common in several
NDDs, network-based systems biology tools and techniques were used in this study
to identify critical molecular players and underlying biological processes that are
common for Parkinson’s, Alzheimer’s and Huntington’s disease. Utilizing multiple
microarray gene expression datasets, several biomolecular networks such as direct
interaction, shortest path, and microRNA regulatory networks were constructed and
analyzed for each of the disease conditions. The network-based analysis revealed
26 genes of potential interest in Parkinson’s, 16 in Alzheimer’s and 30 in Hunt-
ington’s disease. Many new microRNA-target regulatory interactions were identi-
fied. For each disorder, several routes for possible disease initiation and protec-
tion scenarios were uncovered. A unified neurodegeneration mechanism network
was constructed by utilizing the significantly differentially expressed genes found in
common in Parkinson’s, Alzheimer’s and Huntington’s microarray datasets. In this
integrated network many key molecular partakers and several biological processes
that were significantly affected in all three NDDs were uncovered. The integrated
network also revealed complex dual-level interactions that occur between disease
contributing and protecting entities. Possibilities of microRNA-target interactions
were explored and many such pairs of potential interest in NDDs were suggested.
Investigating the integrated network mechanism, we have identified several routes
for disease initiating, as well as alleviating ones that could be utilized in common
for Parkinson’s, Alzheimer’s and Huntington’s disease. Finding such crucial and uni-
versal molecular players in addition to maintaining a delicate balance between neu-
rodegeneration promoters and protectors is vital for restoring the homeostasis in
the three NDDs.
Chapter 1
Introduction
Neurodegeneration is a collection of neurological diseases or medical conditions that
occur when nerve cells die or lose their capacity to function normally. Diseases like
Alzheimer’s, Parkinson’s, Huntington’s, Amyotrophic lateral sclerosis etc., exhibit
loss of neurons that affects multiple facets of basic daily living functions including
memory loss, cognitive decline, mood disorders, difficulty in swallowing, walking
and speech. Currently there are medications and surgical treatments available to
mitigate the symptoms but very little intervention is provided towards halting the
disease progression. Neurodegeneration is a chronic, progressive and debilitating
condition that ultimately is fatal.
As a result of advances in medicine and improvements in quality of life, it is quite
impressive to note that the average human lifespan has increased considerably in
the past century. It would be ideal to spend this long life healthy and independent.
But the aging population is at the greatest risk for neurodegenerative diseases. As of
2012, one in eight older (age ≥ 65) American has been diagnosed with Alzheimer’s
disease (AD). It has been estimated that by 2050, there would be one new case
of AD in every 33 seconds (Bleiler and Laura, 2012). There is an urgent need to
1
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understand these complex neurodegeneration molecular processes so as to identify
effective therapeutic measures to save our growing elderly population.
Even though each neurodegenerative disorder has distinct clinical phenotypical
presentations, there is a growing interest toward searching for a unified underly-
ing mechanism of degeneration. Such a mechanism is suggested to include dys-
function in protein folding and aggregation, oxidative stress, free radical formation,
and mitochondrial function etc.(Chiti and Dobson, 2006; Emerit et al., 2004; Schon
and Manfredi, 2003; Jellinger, 2010). Various genetic, environmental and endoge-
nous factors were suspected to contribute to the deregulation of these biological
processes that eventually manifests a fatal neurodengeneration. Discovering these
kinds of common mechanisms offers hope for simultaneous therapeutic advance-
ment for these diseases.
In this study, we aim to approach the problem for the supposed unified mech-
anism of neurodegenerative diseases proceeding from a systems biology approach,
which analyzes the underlying processes in their entirety and interdependence. Molec-
ular biology networks are the ideal tool for such global approach. Network analysis
offers realistic chances to identify the most relevant of molecular pathways involved
in neurodegeneration, as well as the critical molecular players in these pathways.
An important result of such an analysis is finding potential candidates for new drugs,
which would suppress the expression of disease causing genes.
We selected for our network analysis three widely spread and well-studied neu-
rodegenerative diseases: Parkinson’s, Alzheimer’s and Huntington’s disease. In the
following few paragraphs, we summarize the available information on clinical symp-
toms, genes implicated in the disease pathogenesis, known disease signaling path-
ways, current therapeutic measures, etc. for these three neurodegenerative disor-
ders. This information resulted from a broad literature search, in which the Online
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Mendelian Inheritance in Man database (OMIM) catalog of human genes and ge-
netic disorders (http://www.omim.org/) was the basic source about the genes
already implicated in each of these neurodegenerative diseases.
1.1 Parkinson’s disease (PD)
1.1.1 Introductory notes
James Parkinson has been the first to observe this disease in adults in the year 1817.
In his essay entitled “An Essay of the Shaking Palsy” he described this disease as ini-
tiated with slow, progressive involuntary tremors, followed by difficulty in walking,
swallowing and speech (Parkinson, 2002). Apart from motor symptoms, Parkinson’s
disease patients experienced significant non-motor symptoms including mood and
cognition decline, sleep disturbances, and other autonomic dysfunctions (Micieli
et al., 2003).
With the help of modern-day molecular and cellular research advancement, pro-
gressive degeneration of the dopaminergic (DA) neurons of the Substania nigra (SN)
brain region were found in Parkinson’s disease (PD) brains (Jellinger, 2009), in ad-
dition to the accumulation of misfolded protein aggregates. Both environmental
factors and genetic mutations were suspected to cause PD (Di Monte et al., 2002;
Lesage and Brice, 2009). One of the distinctive features of Parkinson’s disease is
severe damage to the nigrostriatal dopaminergic system. Neurotoxic agents such
as manganese and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were sus-
pected for this type of neuronal damage. MPTP induced Parkinson’s disease animal
models were extensively used to study the neurodegeneration process as well as to
identify potential therapeutic drug targets (Sedelis et al., 2001). Soluble fractalkine
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(CX3CL1, chemokine ligand 1) isoform was shown to reduce impairment of mo-
tor coordination, decrease dopaminergic neuron loss, and ameliorate microglial
(macrophages of brain) activation and proinflammatory cytokine release resulting
from MPTP exposure (Morganti et al., 2012).
1.1.2 PD etiology
Long time belief was that Parkinson’s disease etiology is sporadic (not genetically
inherited) in nature. However, a small percentage of the PD patients were now
known to inherit gene mutations. Genes including ATP13A2, DJ-1, GIGYF2, HTRA2,
LRRK2, PARK2 (parkin), PINK1, SNCA and UCHL1 were associated with either au-
tosomal dominant or recessive form of Parkinson’s disease (Lesage and Brice, 2009).
From the listed genes alpha-synuclein (SNCA) is critical to the pathogenesis in the
early-onset of the rare familial form of PD. Insoluble form of α-syn fibrils were dis-
covered in the protein aggregates called Lewy bodies (LBs), the hallmark patho-
logical characteristics of Parkinson’s disease. The aggregation and accumulation of
abnormal α-syn in dopaminergic neurons have been postulated to be responsible
for the neurodegeneration that ultimately leading to cell death (George, 2002; Rec-
chia et al., 2004). Synucleins were also found in the amyloid-plaques in Alzheimer’s
disease brains.
In general, alpha-synuclein is highly expressed in brain at presynaptic termi-
nals, particularly in the neocortex, hippocampus, striatum, thalamus, and cerebel-
lum components. They function as molecular chaperones and interact with many
proteins thus modifying their cellular activity. Due to its versatile interacting be-
havior, mutant alpha-synuclein has been implicated in the deregulation of many
biological processes including oxidation, neuroinflammation, mitochondrial func-
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Figure 1.1. Parkinson’s disease pathway from KEGG database. Biological pro-
cesses and genes implicated in the Parkinson’s disease. Courtesy: Parkinson’s dis-
ease pathway from KEGG database, available at http://www.genome.jp/kegg/
pathway/hsa/hsa05012.html retrieved on Apr 3, 2013.
tion, ubiquitination etc. (Jellinger, 2009, 2010; Hsu et al., 2000; Polymeropoulos
et al., 1997). Figure 1.1 depicts the various genes already implicated in Parkinson’s
disease along with different deregulated biological processes caused by the several
abnormal protein activities.
To date, several genetic modifiers of PD have been described. Information of
many such genes and their role in PD pathogenesis can be found in literature (Klein
and Schlossmacher, 2006; Gasser, 2009; Shulman et al., 2011; Farrer, 2006; von
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Bohlen und Halbach et al., 2004). Some of these PD-known genes relate to neuronal
growth and neuroprotective mechanisms in Parkinson’s disease (refer Table 1.1).
Recent genome-wide studies have found that mutations in at least 13 PARK loci
and related genes increase both early- and late-onset PD susceptibility (Hicks et al.,
2002; Chung et al., 2011; Klein and Schlossmacher, 2006). Earlier study by Galvin
et al. (1999) had shown that β- and γ-synuclein are associated with hippocampal
axon pathology in Parkinson’s disease and dementia with Lewy bodies. Genome-
wide approaches were also used to identify microRNAs-target mRNA interactions
in PD domain. MicroRNAs (miRNAs) are a class of small RNAs ( 22 nucleotides)
that act as post-transcriptional regulators of gene expression by binding to the com-
plementary sequences in target mRNAs. In recent years, miRNAs have emerged as
potential drug targets in a variety of diseases including infections, metabolism and
inflammation etc (van Rooij et al., 2012). A recent genome-wide miRNA profiling
study for Parkinson’s disease has reported several miRNAs to be differentially ex-
pressed in PD blood samples. Hundreds of genes were reported as targets of these
miRNAs. The predicted target genes belonged to various biological pathways includ-
ing synaptic long-term potentiation, semaphorin signaling in neurons and protein
ubiquination pathway etc. many of which were previously found deregulated in
Parkinson’s disease mechanism (Martins et al., 2011).
1.1.3 PD treatment options
Even though there were some new treatment options available to PD patients, oral
administration of levodopa (precursor of dopamine) has been the gold standard
medication for Parkinson’s disease. But prolonged use of levodopa increases the
risk of developing levodopa-induced dyskinesias (involuntary movement) (Rascol
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Table 1.1. Some of the well-known Parkinson’s disease genes and their molecular
functions.
Known PD genes Functions (references)
CX3CL1 (fractalkine)
Produced by neurons, suppresses the
activation of microglia and plays
a neuroprotective role in 6-OHDA-
induced (synthetic neurotoxic com-
pound) dopaminergic lesions (Pabon
et al., 2011).
FGFs (fibroblast growth factors)
Exhibits potent neurotrophic proper-
ties for dopaminergic (DA) neurons.
Promote DA neuron’s development
and neurite outgrowth, rescue dam-
aged DA neurons after toxic insults,
and prevent apoptosis (Walker et al.,
1998).
L1CAM (L1 cell adhesion molecule)
Enhances the survival of imperiled
endogenous dopaminergic neurons in
Substantia nigra (SN) (Cui et al.,
2010).
MAPK signaling pathways
Contributes to neuroinflammatory re-
sponses and neuronal death which is
triggered by α-syn aggregates or func-
tional deficiencies in parkin or DJ-1
genes (Kim and Choi, 2010).
MT1F, MT2A (Metallothioneins 1 and 2)
Scavenges reactive oxygen species and
free radicals in central nervous system
(Michael et al., 2011).
RAB3A (member of RAS oncogene family)
Suppresses α-syn toxicity in neuronal
models of PD (Gitler et al., 2008).
RNF11 (ring finger protein 11)
Found highly enriched in SN dopamer-
gic neurons as well as its co-localizes
with Lewy bodies (abnormal aggre-
gates of protein) in PD brains (Ander-
son et al., 2007).
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et al., 2011; Thanvi et al., 2007). Recently, deep brain stimulation (DBS) has been
offered as a secondary treatment option in Parkinson’s disease where the benefits
of medication have failed/diminished. DBS therapy has been shown to increase
the neuron firing rate, blood flow and to promote neurotransmitter release as wells
as to stimulate neurogenesis. Although deep brain stimulation improves the motor
symptoms of Parkinson’s disease, it is a serious surgical intervention with major side
effects of infection and intracranial hemorrhage including the risk of death (Okun,
2012). With current advancement of different “omics” technologies along with ef-
fective in-silico testing options, finding successful molecular therapeutic targets for
Parkinson’s disease seems much more possible than before.
1.2 Alzheimer’s disease (AD)
According to a recent US Alzheimer’s association’s report, 5.4 million Americans of
all ages had Alzheimer’s disease in 2012 and the numbers are estimated to increase
in the years to come. Alzheimer’s is the most common form of dementia (serious
progressive loss of cognitive functions). Aging, diet, lifestyle, heart problems, fam-
ily history and gene mutations etc. have been suggested to increase the risk for
developing the disease (Bleiler and Laura, 2012).
1.2.1 AD etiology
Unlike Parkinson’s disease, memory loss is one of the first symptoms in Alzheimer’s.
At first, patients with AD start to forget names, things and words etc. which then
manifests into confusion and disorientation followed by slow and progressive de-
cline in standard of daily living. AD is ultimately fatal. In general, AD etiology is spo-
CHAPTER 1. INTRODUCTION 9
radic but a small percentage of early-onset familial form is also possible. Mutations
in APP, APOE, PSEN1, PSEN2, and MAPT genes were found to cause Alzheimer’s
disease pathogenesis. Histopathologically, AD is characterized by the presence of
amyloid-plaques (which consist of amyloid-β peptides) and Neurofibrillary tangles
(NFTs) in the brain. APP encodes for the amyloid-β precursor protein, and the pre-
senilin genes (PSEN1 and PSEN2) encodes for the proteolytic enzymes that cleave
APP into amyloid-β and other fragments (Wolfe et al., 1999). PSEN1 mutations
were attributed to more than 50% of early onset of familial form of AD (Raux et al.,
2005). Neurofibrillary tangles consist of aggregations of hyperphosphorylated tau
proteins (MAPT) (Selkoe, 2001; Bekris et al., 2010). Accumulation of amyloid-beta
(A-beta) mediates migration of inflammatory molecules across blood brain barrier
(BBB) and it is enhanced by PECAM1 adhesion, thus promoting the disease progres-
sion (Kalinowska and Losy, 2006).
Some of the other genes that were suspected to contribute the disease pathogen-
esis are shown in Table 1.2.
In addition, TGFβ1 has both protective and deleterious effect in AD. Overex-
pression of TGF-beta may initiate or promote amyloidogenesis in Alzheimer’s dis-
ease. TGFβ1 has also been suggested to have an anti-amyloidogenic role; it de-
creases the Aβ load and the formation of neuritic plaques in brain (Tichauer and
von Bernhardi, 2012). This neuroprotective effect of TGFβ1 appears to be at least
partially mediated by the SMAD pathway (Ueberham et al., 2006). Another neu-
roprotective mechanism has been suggested to take place via Humanin-mediated
JAK2/STAT3 signaling pathway. Activation of this pathway has reduced the mem-
ory and cognitive impairment found in Alzheimer’s disease (Chiba et al., 2009; Ni-
ikura et al., 2004). Even after extensive biochemical research, little is known about
how these protein aggregations trigger gradual memory loss and other symptoms in
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Table 1.2. Some of the well-known Alzheimer’s disease genes and their molecular
functions.
Known AD genes Functions (references)
CDK5 (cyclin-dependent
kinase 5)
Along with GSK3B (glycogen synthase kinase-
3beta) leads to accumulation of aberrantly phos-
phorylated forms of the microtubule-associated
protein tau (Mateo et al., 2009).
CDK5R1 (cyclin-dependent
kinase 5, regulatory sub-
unit 1)
Activator of CDK5 which contributes to the hyper-
phosphorylated tau protein aggregate formations
in AD brains (Mateo et al., 2009).
LMO4 (LIM domain only 4)
Play a secondary role in AD by increasing the com-
plexity and the severity of the disease pathogen-
esis (Leuba et al., 2004).
PTEN (phosphatase and
tensin homolog)
Found co-localized with abnormal tau and phos-
phorylated neurofilament proteins in neurons of
AD brains (Sonoda et al., 2010).
APOE, A2M, LRP1, MPO,
JUN, NOS1, SIRT1 ...
Found to increase the abnormal protein aggrega-
tion and other symptoms of Alzheimer’s disease
(Serretti et al., 2005).
Alzheimer’s disease (Selkoe, 2001; Bekris et al., 2010). Apart from genes, the role
of miRNA regulatory mechanisms was also studied in AD. A recent genome-wide
miRNA profiling study has found a substantial number of differentially expressed
miRNAs in the cortical region of AD brains. Many of these miRNAs and their pre-
dicted mRNA target pairs were part of several biological processes that were pre-
viously reported dysfunctional in Alzheimer’s disease mechanism (Nunez-Iglesias
et al., 2010).
1.2.2 AD deregulated biological processes
Many biological processes including neuroinflammation, oxidative stress, dysfunc-
tion of lysosomal/proteasomal degradation, mitochondrial dysfunction etc. have
been associated with Alzheimer’s disease. Figure 1.2 illustrates the different mutant
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Figure 1.2. Alzheimer’s disease pathway from KEGG database. Biological pro-
cesses and genes implicated in the Alzheimer’s disease. Courtesy: Alzheimer’s dis-
ease pathway from KEGG database, available at http://www.genome.jp/kegg/
pathway/hsa/hsa05010.html retrieved on Apr 3, 2013.
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genes and its cellular localization along with the biological processes that are dereg-
ulated in Alzheimer’s disease pathogenesis. Aggregation of amyloid-plaques and tau
proteins were suggested to be the cause for these deregulations (Crews and Masliah,
2010; Doyle et al., 2011; Jomova et al., 2010; Selkoe, 2001; Tuppo and Arias, 2005;
Jellinger, 2010). Blood and inflammatory markers, oxidative stress indicators, along
with clinical examination, brain-imaging techniques, and CSF biochemical markers
show promising steps towards a combinatorial biomarkers approach for early and
accurate Alzheimer’s disease diagnosis (Flirski and Sobow, 2005).
1.2.3 AD treatment options
Current thoughts of therapeutic measures in AD were along the lines of reducing
APP production or by increasing the amyloid-beta clearance. These were suggested
in order to protect the neurons from cell death and to promote synaptic formation
and neurogenesis. Medications such as Donepezil and Memantine, mitochondrial-
targeted antioxidants such as MitoQ, SS31 and neurotrophic factors like BDNF have
been shown to reduce amyloid-β toxicity as well as reverse neuronal atrophy and
improve age-related cognitive impairment (Manczak et al., 2010; Nagahara et al.,
2009; Howard et al., 2012).
1.3 Huntington’s disease (HD)
1.3.1 Introductory notes
Huntington’s is an inherited autosomal dominant motor disorder. Expansion of 36
or more CAG trinucleotide (polyQ) repeats in Huntingtin (HTT) gene is the hall-
mark characteristic of the disease. PolyQ expanded HTT is considered as a trigger
CHAPTER 1. INTRODUCTION 13
of the neurodegeneration that eventually cause all the Huntington’s disease (HD)
symptoms. Offspring of an individual with a mutant allele have a 50% chance of
inheriting the disease. Huntington’s disease is described by progressive motor, cog-
nitive, and emotional disturbances. The motor symptoms include chorea, dystonia,
rigidity, postural instability etc. Depression and personality changes are the major
emotional disturbances part of the disorder. Like Alzheimer’s disease, short-term
memory loss, confusion and disorientation are some of the cognitive issues found in
HD patients. In HD, neurodegeneration is selective for striatal GABAergic medium-
sized spiny neurons. These neurons project to substania nigra and globus pallidus
parts of the brain affecting primarily the motor coordination (Bates, 2003; Reiner
et al., 2011; Albin et al., 1990).
Figure 1.3 depicts HTT gene along with its interacting partners which trigger the
striatal neuronal loss that eventually manifests all the Huntington’s disease symp-
toms. Like the other neurodegenerative disorders, HD also showed protein misfold-
ing, ubiquitin proteasome system deregulation, autophagy dysfunction, metabolic
and mitochondrial dysfunction as well as oxidative stress, which over the years cul-
minates into motor and cognitive disorders (Martinez-Vicente et al., 2010; Gil and
Rego, 2008; Davies et al., 2007; Jellinger, 2010).
Apart from HTT, mutations in HDL3, JPH3 and PRNP genes were also related
to Huntington’s disease pathogenesis (OMIM database, retrieved on Dec 17, 2012).
Some of the known HD related genes are shown in Table 1.3. 25 or more genes that
interact with HTT and are part of Huntington’s disease pathogenesis are listed in lit-
erature (http://en.wikipedia.org/wiki/Huntingtin#cite_ref-pmid11532990_
10-0, retrieved on Apr 8, 2013).
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Figure 1.3. Huntington’s disease pathway from KEGG database. Biological pro-
cesses and genes implicated in the Huntington’s disease. Courtesy: Huntington’s
disease pathway from KEGG database, available at http://www.genome.jp/kegg/
pathway/hsa/hsa05016.html retrieved on Apr 3, 2013.
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Table 1.3. Some of the well-known Huntington’s disease genes and their molecular
functions.
Known HD genes Functions (references)
BCL2 (B-cell CLL/lym-
phoma 2)
Overexpression of BCL2 slows down the Hunting-
ton’s disease progression (Mattson, 2000; Zhang
et al., 2003).
CCKBR (cholecystokinin B
receptor)
Encodes a G-protein coupled receptor for gastrin
and cholecystokinin (CCK), the regulatory pep-
tides of the brain and gastrointestinal tract. It
was reported that there is selective loss of CCK
receptor-containing neurons in cerebral cortex of
Huntington’s patients (Hays et al., 1981).
cytochrome c
It’s release from the mitochondria triggers the
downstream caspase activation leading to apop-
totic neuronal death in many neurodegenerative
diseases. This kind of neuronal death plays a
greater role at the end stage of HD (Kiechle et al.,
2002). An animal model of chronic HD neurode-
generation study has shown that methazolamide
drug could inhibit cytochorome c release from
mitochondria and thus acts as a neuroprotective
agent (Wang et al., 2008).
FGF2 (fibroblast growth
factor 2)
Improves motor performance and extends the
lifespan by 20% by reducing the accumulation of
polyglutamine aggregates in the brain (Jin et al.,
2005; La Spada, 2005).
GAPDH (glyceraldehyde-3-
phosphate dehydrogenase)
Due to its selective binding to the CAG repeats in
huntingtin gene, GAPDH activity was found re-
duced in HD brains there by reducing the cellular
energy production (Burke et al., 1996; Mazzola
and Sirover, 2001).
GPCRs (G-protein coupled
receptors)
Due to their abundant presence in central ner-
vous system, as well as their complex interac-
tions with many downstream targets, have made
GPCRs as potential drug targets in many neu-
rological diseases including Huntington’s disease
((Dowie et al., 2010).
IRS2 (insulin receptor sub-
strate 2)
Decreasing IRS2 signaling could be part of a ther-
apeutic approach to slow down the progression of
HD (Sadagurski et al., 2011).
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1.3.2 HD potential therapeutic measures
Unlike Parkinson’s and Alzheimer’s neurodegenerative disorders, Huntington’s dis-
ease main cause is a genetic defect. This has opened broad venues for developing
effective animal models to study and understand the disease pathogenesis. With
moderate success, these animal models have replicated HD related neuronal loss and
the subsequent motor and cognitive symptoms of the disease. The animal research
work have expanded the understanding of HD pathogenesis and thus suggested
some valuable therapeutic measures to alleviate the disease symptoms. Some of the
suggested beneficial pathways were by up-regulating the innate autophagy process
and via increasing BDNF gene expression. Autophagy process protects against the
toxic insults of mutant huntingtin proteins by enhancing its clearance from the cell.
Brain-derived neurotrophic factor (BDNF) is necessary for survival of striatal
neurons in the brain and it promotes synaptic plasticity in addition to memory for-
mation. It can also act as a neuromodulator affecting the pre-synaptic release of
neurotransmitters in central nervous system. When administered systemically or
delivered via genetically-grafted cells, BDNF has shown to prevent striatal neurons
from cell death in HD animal models. BDNF has also been suggested to reduce
amyloid-beta neurotoxicity in Alzheimer’s disease (Ross and Tabrizi, 2011; Zuccato
et al., 2010; Tapia-Arancibia et al., 2008; Ferrer et al., 2000). Currently, blood mark-
ers, brain imaging are used along with qualitative clinical measures as potential
biomarkers to test for early-onset and/or the progression of Huntington’s disease
(Walker, 2007).
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1.4 Network biology
Traditionally, medical practices have followed reductionist approach in treating dis-
eases, based on the assumption that information about individual body parts is suffi-
cient to explain the whole system. However, unpredicted behaviors evolve as a result
of complex dynamic interactions between the parts, which cannot be explained by
the parts alone. One needs to know the interactions of various parts in order to fully
understand the system. Systems biology is a holistic approach to understand biolog-
ical systems as a whole including its individual components and their interactions.
In an abstract level, behavior of complex systems (e.g., biological cell) can be
represented as a network where the individual components (e.g., DNA, proteins,
metabolites) of the system are the “nodes” of the network and their interactions
(e.g., protein-DNA, protein-protein, and protein-metabolite) are the “edges/links”
that connect the individual components. Network biology is a systems approach to
study the internal workings of a biological system by representing its complexity in
a network form. One such example is human protein-protein interaction (PPI) net-
work shown in Figure 1.4. The variety of techniques developed in network biology
makes possible to analyze and understand the internal molecular architecture and
interactions of a biological cell (Barabási and Oltvai, 2004).
As shown in the previous subsections, not only individual genes but many bi-
ological processes are affected in each of the neurogenerative diseases. Neurode-
generation process is a complex system with many players and multiple interactions
among them. Such systems can be analyzed in a network form to understand the
underlying molecular mechanisms. Network analysis approach has been utilized to
study complex diseases like cancer, virus-host interaction and others. (Cerami et al.,
2010; Taylor et al., 2009; Uetz et al., 2006; Calderwood et al., 2007). With the ad-
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Figure 1.4. Network example. Shown here is the human protein-protein inter-
action network. Courtesy: A human protein-protein interaction network: a re-
source for annotating the proteome (Stelzl et al., 2005). Available at http://www.
sciencedirect.com/science/article/pii/S0092867405008664 retrieved on
Apr 5, 2013.
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vancement of high-throughput technologies like microarrays, protein and exon ar-
rays we are now able to produce information about thousands of genes and proteins
simultaneously. This has inspired a new wave of studies to understand complex dis-
ease mechanisms via network approach that involves all those genes/proteins along
with their interactions. Network-based approaches have been suggested to provide
a new and useful framework for classifying diseases and predicting their outcome,
as well as for identifying therapeutic strategies (Loscalzo et al., 2007; Goh et al.,
2007; Barabási et al., 2011).
1.4.1 Critical network measures
Network topology of biological systems not only provides means to visualize the
complex interactions between the components, it also helps to mathematically de-
rive specific scores/measures to identify key players within the network. Some of
the important network descriptors are as follows. First is node degree. It is one of
the basic characteristics of a network and it tells us how many links the given node
has with other nodes. Nodes with highest degree are called “hubs”. Studies have
shown that highly connected nodes in a biological network tend be both essential
and conserved (Bergmann et al., 2004). Next is network distance (or shortest-path),
the minimal number of links we need to pass through to travel between two nodes.
It describes the navigability of the network (Barabási and Oltvai, 2004). Another
one is betweenness centrality which quantifies the number of times a node acts as a
bridge along the shortest-path between any two nodes in a network. Modules within
the network are often thought to communicate with each other via nodes with high
betweenness centrality score. They are the “traffic-influential” nodes of a network.
Finally, closeness centrality is a network measure which tells how fast it will take to
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spread information from the given node to the entire network. These nodes could
be described as the “monitors” since it is in an excellent position to watch the flow
of information within the network (Estrada, 2011). Identifying as well as target-
ing these central nodes is beneficial from a therapeutic stand point. Thus, network
analysis could offer the vital information about the critical players of any complex
system. Once the important elements of a network are known, further downstream
experimental investigations can be much more focused and less time consuming. In
addition, network analysis could help in creating new study hypotheses.
1.4.2 Some previous network-based research work
Previously, some neurodegenerative disease studies have used network-based anal-
ysis to explore and expand the knowledge-base of disease related genes/proteins.
One such network-based study was performed using the Parkinson’s disease microar-
ray gene expression data. In this study, using protein-protein interactions, Moran
and Graeber et al., (2008) built a network of known genes/proteins involved in
Lewy body formations. Expanding their network by including “candidate genes”,
they have been able to reveal more information about the underlying molecular
mechanism of Lewy body formation in Parkinson’s disease brains.
Another network-based neurodegeneration study was by Goehler et al. in 2004.
They constructed a protein-protein interaction network around Huntington’s dis-
ease gene HTT in order to identify the genes/proteins that directly interact with
it. This immediate neighborhood network helped them to identify a new enhancer
of HTT aggregation, called GIT1 (a G protein-coupled receptor kinase), and addi-
tional tests verified its role in Huntington’s disease pathogenesis. Even though these
studies were network-based, it only included limited use of techniques. A more of
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network-based analysis would be to incorporate different network descriptors such
as degrees and centrality scores of the PPI network to identify new important play-
ers, and to expand the knowledge-base of the underlying molecular mechanisms.
With the advent of many high-throughput technologies, network-based analysis is
an invaluable tool in studying biological and biomedical systems including viral-host
interactions, and complex diseases like cancer, infections and neurodegeneration, as
well as in drug discovery (Ideker and Sharan, 2008).
With encouragement from valuable previous research work (Witten and Bonchev,
2007; Chandrasekaran and Bonchev, 2012; Vladimir Kuznetsov and Bonchev, 2008),
we ventured out to utilize a comprehensive network-based approach to study the
neurodegeneration process. With the “Brain activity map” project on the horizon,
it is the right time to apply such comprehensive holistic methods to study the com-
plex nature of the neurodegenerative diseases as well as to find effective therapeutic
measures.
1.5 Study proposal
As a result of vast number of biochemical, animal and human research work, many
critical genes and molecular mechanisms of neurodegeneration process were found.
Primarily, both genetic and environmental factors were suspected to contribute for
the slow, progressive and irreversible dysfunction as well as specific neuronal loss in
all neurodegeneration conditions. The latter always exhibit protein misfolding and
abnormal aggregate formation in select brain regions. In addition, biological pro-
cesses including inflammation, oxidative stress, synapse formation, mitochondrial
function, microglial activation, reactive oxidative species and free radicals forma-
tion etc. were repeatedly found deregulated in such disease states. All these man-
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ifestations indicate a possibility for the existence of a common unified underlying
molecular mechanism in all neurodegenerative disorders. Network-based analysis
provides valuable tools to study such complex systems which involve many players
together with their intricate web of interactions.
Working hypothesis
“Applying network-based methods to build various types of interaction networks,
one can identify the common underlying molecular mechanisms and the critical
players in all neurodegenerative disorders. In doing so, we anticipate finding new
neurodegenerative disease genes, pathways and/or drug targets.”
We plan to accomplish this study goal by following our specific study proposals:
1. Identify key underlying molecular players of neurodegenerative disorders such
as Parkinson’s, Alzheimer’s and Huntington’s at both gene/protein level and
at pathway level using microarray gene expression data.
2. Find common key genes/proteins and pathways involved in neurodegenera-
tive disorders.
3. Expand the knowledge base of the molecular mechanisms of neurodegenera-
tive disorders with the help of regulatory gene/protein networks and predict
key genes/proteins and pathways involved with considerably high probability
in the disease regulatory mechanisms.
4. Elucidate miRNAs regulatory functions in these diseases.
1.6 Thesis organization
Following our study proposal, we have dedicated individual chapters detailing the
network-based analysis and results of the three neurogenerative disorders namely
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Parkinson’s, Alzheimer’s and Huntington’s disease. The study methodology chapter
explains the study data, statistical analysis and the use of different network descrip-
tors to summarize our research findings. The final chapter is devoted exclusively to
our analysis and results obtained for the common molecular mechanisms found in all
three neurogenerative disorders. The Appendix includes the R program (written in-
house), different graphs/plots used for data quality assessment, and Venn-diagrams
used in the study.
Chapter 2
Methods and Data
For a research work to be successful, it should include a well-thought out methods
section which would explain the study design, the data, tools and different tasks
needed to accomplish the proposed research goal. In this section, we explained in
detail the various steps we followed to streamline the network analysis of Parkin-
son’s, Alzheimer’s and Huntington’s disease. Figure 2.1 is an illustration of our
research work flow
2.1 Step 1: Microarray gene expression data
In a simple form, the central dogma of molecular biology could be stated like DNA
makes RNA, which in turn makes protein. The more active a gene is the more mRNA
it will produce. By measuring the mRNA level, we could examine the gene expres-
sion pattern of the cell. DNA microarray is a powerful technology that provides a
high throughput and detailed view of the entire genome and transcriptome of an
organism by measuring the relative mRNA abundance intensity. Due to their ready
availability, high volume capacity and parallel testing, microarrays have dramati-
24
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Figure 2.1. Methods and Data workflow. Workflow for finding significantly dif-
ferentially expressed genes (SDEGs) and pathways in each and in common in the
selected neurodegenerative diseases: Parkinson’s, Alzheimer’s and Huntington’s.
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cally accelerated many types of molecular biology investigation. They can be used
to find genomic expression patterns that enable advancing new pathophysiological
hypotheses. Such an approach has already yielded interesting new insights in the
study of various cancers, neurological diseases, etc. The known limitation of this ap-
proach is that mRNA level does not necessarily correlates with its functional protein
level in the cell. Also, post-translational modifications essential for determining pro-
tein function are not present on DNA microarray. However, these limitations could
be partially overcome by careful handling of arrays, probe selections and repeat ex-
periments. Moreover, microarray assays are inexpensive and less-time consuming
when compared with proteomics experiments. Better results in understanding the
underlying biological mechanisms are yielded by integrating gene expression and
proteomics approaches (Tian et al., 2004; Ideker et al., 2001).
Neurological disorders such as Parkinson’s, Alzheimer’s and Huntington’s are
chosen as disease models to study the human neurodegenerative process at molec-
ular level. For this study, DNA microarray gene expression data are used to identify
genes involved in neurodegenerative disease conditions. Such microarray datasets
are found in public data repositories such as National Center for Biotechnology Infor-
mation’s (NCBI) Gene Expression Omnibus (GEO) available at www.ncbi.nlm.nih.
gov/geo/ and European Bioinformatics Institute’s (EBI) ArrayExpress database avail-
able at www.ebi.ac.uk/arrayexpress/.
Even though there is progress made in clinical diagnosis of neurodegenerative
diseases, a definite diagnosis is still possible only by neuropathological examina-
tion of the brain. For this study, microarray gene expression of post-mortem brain
tissue samples from control and diseased conditions (called cases) are used. All
samples are age and sex matched along with various criteria including pH, PMI
(post-mortem interval), disease duration etc. (please follow the link listed in Table
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2.1 for more details about each dataset). The original authors of the selected mi-
croarray datasets had taken measures to include case subject samples’ neuropsycho-
logical and/or neuropathological data demonstrating the neurodegeneration mani-
festation clinical diagnosis and symptoms. The control subjects were those with no
known neurodegenerative disease history. For cross disease comparison and valida-
tion, care has been taken to include datasets that were performed using same DNA
microarray technology such as Affymetrix GeneChips with either Human genome
U133A/B or U133 Plus 2.0 Arrays. When searching for Parkinson’s, Alzheimer’s
and Huntington’s microarray gene expression datasets in GEO and ArrayExpress,
Affymetrix datasets were found predominantly. Table 2.1 lists the microarray plat-
forms and gene expression datasets utilized in this study. Unless stated otherwise
any subsequent mention of microarrays in this text is referring specifically to the
Affymetrix GeneChips.
Due to the unavailability, only one post-mortem human brain tissue microar-
ray gene expression dataset was found and used for Huntington’s disease study.
More detailed information about each microarray dataset like sample’s demograph-
ics, brain regions, disease stage, and post-mortem delay etc. can be obtained by
following the links in Table 2.1 footnotes or by querying the dataset names (like
GSE8397) in NCBI’s GEO and also in EBI’s ArrayExpress websites. Table 2.2 lists
brief information about the different microarray gene expression datasets used in
this study. For complete information about the entire sample parameters (such as
age, sex, pH, brain regions, disease duration etc.) collected for each of the microar-
ray dataset can be obtained from NCBI’s GEO and/or EBI’s ArrayExpress websites.
Please use the website link provided in Table 2.1 to access such information.
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Table 2.1. Microarray gene expression datasets and the platforms used.
Disease
condition
Microarray
dataset
Microarray platform
Parkinson’s
GSE8397 a GPL96/97 - Affymetrix HGb-U133A/B Array
GSE20295 c GPL96 - Affymetrix HG-U133A Array
Alzheimer’s
GSE4757 d GPL570 - Affymetrix HG-U133 Plus 2.0 Array
GSE28146 e GPL570 - Affymetrix HG-U133 Plus 2.0 Array
Huntington’s GSE3790 f GPL96/97 - Affymetrix HG-U133A/B Array
ahttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8397 or
http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-8397/?query=gse8397
bHuman Genome
chttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20295 or
http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-20295/?query=gse20295
dhttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4757 or
http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-4757/?query=gse4757
ehttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28146 or
http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28145/?query=gse28145
fhttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3790 or
http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-3790/?query=gse3790
CHAPTER 2. METHODS AND DATA 29
Table 2.2. Brief information about each microarray gene expression datasets used
for analysis.
Disease
condition
Microarray
dataset
Number of
samples
Ratio Male
to Female
Mean age
(±SD)
Brain tissues
(or) regions
Parkinson’s
GSE8397
Cases: 15 9:6 80 (5.7)
SFG, MSN and LSN
Controls: 8 6:2 70.6 (12.5)
GSE20295
Cases: 15 9:6 76.7 (6.2)
BA9, PT and SN
Controls: 15 10:5 71.2 (11.1)
Alzheimer’s
GSE4757
Cases: 19 9:10 84.1 (7.5)
EC
Controls: 15 9:6 80.1(7.9)
GSE28146
Cases: 22
11:19a 86.3 (1.4) EC
Controls: 8
Huntington’s GSE3790
Cases: 39 23:16 58.3 (15.6)
CE, CN and FL
Controls: 33 23:11 57.2 (17)
SFG - superior frontal gyrus; MSN - medial Substania nigra; LSN - lateral Substania nigra;
BA9 - Brodmann area 9; PT - Putamen; SN - Substania nigra; EC - entorhinal cortex; CE -
cerebellum; CN - caudate nucleus; FL - frontal lobe.
aNo separate information about sample’s age and sex details were found.
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2.2 Step 2. Detection of significantly differentially
expressed genes
The statistical tools and methods used in this study were chosen following their wide
use in the community and they are considered as standard procedures for microar-
ray gene expression analysis. Goal of analyzing microarray data is to determine
which genes are differentially expressed across different tissues and clinical condi-
tions. In order to accomplish our study goal of identifying common genes and path-
ways among the different neurodegenerative diseases, we maintained consistency
by following same techniques for pre-processing, normalizing and post-normalizing
across all the microarray gene expression datasets. Several commercial and free
tools like dCHIP, TM4, SAM and software like GeneSpring, Pathway Studio are avail-
able for microarray data analysis (Mehta and Rani, 2011).
For this study, we preferred to use Bioconductor package for analysis because it
is freely available, widely used and relatively easy to write customized programs.
“Bioconductor is an open source and open development software project for the
analysis and comprehension of genomic data” (Gentleman et al., 2004) (http:
//www.bioconductor.org/). Bioconductor is based on the R programming lan-
guage. All the microarray processing is implemented in R (written in-house) using
different packages from Bioconductor software.
2.2.1 Data pre-processing
During the pre-processing step, the appropriate gene expression datasets were iden-
tified as listed in Table 2.1, the raw microarray CEL files were downloaded from
the GEO/ArrayExpress databases, and the microarray chip quality was assessed.
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It was evaluated using a Bioconductor package called arrayQualityMetrics (Kauff-
mann et al., 2009). “arrayQualityMetrics provides powerful, auto- mated, objective
and comprehensive instruments to assess GeneChip reproducibility, identify appar-
ent outlier arrays and compute measures of signal-to-noise ratio”. Each and every
microarray dataset that we used in our study were subjected to arrayQualityMetrics
assessment and no extreme outliers were detected. arrayQualityMetrics also offered
variety of graphs/plots options like MA plot, density plot, boxplot, heatmaps etc. to
readily visualize the quality of the arrays. However, there is no one specific quality
control tool that has been widely used. Other such tools arrayQuality, arrayMvout,
ArrayTool etc. are also available with varying degree of quality control report op-
tions. Relevant quality assessment plots/graphs for one such microarray dataset are
provided in the Appendix A.
2.2.2 Data normalization
Normalization aims to correct for systematic differences (due to sample preparation,
batch processing etc.) between genes or arrays. Unless arrays are appropriately nor-
malized, comparing data from different arrays can lead to misleading results. All
microarray expression datasets were normalized using Robust multi-array average
(RMA) expression measure (Irizarry et al., 2003), which consists of three steps:
background correction, quantile normalization (each performed at the individual
probe level), and robust linear model fit using median polish (log-transformed in-
tensities at the probeset level). Although the RMA algorithm has been extended to
account for background correction for GC content of the oligonucleotides (Wu et al.,
2004) providing improvements in accuracy, particularly for weakly expressed genes,
we chose to use the standard RMA approach for the ease of comparison with other
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similar research results.
The differential gene expression changes were statistically evaluated by the em-
pirical Bayes (eBayes) method (Smyth, 2004) from the limma Bioconductor pack-
age. Empirical Bayesian methods combine information across genes which provide
more statistical power to identify significant changes. Studies have shown that em-
pirical Bayes t-statistic performed better than other test statistics (such as t-test,
ANOVA, SAM, Welch t-statistics etc.) especially when the sample size is small (Murie
et al., 2009; Jeffery et al., 2006; Kooperberg et al., 2005; Jeanmougin et al., 2010).
To account for potential multiple-testing problems, couple of standard procedures
was implemented but with no productive results. Due to the nature of the samples
(post-mortem tissues) used in this study; it was not possible to find many signifi-
cantly changed genes using Bonferroni method, the most conservative procedure
used for multiple-testing correction. Hence, the next best alternative to correct
for multiple-testing problem, the Benjamini-Hochberg adjustment (Benjamini and
Hochberg, 1995) was tried, however not all differentially expressed genesets were
significant enough. For this study, we were investigating the key players and molecu-
lar mechanisms that are common in all three neurodegenerative disorders. In order
to accomplish our study goal, we needed sufficient number of significantly differen-
tially expressed genes (SDEGs) in each disease conditions as well as a reasonable
number of overlapping genes and yet differentially expressed between different dis-
orders. Hence, no multiple-corrections were utilized and the probe-sets with t-test
p-values < 0.05 were considered to be SDEGs in a given disease condition. In this
manner, considerable number of overlapping genes was found and, to partially com-
pensate for not accounting for the multiple correlation, only those SDEGs with the
p-value lower than 0.01 were included in network evaluation.
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2.3 Step 3. Generation of “seed genes” for each
neurodegenerative disorders
All seven microarray dataset listed in Table 2.1 were subjected to the same statis-
tical analysis explained above and significantly differentially expressed genes lists
called “seed genes” were generated for each dataset. To explain this process, we
used Parkinson’s disease microarray datasets as an example here. The final set of
Parkinson’s disease SDEGs/seed genes were derived by overlapping the individual
seed genes of the three microarray datasets namely GSE8397 HG-U133A & B and
GSE20295 HG-U133A. As listed in Table 2.2, GSE8397 dataset had gene expression
data from three types of brain tissue samples namely superior frontal gyrus (SFG),
medial and lateral Substantia nigra (M/LSN). For this dataset, four sets of differen-
tial gene expression changes were evaluated. They were
1. Differential gene expression changes found between control and cases (PD),
irrespective of tissue types. We refer this set as “Diagnosis”.
2. Differential gene expression changes found between control and cases (PD) in
SFG tissue only. We refer this as “SFG”.
3. Differential gene expression changes found between control and cases (PD) in
MSN tissue only. We refer this as “MSN”.
4. Differential gene expression changes found between control and cases (PD) in
LSN tissue only. We refer this as “LSN”.
On completion of evaluation of the four sets of gene expression changes (diag-
nosis, SFG, MSN and LSN) in GSE8397 HG-U133A, an overlap of 414 seed genes
were found (see Figure 2.2). In a similar way, an overlap of 225 seed genes was
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Figure 2.2. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE8397 HG-U133A gene expression dataset for Parkinson’s disease. Cour-
tesy: VENNY
found in the GSE8397 HG-U133B microarray gene expression dataset (see Figure
2.3). Together, 414 + 225= 631 seed genes (after removing duplicates) were found
in GSE8397 U133A and U133B datasets.
Correspondingly using GSE20295 HG-U133A microarray dataset, four sets of
seed genes namely diagnosis, BA9, PT and SN (tissue samples used) were generated
and an overlap of 110 genes were considered SDEGs (p-values < 0.05). Finally,
combining the two Parkinson’s microarray datasets (GSE8397 and GSE20295) we
found 719 (p-values < 0.05) genes to be significantly differentially expressed.
Until now we explained how we generated the “seed genes” for Parkinson’s dis-
ease using GSE8397 and GSE20295 Affymetrix microarray dataset. Continuing in
the similar manner, we evaluated the respective microarray gene expression datasets
(see Table 2.1) and found 1205 “seed genes” for Alzheimer’s and 925 for Hunting-
CHAPTER 2. METHODS AND DATA 35
Figure 2.3. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE8397 HG-U133B gene expression dataset for Parkinson’s disease. Cour-
tesy: VENNY
ton’s disease. The overlap numbers and the Venn diagram illustrations for each gene
expression datasets are given in detail in Appendix B.
Following the p-values< 0.01 cut-off criteria, there were 267, 214 and 531 “seed
genes” for Parkinson’s, Alzheimer’s and Huntington’s diseases respectively. These
seed gene list was used for further network analysis. Concluding this part, 22 genes
were found in “common” in all three neurodegenerative diseases (see Figure 2.4).
The genes were used as “seed” ones in constructing a larger network to explore and
to understand the common molecular mechanisms and the network characteristics
of the three neurodegenerative diseases.
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Figure 2.4. Number of common genes in all three neurodegenerative disorders.
Courtesy: VENNY
2.4 Step 4. Construction of various types of
neurodegenerative disorder networks
We constructed various kinds of networks to understand the interactions between
seed genes and investigate the common molecular mechanisms in neurodegenera-
tion. In order to partially compensate for the non-effectiveness of Bonferroni-based
selection of SDEGs and to have a more concise and yet informative networks, we re-
stricted our “seed list” (list of significantly differentially expressed genes) to include
those genes/proteins with p-values < 0.01.
2.4.1 Pathway Studio software
A popular tool to analyze and construct biological networks and path- ways is Ari-
adne Genomics Pathway Studio (www.ariadnegenomics.com) database software
(Nikitin et al., 2003). It helps to interpret gene expression and other high through-
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put data. It provides tools to build networks as well as analyze pathways. Pathway
Studio software offers many options to construct various kinds of networks such as
direct interaction, shortest-path, common targets and regulators of pairs or multiple
genes. The protein-protein interaction data are taken from the proprietary database
ResNet 9.0 of Ariadne Genomics, provided jointly with the software. ResNet version
9.0 was released October 15, 2011. It covers human, mouse and rat proteins. Pro-
tein definitions are from Entrez Gene database as of April 7, 2011. ResNet database
is compiled by Ariadne Genomics using MedScan technology from over 20 million
NCBI’s PubMed abstracts and 880,967 full-text articles as of May 27, 2011. Cur-
rently the database covers 125,342 entities such as cell process, complex, disease,
functional class, treatment and small molecules including 112,096 proteins. It offers
1,160,524 protein-protein interactions of types binding, chemical reaction, direct
regulation, expression, microRNA regulation, molecular synthesis, molecular trans-
port, promoter binding, protein modification and regulations. ResNet 9.0 database
also includes information about 5581 custom built Ariadne Genomics cell-process,
metabolic and signaling pathways.
For this project, we used direct interaction, shortest-path, and common regu-
lators network options in Pathway Studio software to identify various interactions
between the SDEGs and connecting genes/proteins that could be of additional in-
terest in neurodegeneration process. In the following paragraphs we explain the
types of networks we constructed and their importance in our analysis.
2.4.2 Direct interaction (DI) network
Direct interactions are the simplest form of network representation. Using our list
of “seed genes”. Direct interaction (DI) network reveals the direct interactions be-
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tween those genes. The seed gene lists of each of the chosen neurodegenerative
disorders were subjected to direct interaction network construction. Interactions
between the genes/proteins are of the following types: regulation, protein mod-
ification, promoter binding, direct regulation and microRNA regulations. Due to
insufficient information in the databases, as well as due to their nature, not all
genes/proteins would directly interact with each other; many genes/proteins re-
main isolated (unconnected) nodes in the DI network. The information regarding
the unconnected nodes is maintained separately in Excel files but these nodes are
not included in the later network analysis.
2.4.3 Common regulator network
Another network option in Pathway Studio 9.0 is common regulator network. We
constructed this network with each of the following interaction types: regulation,
protein modification, promoter binding, direct regulation and microRNA regula-
tions. These individual networks revealed a subset of seed genes to be common
regulators of pairs or multiples of genes; these are the genes/proteins that control
the gene expression pattern of other genes/proteins. Based on their degree of lo-
cal connectivity (node degree ≥ 5) the common regulators are classified as “Hubs”
- the genes that represent the most highly connected nodes in the molecular net-
work. The cut-off value for the hub node degree was selected in order to classify
a sufficient number of significantly differentially expressed genes as network hubs.
A node with higher connectivity usually means a higher functional role for the cor-
responding gene/protein in the network. The hub genes may represent key points
of vulnerability in underlying signaling pathways responding to neurodegeneration.
We therefore categorized these genes as either “Genes of interest in SDEGs” or “Al-
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ready known genes in SDEGs” based on whether they could be of interest or have
already been implicated in neurodegenerative disorders. In later chapters, for easy
understanding the network nodes in the figures are highlighted in either blue or
green color based on their categories respectively.
2.4.4 Sources used to search for gene information
Online Mendelian Inheritance in Man (OMIM) database (McKusick-Nathans In- sti-
tute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), Oct 5, 2012,
World Wide Web URL: http://omim.org) was used as the primary source of infor-
mation on genes that were already implicated in each of the three neurodegenera-
tive disorders chosen for this study. For example, we compiled a list of Parkinson’s
disease associated genes found in OMIM by searching for the word “Parkinson’s dis-
ease” in OMIM Gene Map query tool using “Phenotype only Entries” option. This
query in OMIM resulted in a list of previously known PD related genes.
Additionally, Google search engine (available at https://www.google.com/)
was used to find information about the SDEGs and their implication in neurode-
generation process, if any. NCBI’s PubMed database (available at http://www.
ncbi.nlm.nih.gov/pumed) was primarily used as a resource to download the cor-
responding journal articles. At the end, we used the information from OMIM, Google
and NCBI’s PubMed to categorize the SDEGs into either already-known or could be
of potential interest in a given neurodegenerative disorder.
2.4.5 Shortest-path (SP) network
The Shortest-path network (SPNW) enables us to find indirect relationship between
two or more entities through intermediary nodes in the absence of direct relation-
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ship. By constructing networks that include only the shortest-path interactions
among the genes/proteins, the network size is reduced considerably and also true-
positive interactions are likely to be enriched (Managbanag et al., 2008).
By applying the shortest-path network strategy to the list of SDEGs, we could
identify genes/proteins that might contribute to the neurodegenerative process but
have not been related so far to it. This approach is based on the inference that when
genes/proteins with well-defined biological functions (e.g., oxidative stress) interact
with other genes/proteins, the latter have a higher probability to share that func-
tion, as compared to those selected at random (Schwikowski et al., 2000; Witten
and Bonchev, 2007). By exploiting this known biological network property (guilt-
by-association), we could find novel genes/proteins of importance for neurodegen-
erative process and expand the knowledge base of the molecular mechanisms of
these disease conditions.
In Pathway Studio, shortest-path network option with protein modification, pro-
moter binding, and direct regulation interaction types were used to construct a
shortest-path network for each of the neurodegenerative disorder’s seed list. This
type network could introduce many connecting genes/proteins without which some
of the seed genes would remain unconnected nodes in the network. One limitation
of the shortest-path network is that sometimes it could bring in more intermediary
nodes in order to have a unified network. For example, beginning with 531 seed
genes (with p-values <0.01) from the Huntington’s disease microarray dataset, the
shortest-path network grew into a network with 937 nodes. Such huge networks are
not only impractical to do further analysis it will also diminish the importance of the
seed genes in a given scenario. Thus, care has been taken to reduce the number of
connecting nodes in the shortest-path network.
We accomplished the reduction in number of connecting nodes by setting up
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a cut-off rule, to include only those seed genes which had ≥ 25 neighbors in the
Pathway Studio ResNet 9.0 database. The specific threshold value of 25 reflects
the very high average number of neighbors per node in this database. The highly
connected nodes we selected in this manner have a better chance to be directly
connected to the genes known to be related to the diseases under study. The 531
seed Huntingon’s genes were thus reduced to 258 genes. A lower ratio of 1.5 to
2 connecting vs seed genes/proteins was maintained for all datasets. As a rule,
unconnected nodes were removed from the final network.
2.4.6 Construction of compact shortest-path network
The connecting genes/proteins of the shortest-path networks include both essential
and non-essential genes. Essential genes are part of the normal cell functions (e.g.
MAPK is involved in a wide variety of cellular processes such as proliferation, dif-
ferentiation, transcription regulation and development), while non-essential genes
could be disease causing ones. In order to determine whether connecting genes/pro-
teins were already implicated or could be of interest in any neurodegenerative pro-
cess or disorders, we cross-referenced (queried) each such gene/protein in NCBI’s
PubMed database. OMIM database was also searched for any such associations.
The disease-related genes/proteins were categorized as “Already known genes from
the connecting nodes of SPNW”. Based on their biological/molecular role if the genes
are of interest in neurodegenerative disorders then those genes were categorized as
“Genes of interest from the connecting nodes of SPNW”. In later chapters, for easy dis-
tinguishing the network nodes in the figures are highlighted in either red or orange
color for these two categories respectively.
Next, a compact version of shortest-path network (CSPNW) was constructed
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using the genes/proteins listed in all four categories discussed above. Few more
generic genes were added without which some of the genes of interest would re-
main unconnected (not all genes of interest directly interact with previously known
disease related genes). Some genes could be second- or third-level interacting part-
ners to the known genes via intermediary nodes and yet be potentially important to
the disease pathogenesis. The resulted compact shortest-path networks were concise
and yet meaningful to carry out our network analysis of neurodegenerative disor-
ders.
2.4.7 Network topology descriptors
Another criterion for selecting genes/proteins potentially important for neurode-
generative process is their central location in the network built. Pajek is freely avail-
able non-commercial software used for analysis and visualization of large networks
such as Internets, collaboration networks, protein-protein interaction networks etc.
(Batagelj and Mrvar, 1998). The compact shortest-path networks were subjected
to quantitative analysis using Pajek. Network measures such as local connectivity
(i.e., node degree), closeness (network monitors) and betweeness (traffic-influential)
centrality scores were calculated (Estrada, 2011). The mathematical formulae for
various centrality measures are given below.
Node degree ki is defined as the number of connections of node i. It is a basic net-
work connectivity measure, which for an undirected network G = (V, E) is described
as,
ki =
V∑
j=1
ai j
where V is the total number of vertices (nodes), E is the total number of edges, j
represents all other nodes, and the adjacency matrix element ai j is defined as 1 if
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node i is connected to node j, and 0 otherwise.
Closeness centrality CCi is defined as the inverse of the average vertex distance(d).
It can be regarded as a measure of how fast it will take to spread information from
node i to all other nodes in a network sequentially. It can be mathematically ex-
pressed as
CCi =
V − 1
di
where V is the total number of vertices (nodes).
Betweeness centrality BCi is defined by the fraction of all shortest-paths passing
through the vertex. It is a measure of the influence a node has over the spread of
information through the network. It can be described as
BCi =
∑
i
∑
j
ρ(i, k, j)
ρ(i, j)
where ρ(i, j) is the number of shortest-paths from node i to j, and ρ(i, k, j) is the
number of the shortest-paths that pass through node k in the network.
2.4.8 MicroRNA regulatory network (MRN)
A critical moment in understanding complex biological systems (such as diseases) is
to explore underlying molecular mechanisms. Regulatory network is one such way
to describe potential pathways to regulate global gene expression programs in a bio-
logical system. Differential gene expression is achieved through complex regulatory
networks that are controlled in part by two types of regulators: transcription factors
(TFs) and microRNAs (miRNAs). TFs and miRNAs are critical modulators of gene
expression and signaling pathways and provide potential novel targets for under-
standing biological behavior and for therapeutic applications. The main function of
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transcription factors is transcriptional regulation of target genes, whereas miRNAs
are post-transcriptional regulators. Few miRNAs (e.g., miR-133b, miR-7 in Parkin-
son’s) have already been found to be involved in neurodegeneration. This kindled
our interest to explore for microRNA regulation in our seed genes.
First step we ventured out to find miRNAs that would target our seed genes. In
order to identify the microRNAs by employing seed genes we constructed shortest-
path network with only miRNA regulation type interactions using Pathway Studio’s
ResNet 9.0 database. This network revealed the miRNAs that could be of interest in
a given disease type. Secondly, in order to construct regulatory network, we used
the direct interaction network option in Pathway studio utilizing the seed genes and
the corresponding miRNAs (identified in the earlier step). We indeed identified
many microRNA regulations of our seed genes which will be discussed in detail in
the following chapters. The MicroRNA regulatory network (MRN) also revealed
a probable integrated regulation by both transcription factors and microRNAs in
neurodegeneration process. However, our microRNA regulatory analysis should be
offered with some caution, because currently a high percentage of miRNA-targets
interactions in Pathway Studio ResNet 9.0 database are based on predictions instead
of experimental validation, as verified from the references given in this database.
2.5 Step 5. Finding biological relevance in
neurodegenerative disorder networks
Gene Ontology (GO), an expert-curated database, assigns a list of genes into various
biologically meaningful categories such as biological processes, molecular functions,
and cellular components. p-values are used to rank the significantly modulated
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genes into different GO categories. The Database for Annotation, Visualization and
Integrated Discovery (DAVID) (Glynn Dennis et al., 2003; Huang et al., 2009a,b) is
a widely used web-based application focusing on GO classification. It provides bio-
logical functional interpretation of large lists of genes derived from genomic studies
such as microarray, proteomics experiments.
Next step is to evaluate whether the listed genes were part of already well- es-
tablished biological pathways. Tools like Core analysis in Ingenuity’s IPA (Ingenuity
Systems, www.ingenuity.com) and Pathway Enrichment Analysis in Pathway Stu-
dio are widely used to identify enriched canonical pathways in a given list of genes.
The list of seed genes were subjected to both tools in the search for known pathways
to be affected in neurogenerative disorders.
2.6 Step 6. Mechanistic Analysis
The results from DAVID analysis (obtained in Step 5) were examined in an attempt
to characterize the integrated molecular mechanisms involved in neurodegenera-
tion process. In general, the output of DAVID analysis includes those GO categories
(such as biological process, cellular component and molecular functions) along with
KEGG pathways that are enriched in a given list of genes. Kyoto Encyclopedia of
Genes and Genomes (KEGG) “is a database resource for understanding high-level
functions and utilities of the biological system, such as the cell, the organism and
the ecosystem, from molecular-level information, especially large-scale molecular
datasets generated by genome sequencing and other high-throughput experimental
technologies” (available at http://www.genome.jp/kegg/) (Kanehisa and Goto,
2000). The KEGG pathways that were significantly enriched (p-value ≤ 0.05 after
Benjamini-Hochberg FDR adjustments) and previously known in neurodegenerative
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disorders under study were identified and further investigated. Google and NCBI’s
PubMed databases were used to search for such previously known biological path-
ways in neurodegenerative disorders. Later, all the genes from the enriched KEGG
pathways were combined into a list of genes called “mechanism genes”. For each
disease condition, such a “mechanism genes” list was prepared.
Based on their molecular functions we further classified these “mechanism genes”
as either disease causing (leading to neuronal loss/death) or disease alleviating
(helps in neuronal survival) agents. Once again Google and NCBI’s PubMed databases
were used to identify such previous implications. For easy understanding, the loss
versus survival classification is represented by highlighting the “mechanism genes”
in purple or yellow, respectively. Using the “mechanism genes” direct interaction net-
work was constructed as well as investigated for integrated disease mechanism. As
will be shown in the chapters to follow in each of the three diseases investigated we
could outline three possible mechanisms for initiating the disease from an extracel-
lular signaling.
Chapter 3
Parkinson’s Disease Network Analysis
3.1 Introduction
As mentioned in Methods and Data chapter, for our Parkinson’s disease (PD) net-
work analysis we used GSE8397 and GSE20295 microarray gene expression datasets
from NCBI’s GEO database. The GSE8397 microarray dataset was published in 2006
by Moran et al. The data contain 15 cases of neuropathologically confirmed PD and
eight controls. This was the first whole genome expression analysis of the Substantia
nigra (SN). Some of the important findings of this research work were remarkable
quantitative gene expression difference between the Parkinsonian Substantia nigra
and control tissue, reported several new candidate genes which map to PARK loci,
identified 570 “priority genes” after the Benjamini-Hochberg FDR correction. Two
years later, (Moran and Graeber, 2008) published a network-based analysis using
the then Pathway Studio’s ResNet database version 5.0. No effect for sex differ-
ence in Parkinson’s disease has been found in the expression levels and clustering
of probes. Several direct interaction networks has been constructed for the interac-
tions between their priority genes and known-PD genes, as well as for genes related
47
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to Lewy body formations, with nearly 30% of the priority genes remaining uncon-
nected. Cancer, diabetes and inflammation disease conditions have been associated
with the top up-regulated priority genes. Drugs like clozapine, cocaine and haloperi-
dol, which are used in the treatment of PD and cause side effects, have been found
to interact with a large number of PD priority genes.
The second microarray dataset GSE20295 was published by Zhang et al. in 2005.
That research group had highlighted some of the deregulated genes responsible
for either disease aggravation (MKNK2) or neuroprotection (HSBP1, SMA5, and
FGF13). Deregulation was noticed in various genes belonging to metallothionein
group and the heat shock protein group. These patterns of multiple molecular pro-
cess deregulations have been found across different brain regions studied. Another
expression pattern discovered supports the hypothesis for ubiquitin/proteasome sys-
tem (UPS) dysfunction in Parkinson’s disease. A decrease in Complex I activity has
also being found to reinforce the suspected mitochondrial deregulation in PD.
To the best of our knowledge, we present the first molecular level study with
comprehensive network-based analysis of Parkinson’s disease proceeding from the
above mentioned microarray datasets. Helped by the rapidly accumulated new bio-
logical information, advanced ResNet 9.0 database, and a variety of specific network
reconstructions and analyses, we were able to expand upon the previous author’s
analysis of this disease paradigm, and to explore the underlying cellular mechanisms
and molecular players of this disease domain.
3.2 Parkinson’s disease direct interaction network
We initiate our Parkinson’s disease network analysis using the 267 “seed genes”,
selected as explained in Methods and Data. Out of the 267 significantly differentially
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Figure 3.1. Parkinson’s disease direct interaction network. The 15 genes/pro-
teins implicated previously in PD pathology are highlighted in green and the twelve
genes/proteins of potential interest for that disease are highlighted in blue.
expressed genes (SDEGs), 67 genes were directly connected to each other based on
the different interaction types like regulations, promoter binding, direct regulation,
protein modification and microRNA’s regulation. This interaction network (Figure
3.1) has a relatively low average node degree of 2.84. Genes like MAPK8, RAB3A,
STXBP1, SYN1 and VAMP2 are the top five hubs (high connectivity nodes) with
node degree ≥ 7. One of the well-known Parkinson’s gene SNCA (α-synuclein) was
among the top five most influential (betweenness centrality) and highest accessible
(closeness centrality) nodes in the network.
Based on their physiological/molecular role, 15 out of the 67 genes (ACHE, ATR,
CX3CL1, FGFR1, GRIA1, L1CAM, MAPK8, MT1F, MT2A, PRDX2, RAB3A, RNF11,
SNCA, SNCG and SPTAN1), have already been implicated in Parkinson’s disease
paradigm either as neuroprotective and therapeutic agents or as disease aggravat-
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ing ones (see Chapter 1.). In Figure 3.1, these previously PD-known genes are high-
lighted in green.
3.2.1 Molecular functions of proposed candidate genes
Useful information about their characteristic physiological roles has also been found
in the literature, as a preliminary basis for classifying twelve genes (BSN, DCLK1,
KCNQ2, NCAM1, NEDD4L, PAK1, PCDH8, STXBP1, SYN1, UBE2N, UNC13A and
VAMP2) colored in blue in Figure 3.1 as potentially involved in Parkinson’s disease.
The molecular functions of some of these candidate genes are summarized here.
NCAM1 (neural cell adhesion molecule 1) is important in cognitive processes such
as learning and memory. It plays a major role in both body and brain immune
surveillance system (Mirnics et al., 2005). NCAM1 facilitates the release, repo-
sitioning, and/or expansion of the synaptic complex. BSN (bassoon presynaptic
cytomatrix protein), is a scaffolding protein involved in organizing the presynap-
tic cytoskeleton, the specialized sites where neurotransmitters are released from
the synaptic vesicles. (NCBI — Gene website. Retrieved on 25-Feb-2013, from
http://www.ncbi.nlm.nih.gov/gene/8927; updated on 24-Feb-2013). Camp-
bell et al. (2012) have shown that STXBP1 (syntaxin binding protein 1) has a vital
part in the process of calcium ion—dependent exocytosis in neurons, as well as in
neuroendocrine cells. It facilitates membrane fusion and neurotransmitter release.
Additionally, SYN1 (synapsin I) was found to be a key player in synapse forma-
tion and plasticity (Cesca et al., 2010). During an action potential (an important part
of the neuron firing process), synapsins are phosphorylated by PKA (cAMP depen-
dent protein kinase), releasing the synaptic vesicles and allowing them to move to
the membrane and release their neurotransmitter. VAMP2 (vesicle-associated mem-
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brane protein 2), gene is thought to participate in neurotransmitter release at a
step between docking and fusion. A recent study (Diekstra et al., 2012) has shown
that single nucleotide polymorphisms in UNC13A (unc-13 homolog A) gene may
be associated with sporadic amyotrophic lateral sclerosis (ALS). It regulates neuro-
transmitter release at synapses, including at neuromuscular junctions. α-synuclein
were shown to promote disruption of ubiquitin proteasome system (Betarbet et al.,
2005). UBE2N (ubiquitin-conjugating enzyme E2N) targets proteins for degrada-
tion via the proteasome. In recent years, synaptic vesicle trafficking defects have
been increasingly implicated as an important factor in many PD models, either via
direct interactions with the synaptic vesicle (SV) cycling machinery or via indirect
effects caused by mitochondrial dysfunction (Esposito et al., 2012). Even though
genes BSN, NCAM1, STXBP1, SYN1, VAMP2 and UNC13A are not shown to be di-
rectly related to PD, they all seems to play an important role in the regulation as
well as the release of neurotransmitters and synaptic vesicles during the SV cycle
process.
3.2.2 Network attributes of proposed candidate genes
Additional arguments for considering the above mentioned genes as associated with
Parkinson’s disease are provided from network perspective. Figure 3.1 reveals the
direct interacting partners for each candidate gene. For example, BSN, STXBP1,
SYN1, VAMP2, and UNC13A directly interact with RAB3A, a gene well-known in
PD, where RAB3A is able to provide substantial rescue against α-synuclein-induced
degeneration of dopaminergic neurons. Besides with RAB3A, SYN1 is also directly
connected to GRIA1 and SNCA, two known PD genes. Studies have suggested glu-
tamate receptor (GRIA1) antagonists as potential treatment agent for Parkinson’s
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disease (Lai et al., 2003).
In the direct interaction network, potential candidate genes like PAK1 and UBE2N
are among the top five nodes with high closeness (visibility) centrality score. An-
other of the proposed candidate genes SYN1, was among the top five hub nodes as
well as among the top five nodes with highest betweenness (traffic-influential) cen-
trality score. Being a first-level direct interacting neighbors of a known gene (guilt-
by-association), makes also BSN, NCAM1, PAK1, PCDH8, STXBP1, SYN1, UBE2N,
UNC13A or VAMP2 genes of potential interest in Parkinson’s disease. The physio-
logical role these genes play in synaptic vesicle trafficking, neurotransmitter release,
and ubiquitination, as well as their other network attributes like being hubs, network
traffic-influential and/or monitoring nodes, increases the chance of these genes to
be involved in the PD pathology, which reinforces the arguments in favor of their
experimental validation.
3.3 Parkinson’s disease shortest-path network (SPNW)
Based on their number of neighbors (≥ 25) in the Pathway Studio’s ResNet 9.0
database we selected 105 out of the 267 SDEGs for constructing a more compact
shortest-path network (SPNW), the nodes of which would have a higher chance to
be connected to some of the known PD genes. Interaction types included promoter
binding, protein modification and direct regulation. 193 genes were software-added
to connect the 105 seed genes along the shortest-paths between any pair of those.
The connecting genes were examined in sources like OMIM, and NCBI’s PubMed
databases, along with Google search engines to verify whether they have already
been or not implicated in PD. In the second case, whether they could be of poten-
tial interest in PD diagnosis was decided based on the gene’s physiology/molecular
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characteristics and network location (guilt-by-association). In addition to that, we
also analyzed the most highly connected common regulators of SDEGs (discussed in
detail in Chapter 2.) and categorized them as already known and not known but of
potential interest in PD diagnosis.
Table 3.1. Summary of the genes of interest and genes already known in Parkinson’s
disease.
Different categories
Number of
genes
Node color in figure
Genes of interest from SDEGs 16 blue
Known PD genes from SDEGs 15 green
Genes of interest in SPNW connecting nodes 35 orange
Known PD genes in SPNW connecting nodes 21 red
A more compact version of this 267-genes shortest-path type network was con-
structed using the four categories of genes from Table 3.1 and few generic genes
without which some of the genes of interest would remain unconnected. The com-
pact SPNW (see Figure 3.2) is considerably better connected (average node degree
6.79) than the one based on direct interactions. Many of the known PD genes, such
as AKT1, CASP3, CDK5, MAPK1, MAPT and SNCA are highly connected in this com-
pacted network version. CDK5 and MAPK1 are among the ten hub genes (AKT1,
CASP3, CDK5, CREB1, CTNNB1, EGFR, MAPK1, SP1, SRC and TP53) with node de-
gree > 15. In biological networks, highly connected nodes tend to be part of critical
functions or pathways and some of the founded hubs like TP53, MAPK1, AKT1 and
CASP3 being a typical example.
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Figure 3.2. Parkinson’s disease compact shortest path network.The genes/pro-
teins implicated in PD pathology are highlighted in green and red. The genes/pro-
teins of potential interest are highlighted in blue and orange. (see Table 3.1. for
gene highlighting details).
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3.3.1 DAVID enrichment analysis
The nodes included in the network were then subjected to enrichment analysis using
DAVID software tool which systematically maps the given gene list to the associated
biological annotation terms (e.g., GO terms or Pathways). Different statistically sig-
nificantly enriched Gene Ontology categories/subcategories and pathways related
to brain and nervous system (with Benjamini-Hochberg multiple correction) are pre-
sented in Table 3.2.
DAVID analysis identified several clusters of genes involved in neuron develop-
ment, differentiation, projection and apoptosis, synaptic transmission, vesicle trans-
port and regulation as biological processes affected by Parkinson’s disease. Indeed,
many of the enriched genes like CDK5, FGFR1, L1CAM, NR4A2, PRKCA, RAB3A,
RAC1 and SNCA have already been studied as mediators, suppressors or regulators
of neurodegeneration. Pathways such as ErbB signaling and Neurotrophin signal-
ing are enriched in this PD related gene list. Both these pathways were considered
as major players to promote survival of dopaminergic neurons (Sharif and Prevot,
2010). Synaptosomes, axons, and membrane-bounded vesicles are some of the cel-
lular components that are found affected by PD.
3.3.2 IPA analysis
Similar analysis was also carried out using Ingenuity’s IPA software to examine path-
ways that were enriched in our gene list. Many signaling pathways (see Figure
3.3) including 14-3-3 mediated, neuregulin, semaphorin, ephrin, gap-junction, ax-
onal guidance, Huntington’s disease, as well as different growth factor signaling like
EGF, FGF, and NGF, were found to overlap and to be enriched in Parkinson’s disease
pathology. This finding extends over the recent report of (Matigian et al., 2010).
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Figure 3.3. Enriched IPA canonical pathways in Parkinson’s disease.
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Neuregulins along with epidermal growth factors play a diverse role in neuronal
development and as well as differentiation. Systemic administration of neuregulin-
1β1 protects dopaminergic neurons in a mouse model of Parkinson’s disease. (Carls-
son et al., 2011). Semaphorins and ephrins are prominent families of axon guidance
cues during normal nerve growth and also after injury. Previous studies have shown
binding interactions between 14-3-3 proteins, synuclein-alpha and LRRK2 (leucine-
rich repeat protein kinase 2), the genes linked to sporadic and familial form of PD
(Steinacker et al., 2011). It was symptomatic to find out major neurodegenerative
conditions like Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and Hunt-
ington’s disease signaling, to be enriched in Parkinson’s disease conditions as well.
Discovering these overlapping pathways will help to better understand the complex
neurodegenerative diseases mechanism and to search for therapeutic agents com-
mon for the entire family of these diseases.
Table 3.3. Genes of interest for Parkinson’s disease identified by guilt-by-association
with the known PD-related genes.
Genes of Interest
Interacts with
no. of known
PD genes
CTNNB1 10
EGFR 6
PAK1 5
CEBPA, CTNND1, ADAM17 4
CDKN1B, KLF1, ROCK1, SYN1 3
AKT2, BAK1, DNM1, DYRK1A, NF2, TUBB3 2
EIF4E, ITSN1, MECP2, NCAM1, NEDD4L, NOS1AP, RAS-
GRF1, RHOA, STX1A, STXBP1, SYNJ1, UBE2N 1
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3.3.3 Guilt-by-association analysis
Table 3.3 shows the genes of potential interest as determined by being neighbors of
the known PD genes (guilt-by-association). CTNNB1 (catenin, beta 1) has the record
environment of ten (!) nearest neighbors in the compacted shortest-path network
(CSPNW, Figure 3.2) all of which known to be involved in Parkinson’s disease (AKT1,
CASP3, CASP6, CDK5, CREB1, MAPK8, NR4A2, PTEN, RAC1 and SMAD3). This
makes CTNNB1 number one candidate gene of interest. This gene, along with Wnt1
and Fzd-1 critically contributes to the survival and protection of adult midbrain DA
neurons (L’episcopo et al., 2011). In addition, it has a high betweenness centrality
which increases its global influence in the network.
The next strongest candidate for implication with Parkinson’s disease is EGFR
(epidermal growth factor receptor) gene having six PD-related neighbors (CASP3,
CDK5, PRKCA, RNF11 and TP53). It is one of the top ten nodes with highest node
degree, closeness as well as betweenness centrality scores. This greatly contributes
EGFR to be one of the critical positions in the compact shortest-path network with
greater visibility and traffic-control. In general, many studies have shown that EFGR
signaling play a major role in neurogenesis, neuron survival and maintenance (Chen
et al., 2007; Dumstrei et al., 1998; Lillien and Raphael, 2000; Ayuso-Sacido et al.,
2010). In a recent study, EGFR has been suggested as a preferred target treating
amyloid-beta induced memory loss in Alzheimer’s disease (Wang et al., 2012).
Third interesting PD candidate is PAK1 (p21 protein (Cdc42/Rac)-activated ki-
nase 1) gene having five PD-related neighbors (AKT1, CASP3, CDK5, RAC1, and
TP53). PAK1 regulates neuronal polarity, morphology, migration and synaptic func-
tion (Nikolic´, 2008). There are also strong indications that PAK1 is required for nor-
mal cognitive function. The gallery of Parkinson’s disease potentially related genes
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includes also CEBPA (CCAAT/enhancer binding protein (C/EBP), alpha), which in-
teracts with four known PD genes (GATA2, IL12B, MT2A, and TP53). CEBPA has
been shown to bind to the promoter and modulate the expression of leptin, a hor-
mone having easy accessibility to the brain. It is important to note that leptin re-
ceptors are expressed in neurons and other brain regions and are known to regulate
neural development and neuroendocrine functions. Leptin could be a potential drug
candidate for neurodegeneration (Tang, 2008).
3.3.4 Molecular functions and network attributes of some of the
critical connecting genes
The compact shortest-path network included many noteworthy connecting proteins
like APP, CREB1, HSP90AA1, MAPT and PTEN which were previously implicated
to play critical roles in many neurodegeneration disease pathogenesis and cou-
ple of them were indicated to have neuroprotective mechanism. APP (syncluein,
alpha), is the major component of the filamentous inclusions found in the Lewy
bodies and Lewy neuritis, the characteristic hallmark features of many neurode-
generative diseases including Parkinson’s, Alzheimer’s, dementia with Lewy bodies
and multiple system atrophy (MSA). Neurodegenerative diseases caused by these
abnormal aggregations of alpha-syncluein proteins are specially classified as alpha-
synucleinopathies (Galvin et al., 2001; Spillantini and Goedert, 2000; Stefanis, 2012;
O’Brien and Wong, 2011). Similarly, tauopathies are a class of neurodegenera-
tive diseases that are associated with the aberrant accumulations of tau proteins
(MAPT) in the brain. Hyper phosphorylated tau proteins are the main component
of neurofibrillary tangles (NFTs), another typical pathological feature of neurode-
generation. Tau proteins deformation are found in both genetic and sporadic forms
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of Parkinson’s and Alzheimer’s diseases in addition to other neurodegenerative dis-
eases such as progressive supranuclear palsy (PSP), Down’s syndrome, Pick’s disease
(Spillantini and Goedert, 2001; Pittman et al., 2006; Lei et al., 2010; Churcher,
2006). Many molecular evidence suggests potential interaction between alpha-
syncluein and tau proteins (Galpern and Lang, 2006). PTEN gene mutations also
contribute to the NFT formations and the deregulation of tau phosphorylation (Son-
oda et al., 2010; Zhang et al., 2006; Kerr et al., 2006). Detailed biochemical and
genetic studies about APP, MAPT and PTEN molecular processing will be crucial to
the development of therapeutic targets to treat many neurodegenerative diseases.
CREB1 and HSPs were suggested for such therapeutic measures in neurodegen-
erative disorders. In a mice model study (Mantamadiotis et al., 2002), it is indicated
that postnatal disruption of CREB1 along with CREM showed progressive neurode-
generation in the hippocampus and in the dorsolateral striatum. This evidences that
both CREB1 and CREM can promote nerve cell survival globally in developing brain
while more selectively in adult brain. Earlier studies have demonstrated that in-
crease in the expression of HSPs especially HSP70 by gene transfer or HSPs inducers
can reduce the aberrant protein misfolding and inhibit the pro-apoptotic pathway
to attenuate dopaminergic neuron degeneration (Meriin and Sherman, 2005).
Besides being major contributors of neurodegeneration process, APP, CREB1,
HSP90AA1, MAPT and PTEN have varying degree of interactions with many known
Parkinson’s disease genes (see CSPNW, Figure 3.2). Among these five genes, CREB1
appears to have major network advantage as being one of the top ten nodes with
highest local connectivity, visibility and traffic-influential node in the compact shortest-
path network. In addition, genes like APP, MAPT and HSP90AA1 are among the top
25 nodes with highest connectivity and higher accessibility to all other nodes as
measured from their node degree and closeness centrality score. Other genes from
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Table 3.3 might also be investigated for possible relations to Parkinson’s disease,
which are also interacting with many known PD genes.
3.4 Integrated Parkinson’s disease mechanism
Apart from finding important biological players of Parkinson’s disease process, we
continued with our major study goal to trace down the underlying common molec-
ular mechanisms of this disease. In our quest we proceeded from the significantly
enriched KEGG pathways (p-value < 0.05 after Benjamini-Hochberg FDR adjust-
ments) found in DAVID analysis. As described earlier, the genes used to construct the
compact shortest-path network were subjected to DAVID gene set enrichment analy-
sis which includes KEGG pathway classifications. Kyoto Encyclopedia of Genes and
Genomes (KEGG) “is a database resource for understanding high-level functions and
utilities of the biological system, such as the cell, the organism and the ecosystem,
from molecular-level information, especially large-scale molecular datasets gener-
ated by genome sequencing and other high-throughput experimental technologies”
(available at http://www.genome.jp/kegg/) (Kanehisa and Goto, 2000).
3.4.1 KEGG analysis
DAVID analysis revealed many KEGG pathways that were significantly affected in
our PD gene list. After reviewing previous Parkinson’s disease research literature,
we selected 16 out of 34 such KEGG pathways (see Table 3.4 for details) to identify
common molecular mechanisms of PD. The selected pathways belong to KEGG’s
categories of signal transduction, cell motility, cell communication, immune system,
nervous system and neurodegenerative diseases.
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Literature review showed less interest to pathways involved in Parkinson’s dis-
ease but instead revealed many genes/proteins of the individual pathways to be
involved in PD mechanism. Next few lines will explain the molecular functioning
of couple of the genes/proteins of different pathways (listed in Table 3.4) and how
they are related to Parkinson’s disease manifestation. FYN (oncogene related to
SRC, FGR, YES) protein-tyrosine kinase oncogene belongs to focal adhesion path-
way. Previous study (Nakamura et al., 2001) has shown that alpha-synuclein was
phosphorylated by activation of FYN-mediated signaling which might influence the
mobility of synaptic vesicles, neurotransmitter release and axonal transport. VEGF
(vascular endothelial growth factor) molecule, part of the same named signaling
network, is known to promote microglial proliferation, neurogenesis and angiogen-
esis. VEGF was shown to provide neuroprotective effects via both direct and indirect
mechanisms with other players of VEGF signaling pathway (Yasuhara et al., 2004).
Figure 3.4 is our modest attempt to show the essential part of the integrated
Parkinson’s disease mechanism using the 46 genes/proteins found in common in all
the 16 KEGG pathways listed in Table 3.4 Following earlier convention, in Figure 3.4
we have highlighted in green those genes that were already implicated in PD and
in blue the genes that could be of potential interest to Parkinson’s disease. Based
on their molecular functions we further classified the 46 genes as either disease
causing (leading to neuronal loss/death) or disease alleviating (helps in neuronal
survival) agents. This loss versus survival classification is expressed in Figure 3.4
via highlighting the 18 loss causing genes in purple and those 26 genes that helps in
neuron survival in yellow. Due to the high interconnectedness of our biomolecular
network we were unable to see any clear separation between the loss or survival
genes, they are part of a single integrated system. There was a considerable overlap
between the pathways these genes are part of. Visual inspection of the 16 pathways
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Figure 3.4. Integrated Parkinson’s disease mechanism. The 46 genes/proteins
are found in common in all 16 enriched KEGG pathways. Genes/proteins implicated
in PD pathology are highlighted in green/red and the genes/proteins of potential
interest are highlighted in blue/orange (See Table 3.1.) for details.
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in KEGG database also revealed that there is no definite compartmentalization of
different processes within a biological cell. One process/pathway feed into another
or multiple pathways, e.g., WnT signaling pathway includes players from MAPK,
focal adhesion, adherens junction, and Alzheimer’s disease pathways.
3.4.2 Proposed Parkinson’s disease initiation routes
On examining the integrated mechanism network we suspect that the Parkinson’s
disease mechanism could be initiated via one of the three routes triggered by the
extra-cellular ligands namely, CX3CL1, IL12B and SEMA6D. First route is through
fractalkine (CX3CL1) together with DRD1 (dopamine receptor D1) modulates GRIA1
gene expression. There is also interaction between CX3CL1, ADAM17 (metallopepti-
dase domain 17), and LCAM1 which then follow a downstream path into cytoplasm
and finally to the nucleus for further regulation of gene expression. CX3CL1 lies
upstream to and its gene expression is positively activated by ADAM17 and TP53
genes/proteins. As mentioned earlier, fractalkine suppresses microglial activation
which contributes to neuronal survival. Studies have shown that ADAM17 medi-
ated fractalkine cleavage would ultimately limit activation of microglia and sup-
port neuronal survival (Zujovic et al., 2000). There is two-way opposing gene ex-
pression modulation between CX3CL1 and SRC. Inside the cytoplasm AKTI, CASP3,
MAPK1, MAPK8 genes/proteins are the direct (first-level) downstream targets of
CX3CL1. Except GRIA1 and CASP3, all other downstream target genes of CX3CL1
are positively activated by CX3CL1. Many animal PD model studies have shown that
ADAM17, CX3CL1, DRD1, GRIA1, and LCAM1 genes could be therapeutic targets
for Parkinson’s disease (Benarroch, 2012; Cui et al., 2010; Johnson et al., 2009;
Pabon et al., 2011).
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Second route is initiated via SEMA6D and its receptor PLXNA1 (plexin A1) which
in turn regulates RHOA and AKT1 gene expression inside the cytoplasm. SEMA6D,
the upstream target of PLXNA1 was negatively modulated. Inside cytoplasm MAPK1
gene expression was negatively modulated by SEMA6D thereby controlling the down-
stream activity of MAPK1. Apart from SEMA6D modulation, CAPN1 (calpain 1,
(mu/I) large subunit) negatively regulates the expression of both PLXNA1 and SNCA
in so doing CAPN1 can modulate PLXNA1 and SNCA’s downstream actions inside
the cytoplasm. Semaphorins, secreted proteins involved in the guidance of neu-
ronal and nonneuronal cells, interact with receptor complexes formed by plexins
and neuropilins. Earlier studies have shown semaphorins along with their receptors
to promote or guide neuronal axon projection as therapeutic approaches for treat-
ment of Parkinson’s disease (Majed et al., 2006; Tamariz et al., 2010). Studies in
rodent and cell culture models of PD suggest that treatment with calpain inhibitors
can prevent neuronal death and restore functions thus suggesting that calpain inhi-
bition could be a therapeutic strategy in PD (Samantaray et al., 2008).
Third route of the proposed integrated Parkisnon’s disease mechanism takes
place via another extra-cellular ligand IL12B (interleukin 12B) which lies upstream
to MAP kinases, RAC1 and AKT1 that are present inside the cytoplasm, and all
these genes negatively regulate the gene expression of IL12B. Many studies have
suggested that neuroinflammation and activated microglia contribute to neurode-
generative processes. Studies have indicated that interleukins help in differentiation
and survival of neuronal cells that were stressed out by activated microglial actions
(Müller et al., 1998; Rentzos et al., 2009).
Thus, from the integrated disease mechanism network we propose three routes
to enhance the survival of the dopaminergic neurons, which could be a source for
potential therapeutic targets in Parkinson’s disease.
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3.5 Parkinson’s diseasemicroRNA regulatory network
3.5.1 Construction of PD microRNA network
A shortest-path network (SPNW) was constructed using all the 267 seed genes/pro-
teins with only microRNA (miRNA) interactions from the ResNet 9.0 database in
Pathway Studio software. This allowed identifying 71 regulatory miRNAs, which
were used to create a smaller size regulatory network having only direct microRNA-
target interactions (see Figure 3.5).
Table 3.5. Genes of interest determined from Parkinson’s disease microRNA regu-
latory network
Genes of Interest Targeted by no. of miRNAs
RIMS3, SEMA6D, SYNJ1 7
PCDH8 6
AQP11, VAMP2 5
DCLK1, PAK1 4
BSN, NCAMP1, STXBP1, UBE2N 3
CACNA1G, GLS, NEDD4L 2
ACACB, KCNQ2 1
Table 3.5 shows the genes of interest in the MicroRNA Regulatory Network (MRN)
and how many miRNAs are targeting each gene’s mRNA. In the regulatory network
(Figure 3.5), miR-218-1 is found to be the top player regulating the expression of
16 genes of which three (PCDH8, RIMS3 and STXBP1) are potential genes of in-
terest to Parkinson’s disease. In animal model study, it was shown that miR-218-1
is expressed in hippocampus (Bak et al., 2008) and also through a volumetric MRI
imaging study it was implicated that there is a progressive hippocampal volume loss
in PD human subjects (Camicioli et al., 2003).
Other microRNAs like miR-29a, miR-132, miR-133a1, miR-182, and miR-330
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Figure 3.5. Parkinson’s disease miRNA regulatory network.The genes/pro-
teins and microRNAs implicated in PD pathology are highlighted in green and the
genes/proteins of potential interest are highlighted in blue. Genes/proteins that
code for transcription factors (TFs) are highlighted in yellow.
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were found to regulate the expression of the known Parkinson’s related genes ACHE,
CX3CL1, FGFR1, L1CAM, and SPTAN1. Being direct interacting partners with known
PD-related genes these miRNAs could make them potential regulatory targets in un-
derstanding Parkinson’s disease mechanism.
3.5.2 Some of the well-known miRNAs in PD
The microRNA regulatory network also incorporates some of the already implicated
miRNA’s (miR-133b, miR-153, miR-34c, miR-7 and miR-let-7) mediated translation
regulations that are relevant to PD pathophysiology. Studies (Harraz et al., 2011;
Miñones Moyano et al., 2011; Mouradian, 2012) have shown that the gene expres-
sion of DJ1, PARKIN, PITX3, and SNCA were targeted by these miRNAs. These genes
were shown to regulate dopaminergic neuron differentiation and activity, oxidative
stress mediated cell death, and mitochondrial energy production dynamics, all of
which are widely accepted as part of the PD molecular mechanisms.
3.5.3 Highly targeted genes of interest in PD
On further examination, microRNA regulatory network revealed that the expres-
sion of candidate genes like RIMS3, SEMA6D and SYNJ1 was tightly regulated by
multiple miRNAs. RIMS3 (regulating synaptic membrane exocytosis 3) and other
RIM family members are generally believed to be RAB3 isoforms (RAB3A/B/C/D)-
specific effectors that regulate synaptic vesicle exocytosis in neurons and in some
endocrine cells (Simunovic et al., 2009). Release and re-uptake of neurotransmit-
ters in the synaptic junction is a highly coordinated process and RIMS3, and RAB3A
along with other proteins play an important role during neurotransmitter release.
Extra-cellular ligand SEMA6D was proposed as one of three initiators involved
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in integrated Parkinson’s disease mechanism network (see Figure 3.4). In general,
semaphorins act as axonal growth cone guidance molecules and the miRNA regula-
tory network revealed that SEMA6D gene expression was regulated by seven miR-
NAs (miR-124-1, miR-128-1, miR-16-1, miR-19a, miR-23b, miR-30a and miR-9).
Previous studies have shown various miRNAs in the development and propagation
of Alzheimer’s disease neuropathology. Especially miR-124-1, miR-128-1 and miR-9
were found altered in abundance in fetal, adult and Alzheimer hippocampus where
miR-9 and miR-124-1 are brain-specific and miR-128 is brain-enriched microRNAs
(Lukiw, 2007). It is of interest to mention that many of the microRNAs that were
listed above to regulate SEMA6D in the miRNA regulatory network have been previ-
ously implicated in Alzheimer’s, which show protein accumulation neuropathology
similar to Parkinson’s disease. This is one more sign for the existence of common
regulatory mechanisms in neurodegenerative diseases.
Another highly microRNA-regulated gene is SYNJ1 (synaptojanin 1) (see Table
3.5), a polyphosphoinositide phosphatase found enriched in the brain and located
at nerve terminals, as well as associated with synaptic vesicles and coated endo-
cytic intermediates. Synaptojanins were suggested to accelerate the synaptic vesi-
cle recovery/trafficking process at the synapse (Harris et al., 2000). Dysfunction
of synaptic transmission and membrane trafficking are implicated in PD. Based on
its molecular function, SYNJ1 could be of potential interest in Parkinson’s disease
molecular mechanism.
In addition to miRNA mediated regulation, the network also included four genes
AFF1, ATF7IP, ATOH8 and TBC1D2B that encode for transcription factors (TFs).
These significantly differentially expressed TFs indicate a possible integrated regu-
lation of the transcription of Parkinson’s related genes. The microRNA analysis in
this section should be taken with some caution, because currently a considerable
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percentage of miRNA-target interactions in ResNet 9.0 database are based on pre-
dictions but not on experimental validation.
3.6 Summary
The microarray expression data used in our study were a combination of data pro-
duced and interpreted by different authors (Moran et al., 2006; Zhang et al., 2005)
and referring to different regions of brain. Aiming at a search for a common molec-
ular mechanism for neurodegenerative diseases, we renormalized the data for a
better comparability. Then, a number of specific biomolecular networks were built
and analyzed in a variety of ways. As a result, while confirming some of the pre-
vious finding, including part of the novel predicted Parkinson’s genes, more such
PD-related genes were proposed in this chapter based on guilt by association anal-
ysis and accounting for the importance of certain nodes in network topology.
As well known, the guilt-by-association approach is based on analysis of the
nearest network neighborhood of genes with proved function in the search of in-
terest. Many Parkinson’s disease genes were found in the OMIM database, such as
LRRK2, PARK2, PARK7, PLA2G6, PINK1, SNCA, and UCHL1. However, our list of
significantly differentially expressed genes did not include any of these genes except
SNCA. We found that the log fold-change of PARK2, PARK7 and PLA2G6 was only
around 0.03, which was not significant enough to detect changes in gene expres-
sion. Even though PINK1 and UCHL1 were significantly differentially expressed in
some brain tissue types (both in medial Substantia nigra, while UCHL1 also in lateral
Substantia nigra) they did not qualify for our “seed genes” list used to construct the
PD networks since they were not found significantly differentially expressed in all
Parkinson’s disease datasets. Affymetrix HG-U133A GeneChip did not have probe
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for LRRK2 gene but instead included LRRK1 gene probe. Again, LRRK1 did not
meet the criteria for “seed genes” list since it did not show strong differential gene
expression and its log fold-change was also only around 0.03. While the lack of
statistically significant presence of the above mentioned PD-related genes could be
attributed to the loss of expression intensity in the post-mortem brain samples com-
pared to a functioning brain, in this study we focused our attention mainly to the
genes showing considerable change in the Parkinson’s disease samples.
Despite the reduced base of known PD-genes needed for the guilt-by-association
predictions we were able to identify from our direct interaction network BSN, NCAM1,
PAK1, PCHD8, STXBP1, SYN1, UBE2N, UNC13A and VAMP2 as novel Parkinson’s
disease candidate genes. Second-level interacting partners generally have much
lesser chance to be included in the list of candidate genes. However, this chance
increases when the gene is known to show certain functions that may be related
to the disease of interest. Such is the case with DCLK1 gene via its role in synap-
tic plasticity and neurodevelopment. Another group of novel PD gene candidates
was found from similar analysis of the shortest path network. Such is the case with
NEDD4L, SYNJ1, TUBB3 as direct partners and ACACB, CACNA1G, KCNQ2, and
SEMA6D as second-level partners to already known PD genes. All 17 genes listed
here are significantly differentially expressed in PD.
Our network analysis indicated that apart from the strongly differentially ex-
pressed genes some connecting genes/proteins from the shortest path networks could
be of similar importance in the deregulation of the disease mechanisms. Consider-
ing such connecting genes/proteins via their guilt by associations to already known
PD genes we concluded that CTNNB1, EGFR, ADAM17, CEBPA, CTNND1, CDKN1B,
KLF1, ROCK1 and TIAM1 could also be genes of potential interest in Parkinson’s
disease realm. Some of the genes of this list were found to play an important role
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in network topology. Thus, CTNNB1 and EGFR are among the top ten highly con-
nected nodes (with degree > 15), among the top ten nodes with higher accessibility
to all other nodes as assessed by the closeness centrality, and among the top ten
traffic influential nodes in the network as judged by their betweenness centrality.
Genes like ADAM17, CEBPA and CTNND1 are among the top 25 high connectiv-
ity nodes (with degree ≥ 8) and also among the top 25 traffic-influential nodes in
the network. Besides helping in identifying novel PD-related genes, the same line
of network analysis has shown that APP, MAPT and PTEN, well-known contribu-
tors of many other neurodegenerative diseases including Alzheimer’s, MSA, Pick’s,
PSPs etc., are important connecting genes/proteins in the Parkinson’s shortest path
network. Finding such genes with common role in neurodegeneration process rein-
forces our study goal.
In addition to the numerous miRNAs already known to affect the expression of
PD-relevant genes (Harraz et al., 2011; Miñones Moyano et al., 2011; Mouradian,
2012) we added another seven. With caution because some of their regulatory in-
teractions are not yet validated, we predict that miR-132, miR-133a1, miR-181-1,
miR-182, miR-218-1, miR-29a, and miR-330 could be potential regulators in Parkin-
son’s disease mechanisms, due to their direct interaction with known PD related
genes. Further investigation of the above mentioned miRNA-related regulatory in-
teractions of candidate and known PD-genes would deepen our understanding of
the molecular mechanisms of complex diseases like Parkinson’s. Examining the mi-
croRNA regulatory network, one may conclude that disease pathogenesis is complex
enough to be explained not only from protein-coding genes, but also via regulatory
mechanisms mediated by the small non-coding microRNAs.
All genes listed in this summary were shown through gene set enrichment anal-
ysis to be key players in various cellular mechanisms like neuron development and
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differentiation, synaptic transmission, vesicle transport and endocytosis, apoptosis,
and memory/learning, which are altered in the underlying Parkinson’s pathophysi-
ology and potential compensatory responses. Moreover, enrichment of Alzheimer’s,
ALS and Huntington’s disease signaling pathway was found to be also affected in
PD brains. This supports our hypothesis for the presence of an underlying com-
mon mechanism for all neurodegenerative diseases. More evidence in favor of our
hypothesis along this line is presented in the next chapters.
In the final stage of our systems biology approach to Parkinson’s disease we used
the 16 KEGG pathways found enriched by DAVID analysis to build an integrated
mechanistic Parkinson’s disease network containing 46 genes. We propose on this
basis three routes of PD molecular mechanisms proceeding from signaling initiated
via the extra-cellular ligands CX3CL1, SEMA6D and IL12B. Further analysis of these
routes could reveal novel therapeutic targets for Parkinson’s disease. However, the
above findings could be considered as the tip of the iceberg in understanding the
intertwined nature of these complex neurodegenerative diseases.
Chapter 4
Alzheimer’s Disease Network Analysis
4.1 Introduction
Brain tissue samples usually consist of diverse cell types. We need to isolate individ-
ual cell types from a heterogeneous tissue sample in order to understand its specific
role in a disease mechanism. One such technique is laser capture microdissection
(LCM). Neurofibrillary tangles (NFTs) constitute one of the cardinal histopathologi-
cal features of Alzheimer’s disease. Earlier research work by Dunckley et al. in 2006
(GEO dataset GSE4757) claims that LCM can be utilized in a wide range of neurode-
generative diseases to isolate and characterize specific pathologically affected cell
types. The method provides valuable new information about the gene dysregulation
that occurs during disease pathogenesis. Applying LCM, Dunkley et al. proposed
three AD candidate genes APOJ, TIMP3 and IRAK1 which were up-regulated and
co-localized to NFTs. All three genes were shown to promote NFT formation and
neuronal cell death in AD.
In our study we used the above mentioned gene expression dataset along with
GSE28146 published by Blalock et al. in 2011. The latter study provided strong
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reciprocal validation for two technically dissimilar microarray analyses (using LCM
and heterogeneous tissue sample) of Alzheimer’s disease. The authors report that
LCM had uniquely identified previously undetected alterations in AD, including up-
regulated vasculature development, as well as down-regulation of genes important
for stabilization of ryanodine receptor-related intracellular Ca2+ release. Through
DAVID analysis of the GSE28146 dataset we also observed vasculature development
pathway to be affected in Alzheimer’s disease.
For Alzheimer’s disease (AD) network analysis we used 214 “seed genes” from
GSE4757 and GSE28146 microarray gene expression datasets (see Methods and
Data chapter for details). To the extent of our knowledge, this is the first study
to implement network-based analysis of Alzheimer’s disease using the above men-
tioned microarray datasets. We constructed various types of network to identify
critical molecular players and mechanisms involved in AD.
4.2 Alzheimer’s disease direct interaction network
We found 214 significantly differentially expressed genes (SDEGs), of which 48
genes were directly connected to each other based on the different interaction types
like regulations, promoter binding, direct regulation, protein modification and mi-
croRNA’s regulation. This interaction network (Figure 4.1) has an average node
degree of 2.20 with BCL6, DCN, JAK2, PECAM1 and SMAD3 as top five hub genes.
Some of these hub genes (BCL6, DCN and SMAD3) along with C1QA and PSEN1
(a well-known gene to cause familial early-onset of AD) have high betweenness
centrality score which position them among the top influential nodes in the net-
work. 14 out of 48 SDEGs (CDK5R1, DCN, GRIN2A, HSPB2, ICAM2, JAK2, LMO4,
NEFL, NEFM, PECAM1, PSEN1, SMAD3, SYN1 and TGFBI) are already associated
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Figure 4.1. Alzheimer’s disease direct interaction network. The 14 genes/pro-
teins implicated in AD pathology are highlighted in green and the three genes/pro-
teins of potential interest for that disease are highlighted in blue.
in Alzheimer’s disease pathology (see Chapter 1). On the basis of their biological
functions an additional three genes (CAMK4, CSF1R and GAB1) from our SDEG
set could be considered as potentially related to AD mechanism. See Figure 4.1 for
details about known and potential novel genes/proteins related to AD.
4.2.1 Molecular functions of some well-known and candidate
genes
Figure 4.1 illustrates the well-connected direct interactions among many genes that
contribute to the neurodegeneration process in Alzheimer’s disease. The direct asso-
ciation of GRIN2A, NEFM, NEFL and SYN1 with CDK5R1, an activator of CDK5 that
leads to the accumulation of aberrantly phosphorylated protein tau, contributes to
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Alzheimer’s disease. CDK5R1 is in turn has a first level network interaction with
a well-known early onset familial AD mutant gene PSEN1. Regional alteration and
reduced expression of GRIN2A, NEFL, NEFM and SYN1 were thought to influence to
the severity of Alzheimer’s disease (Tsang et al., 2008; Qin et al., 2004; Pollak et al.,
2003). In addition, CAMK4 and GAB1 could be considered as candidate genes, due
to their direct associations with JAK2, PECAM1 and LMO4, already known AD genes.
Besides, the native biomolecular functions of these genes are noteworthy. They
could be potential neuroprotective agents in Alzheimer’s disease domain. CAMK4
phosphorylation of CREB/CRE and the subsequent CRE-mediated gene expression
in the neuronal nucleus plays an important role in the consolidation/retention of
hippocampus-dependent long-term memory formation. Disruption of this balanced
pathway was suspected to cause impairments in both long-term potentiation and
memory formation (Kang et al., 2001). Moreover, CAMK4 being part of Wnt signal-
ing pathway, could have a pertinent role in Wnt-mediated neuroprotection against
amyloid-beta accumulation in AD (Inestrosa and Toledo, 2008).
There is growing evidence that oxidative stress is involved in the pathogenesis
of most of the neurodegenerative disorders, including AD (Christen, 2000; Emerit
et al., 2004; Jellinger, 2010; Gil and Rego, 2008; Jellinger, 2009; Klein and Schloss-
macher, 2006). GAB1 has been identified as an important component in oxida-
tive stress signaling and influencing the cell survival (Holgado-Madruga and Wong,
2003). Although CSFIR (colony stimulating factor 1 receptor) is a second-level in-
teracting partner to AD known gene, based on its intrinsic neuroprotective function,
it could also be a potential gene of interest in Alzheimer’s disease condition. In a
recent study, CSF1R depleted mice show increased neuronal loss after injury and
vice versa. Its ligands CSF1 and IL34 exhibit neuroprotection against excitotoxicity
induced by neurodegeneration (Luo et al., 2013). Up-regulation of CSF1R could
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play potential role in neuronal survival after injury and degeneration.
With their innate physiological roles as well as being direct interacting partners
(guilt-by-association) to already known AD genes increases the chances of the three
genes as novel candidate genes for Alzheimer’s disease.
4.3 Alzheimer’s disease shortest-path network
Using Ariadne’s Pathway Studio software a shortest-path network (SPNW) was built
with 96 Alzheimer’s disease SDEGs. Interaction types included in this network were
promoter binding, protein modification and direct regulation. These 96 out of 214
SDEGs were selected on the basis of their number of neighbors (≥ 25) in the Path-
way Studio’s ResNet 9.0 database. 131 genes were software-added to connect the
96 seed genes along the shortest-paths between any pair of those. Following our
categorization technique (discussed in detail in Chapter 2.), the 96 SDEGs along
with the 131 software-added connecting genes were classified into the genes that
were already related to AD and the genes that could be of potential interest in AD
diagnosis and medical treatment. Table 4.1 summarizes the different categories and
the corresponding numbers of genes in each.
Table 4.1. Summary of the genes of interest and genes already known in Alzheimer’s
disease.
Different categories
Number of
genes
Node color in figure
Genes of interest from SDEGs 5 blue
Known AD genes from SDEGs 17 green
Genes of interest in SPNW connecting nodes 24 orange
Known AD genes in SPNW connecting nodes 26 red
Utilizing all genes in Table 4.1, along with few additional genes without which
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some of the genes of interest would remain unconnected, a more compact version
of the 214-genes shortest-path network was constructed. Compared with direct in-
teraction network this compact SPNW was better connected with an average node
degree of 8.81 and genes like CREB1, MAPK1, JUN, SP1 and TP53 as highly con-
nected nodes (hubs). In this network, we found 24 such genes with node degree
> 10. Many of these hub genes were also the nodes with high closeness (better
accessibility) and betweenness (traffic-influential) centrality scores in this compact
SPNW. Figure 4.2 illustrates the interactions between the known and the genes of
interest in the AD compact SPNW.
Table 4.2. Genes of interest for Alzheimer’s disease identified by guilt-by-association
with the known AD-related genes.
Genes of Interest
Interacts with
no. of known-
AD genes
SRC 13
MDM2 11
NRF1 5
CAMK4, ESRRA, PTK2B, SRF 4
CR2, NOX4 2
CHRM3, CSF1R, HEY2, IL3 1
4.3.1 Guilt-by-association analysis
Here we show that some genes listed in Table 4.2 could be of potential interest in
Alzheimer’s disease due to their immediate proximity (guilt-by-association) to some
of the already known AD-genes.
Even though the tyrosine kinase SRC (v-src sarcoma (Schmidt-Ruppin A-2) vi-
ral oncogene homolog (avian)) is a very generic gene/protein, which controls a
wide variety of processes, pathways, and actions, and is responsible for key events
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Figure 4.2. Alzheimer’s disease compact shortest path network.The genes/pro-
teins implicated in AD pathology are highlighted in green and red. The genes/pro-
teins of potential interest are highlighted in blue and orange. (see Table 4.1. for
gene highlighting details).
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in the body, we found it to be the first-level neighbor to 13 (!) already known
Alzheimer’s disease genes (ADRBK1, AR, CASP3, CDH1, JAK2, JUN, NFE2L2, NOS1,
PECAM1, SP1, STAT1, STAT3 and VAV1). This association with many known AD
genes makes SRC a strong candidate for a role in Alzheimer’s pathology. Moreover,
it has been demonstrated that accumulation of amyloid-beta stimulates microglial
(macrophages of brain) activation via SRC tyrosine kinase pathway. Murine AD
model study has shown that a cancer drug named Dasatinib could inhibit SRC tyro-
sine kinase activity of microgliosis in the AD diseased brains. Decreased microglial
activity was correlated with improved cognitive performance in mouse (Dhawan
and Combs, 2012). Cell culture study also suggests that SRC tyrosine kinase inhibi-
tion shows promising route in mitigating the effects of amyloid-beta accumulation
in brains which could be tested in human Alzheimer’s disease brains (Zambrano
et al., 2004).
Based on its high proximity to AD related genes, our next candidate gene of in-
terest is MDM2; it is directly connected to eleven already known Alzheimer’s disease
genes. MDM2 (p53 E3 ubiquitin protein ligase homolog (mouse)) has E3 ubiquitin
ligase activity, which targets tumor suppressor protein p53 for proteasomal degra-
dation. It has been shown that amyloid-β signaling pathway disrupts biochemi-
cal pathways involving lipid metabolism, ultimately affecting tau phosphorylation
which contributes to AD (Di Paolo and Kim, 2011). Perturbation of lipid metabolism,
especially of cholesterol homeostasis, has been illustrated in a another severe pro-
gressive neurodegeneration called Niemann-Pick Type C (NPC) disease (Qin et al.,
2010). NPC has often been used as a model system to study AD pathology, since
both share several features, including neurofibrillary tangles, autophagic/lysosomal
dysfunction, inflammation, and cholesterol metabolism abnormalities. In a mouse
NPC model, it has been demonstrated that cholesterol perturbation-induced axonal
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growth cone collapse and decrease in phosphorylated p53 were reduced by inhibi-
tion of MAPK and MDM2 E3 ligase. Due to its inhibitory role in neurodegeneration
and also neighboring with many previously implicated AD genes marks MDM2 as a
potential gene of considerable interest.
Another proposed candidate gene is NRF1; it neighbors with five (CREB1, ESR1,
NFE2L2, NOS1 and TP53) genes that are related to Alzheimer’s disease mechanism.
One of the distinctive characteristic features of several neurodegenerative diseases
is the aberrant accumulation of protein (like α-synuclein, amyloid-β) aggregations.
This protein buildup leads to mitochondrial dysfunction which eventually increases
the ROS production in the brain (Jomova et al., 2010; Emerit et al., 2004). Both
NRF1 and NRF2 are transcription factors that play a pivotal role in the protection
against the toxic effects of reactive oxygen species (ROS). Studies have suggested
that NRF1 and NRF2 promote mitochondrial biogenesis as well as play crucial role
in neuronal survival after acute brain injury. (Dhar et al., 2008; Hertel et al., 2002).
4.3.2 Molecular functions and network attributes of some of the
critical connecting genes
The compact shortest-path network included many significant connecting proteins
like APP, BACE1, CCNA2, CREB1, E2F1 and EGR1 which were previously impli-
cated to play critical roles in many neurodegeneration disease pathogenesis includ-
ing Alzheimer’s. Abnormal proliferation of APP is the major contributor of the neu-
rodegeneration process in AD. Pathogenic alterations of BACE1, CCNA2, CREB1,
E2F1 and EGR1 are evident in the disease progression. BACE1 initiates the amyloid-
beta formation (Cole and Vassar, 2007). In general, cyclins (CCNA2) were shown
to increase the severity of Alzheimer-related pathology and other types of dementia
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(Smith et al., 1999). In addition, cyclins are regulators of CDK kinases. It has been
indicated that APP and tau, the major two proteins implicated in AD, are the physio-
logical substrates for cyclin-dependent kinase especially by a neuron-specific cyclin
kinase called CDK5 (Iijima et al., 2000). Similarly, E2F1 were found co-localized
with amyloid-beta plaques. It may ultimately contribute to neuronal cell death in
AD (Jordan-Sciutto et al., 2002). CREB1 along with CREM were suggested to play
major therapeutic role in neurodegeneration (Mantamadiotis et al., 2002).
Apart from having pivotal in neurodegeneration mechanism, the above men-
tioned connecting genes interact with many previously known-AD genes. Except
BACE1, all other genes are among the top 30 nodes with highest connectivity (de-
gree > 8) in the compact shortest-path network. CREB1 turns out to be one of
the critical nodes in the network. It has many advantages being one of the top five
highly connected nodes, having better visibility as measured the closeness centrality
as well as by its capacity to control the flow of traffic within the network as assessed
by the betweenness centrality. Thus, due to their favorable network centrality and
neighborhood connectivity, as well as by their physiological roles, the genes listed
in Table 4.2 are our suggestions for candidate genes in Alzheimer’s disease, which
would require experimental validation.
4.3.3 DAVID enrichment analysis
Apart from individual gene assessment, we also carried out gene set enrichment
analysis using DAVID software tool to identify different biological processes and/or
pathways affected in Alzheimer’s disease. Table 4.3 lists some of the Gene Ontology
categories/subcategories related to nervous system and functions that were statisti-
cally significantly enriched in AD (with Benjamini-Hochberg multiple correction).
CHAPTER 4. ALZHEIMER’S DISEASE NETWORK ANALYSIS 86
Ta
bl
e
4.
3.
G
en
e
se
t
D
AV
ID
en
ri
ch
m
en
t
an
al
ys
is
of
A
lz
he
im
er
’s
di
se
as
e
co
m
pa
ct
sh
or
te
st
-p
at
h
ne
tw
or
k.
C
at
eg
or
y
Te
rm
G
en
e
co
un
t
Fo
ld
En
ri
ch
m
en
t
B
en
ja
m
in
i
G
O
TE
R
M
_C
C
_F
AT
G
O
:0
04
30
05
ne
ur
on
pr
oj
ec
ti
on
15
8.
37
1.
58
E-
07
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
75
68
ag
in
g
8
13
.4
8
8.
02
E-
05
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
04
35
23
re
gu
la
ti
on
of
ne
ur
on
ap
op
to
si
s
7
14
.4
1
2.
76
E-
04
G
O
TE
R
M
_C
C
_F
AT
G
O
:0
03
04
25
de
nd
ri
te
8
9.
36
3.
87
E-
04
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
03
01
82
ne
ur
on
di
ff
er
en
ti
at
io
n
12
5.
08
5.
43
E-
04
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
71
69
tr
an
sm
em
br
an
e
re
ce
pt
or
pr
ot
ei
n
ty
ro
si
ne
ki
na
se
si
gn
al
in
g
pa
th
w
ay
9
7.
45
6.
43
E-
04
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
69
79
re
sp
on
se
to
ox
id
at
iv
e
st
re
ss
8
9.
04
6.
66
E-
04
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
04
23
25
re
gu
la
ti
on
of
ph
os
ph
or
yl
at
io
n
12
4.
77
8.
15
E-
04
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
19
44
va
sc
ul
at
ur
e
de
ve
lo
pm
en
t
9
6.
64
0.
00
1
G
O
TE
R
M
_C
C
_F
AT
G
O
:0
04
52
02
sy
na
ps
e
10
5.
37
0.
00
1
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
04
86
66
ne
ur
on
de
ve
lo
pm
en
t
10
5.
47
0.
00
2
G
O
TE
R
M
_C
C
_F
AT
G
O
:0
03
15
94
ne
ur
om
us
cu
la
r
ju
nc
ti
on
4
34
.6
9
0.
00
2
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
76
11
le
ar
ni
ng
or
m
em
or
y
6
10
.0
2
0.
00
5
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
03
11
75
ne
ur
on
pr
oj
ec
ti
on
de
ve
lo
pm
en
t
8
5.
79
0.
00
6
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
86
37
ap
op
to
ti
c
m
it
oc
ho
nd
ri
al
ch
an
ge
s
4
23
.9
1
0.
00
8
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
03
02
re
sp
on
se
to
re
ac
ti
ve
ox
yg
en
sp
ec
ie
s
5
12
.3
5
0.
00
9
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
70
05
m
it
oc
ho
nd
ri
on
or
ga
ni
za
ti
on
6
8.
06
0.
01
0
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
03
52
35
io
no
tr
op
ic
gl
ut
am
at
e
re
ce
pt
or
si
gn
al
in
g
pa
th
w
ay
3
61
.7
7
0.
01
1
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
72
68
sy
na
pt
ic
tr
an
sm
is
si
on
8
4.
97
0.
01
1
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
72
59
JA
K-
ST
AT
ca
sc
ad
e
4
19
.0
1
0.
01
3
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
01
92
26
tr
an
sm
is
si
on
of
ne
rv
e
im
pu
ls
e
8
4.
24
0.
02
4
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
74
09
ax
on
og
en
es
is
6
5.
76
0.
03
2
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
00
80
88
ax
on
ca
rg
o
tr
an
sp
or
t
3
30
.8
9
0.
03
5
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
05
08
77
ne
ur
ol
og
ic
al
sy
st
em
pr
oc
es
s
15
2.
30
0.
03
6
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
05
14
02
ne
ur
on
ap
op
to
si
s
3
29
.2
6
0.
03
8
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
04
86
67
ce
ll
m
or
ph
og
en
es
is
in
vo
lv
ed
in
ne
ur
on
di
ff
er
en
ti
at
io
n
6
5.
32
0.
04
2
G
O
TE
R
M
_B
P_
FA
T
G
O
:0
04
88
12
ne
ur
on
pr
oj
ec
ti
on
m
or
ph
og
en
es
is
6
5.
22
0.
04
5
CHAPTER 4. ALZHEIMER’S DISEASE NETWORK ANALYSIS 87
DAVID analysis revealed (see Table 4.3) some of the biological processes like
oxidative stress, neuron apoptosis, tyrosine kinase signaling pathway, regulation of
phosphorylation and aging affected in Alzheimer’s disease, which were also dis-
cussed above as part of AD mechanisms. It is valuable to note that the ALS path-
way, characterizing another debilitating neurodegenerative condition called Amy-
otrophic lateral sclerosis, was also enriched among Alzheimer’s disease genes. En-
richment of ALS disease pathway along with Huntington’s disease pathway was re-
ported by Ingenuity’s IPA analysis. One more promising step towards our study goal
of identifying and reporting common genes and pathways in major neurodegenera-
tive disorders is achieved.
4.4 Integrated Alzheimer’s disease mechanism
The results of DAVID analysis were further evaluated in an attempt to elucidate
details of the underlying molecular mechanism of Alzheimer’s disease. DAVID anal-
ysis revealed twelve KEGG pathways that were significantly (p-value <0.05 with
Benjamini-Hochberg multiple correction) affected in AD. The pathways were found
to take part in signal transduction, immune system, cell communications, nervous
system and in general neurodegenerative diseases categories. The pathways clas-
sification was helped by previous Alzheimer’s disease research literature reviews
(Agadjanyan et al., 2005; Arikkath and Reichardt, 2008; Auffret et al., 2010; Chao
et al., 2006; Chaudhury et al., 2003; Chen et al., 2000; Das and Golde, 2006; Matt-
son and Chan, 2003; Puglielli, 2008; Solerte et al., 1998; Town et al., 2008; Xia and
Hyman, 1999). The genes from the enriched KEGG pathways (listed in Table 4.4)
were then consolidated into a list of 37 common genes.
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Figure 4.3. Integrated Alzheimer’s disease mechanism. The 37 genes/proteins
are found in common in all 12 enriched KEGG pathways. Genes/proteins implicated
in AD pathology are highlighted in green/red and the genes/proteins of potential
interest are highlighted in blue/orange (See Table 4.1. for details).
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4.4.1 KEGG analysis
To analyze the interactions among these 37 common genes, we constructed an inte-
grated AD mechanism network (see Figure 4.3). We found several routes of disease
initiation via three extra-cellular proteins namely, CD4, DCN and IL8. Below we
summarize the biological functions of the three proteins and their role in Alzheimer’s
disease pathogenesis. Increased accumulation of amyloid-beta plaques in AD brain
has been shown to attract a surge of inflammatory mediators including chemokines,
cytokines and interleukins leading to chronic inflammation that triggers neuronal
death (Akiyama et al., 2000). IL8 (interleukin 8) is a member of the CXC chemokine
family and one of the major mediators of the inflammatory response. Studies have
shown overproduction of IL8 along with other interleukins found in specific regions
affected in Alzheimer’s disease. Under normal conditions, IL8 promotes cell-cell
communications in central nervous system, but increased amyloid-beta production
leads to chronic stimulation of IL8 response which is suspected as cause for ab-
normal physiology in AD brains (Gitter et al., 1995). Similarly, overproduction of
CD4 has been associated with indirect neuronal damage in infectious and immune-
mediated diseases of the central nervous system. Persistent amyloid-beta stimulus
in AD brains has been implicated in chronic CD4 activation which results in prema-
ture immunosenescence (gradual deterioration of the immune system brought on
by natural age advancement) manifestation (Larbi et al., 2009). DCN (decorin) is a
small cellular or pericellular matrix proteoglycan. Earlier immunohistological study
of AD brain tissues has found that decorin was primarily localized to the periphery of
the amyloid plaque and to the edges of amyloid fibril bundles within the plaque pe-
riphery. It has been suggested that decorin molecules may contribute to regulating
the size of amyloid accumulation and/or in maintaining their spherical shape (Snow
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et al., 1992). In order to achieve continued homeostasis, a delicate balance has to
be maintained between APP gene expression and various inflammatory mediators.
Thus, the three extra-cellular molecules of the integrated AD mechanism net-
work have already been implicated in Alzheimer’s disease pathogenesis in one way
or another. The integrated network uncovered direct interactions between these
three extra-cellular molecules and amyloid beta (A4) precursor protein, APP in-
side the nucleus. In addition, the network revealed mutually-connected interac-
tions between APP, BACE1 and PSEN1 genes/proteins. Deregulation of APP, BACE1
(beta-site APP-cleaving enzyme 1) and PSEN1 are well-known causes of Alzheimer’s
disease where APP and PSEN1 mutations are associated with familial form of the
disease and BACE1 gene codes for one of the proteases that cleaves APP whose accu-
mulation is the hallmark of Alzheimer’s disease. Apart from direct interactions with
APP, BACE1 and PSEN1, the three extra-cellular molecules also trigger the down-
stream targets of MAP kinases, and caspases directing cell death.
4.4.2 Classification of disease causing and therapeutic media-
tors
Further, each of the 37 common genes of the enriched KEGG pathways was sub-
jected to Google and NCBI’s PubMed search for their biological/molecular functions,
as well as for their potential role in AD pathogenesis. Based on this search, we cat-
egorized these 37 genes as either disease causing (leading to neuronal death) or
possible therapeutics (helping with reducing the harmful effects and/or preventing
neuronal loss) for Alzheimer’s disease. This categorization is depicted in Figure 4.3
where the genes are highlighted either in purple or yellow, respectively.
As mentioned earlier, by modulating SRC tyrosine kinase gene expression we
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could employ some inhibition of amyloid-beta accumulation in AD brains. But in
general, the integrated disease mechanism network resulted into a well-connected
destructive pathway with almost 80% of the 37 common genes found to play harmful
roles in AD pathogenesis. We could try exerting gene/protein expression regulation
through some of the transcription factor in the integrated network. However, the
transcription factors found in this network were very generic and they are required
for normal functioning of the cell. Thus, it was difficult for us to find/propose a node
in the integrated Alzheimer’s disease mechanism network through which we could
modulate the expression of disease causing/aggravating genes. It was mentioned
before that the amyloid-beta production has to be delicately balanced in order to
maintain homeostasis within the cell. The integrated network revealed none to
very little room to modulate APP gene/protein expression.
4.4.3 Proposed therapeutic measures
Apart from transcription factor’s regulations, microRNAs provide additional post-
transcriptional modulation of target gene expression. Even though many of mi-
croRNA’s biological functions are still unclear, they offer many attractive features
from a drug development standpoint such as small size, specific regulation, con-
served nucleotide sequence etc., which makes them potential therapeutic entities.
Currently, microRNAs as medical treatment means in various disease conditions
are pursued either through the use of synthetic active microRNAs called mimics
or through the use of anti-microRNAs. For example, miR-208 is used in cardiac dis-
eases, miR-155 in chronic inflammatory diseases and miR-122 in Hepatitis C Virus
(van Rooij et al., 2012). Many microRNA clinical trials are also ongoing.
We then sought after microRNA regulation in order to suppress the malicious
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effects of Alzheimer’s disease genes. For this, we used Pathway Studio’s ResNet 9.0
database to identify the microRNAs that targets APP, BACE1, PSEN1, as well as the
three extra-cellular molecules CD4, DCN and IL8. We found 22 such microRNAs
including five of the already AD-known microRNAs namely, miR-153, miR-17, miR-
20a, miR-29b-1 and miR-9. For example, BACE1 (beta-site APP-cleaving enzyme 1)
is the target gene for miR-29a/b-1. BACE1 enzyme is essential for the generation of
amyloid-beta, the hallmark neuropathological lesions in Alzheimer’s disease brain.
Earlier study shows that loss of miR-103, miR-29a/b-1 and miR-9 can contribute to
increased BACE1 and Aβ levels in sporadic AD (Hébert et al., 2008). In addition
to APP and BACE1 gene expression regulation, miR-9 was suspected to regulate
PSEN1, a familial early-onset AD gene. Loss of PSEN1 impacts memory, synaptic
plasticity and induces neurodegenerative changes (see above for more details). In
a PSEN1 null mice model study, miR-9 down-regulation was correlated to severe
brain defects (Barbato et al., 2009). Using transgenic mouse model of AD, it was
found that miR-153 downregulated the expression of APP and APLP2 (a homologue
of APP) proteins (Liang et al., 2012). Another study strongly suggests that miR-
17-5p along with miR-20a and miR-106b may contribute, at least in part, to the
developmental regulation of APP expression in brain and in differentiating neurons
(Hébert et al., 2009).
With possible therapeutic role of microRNAs in mind, we incorporated the 22
microRNAs into our integrated Alzheimer’s disease mechanism network (see Figure
4.4). Following this we examined the microRNAs and their targets. BACE1 had the
highest microRNA regulation being targeted by nine miRNAs, next were APP and
CD4, each of which was targeted by five microRNAs, then IL8 with three microRNA
regulation, and one each for PSEN1 and CD4. In addition, miR-320a was found
to target both APP and IL8, similarly miR-181a1 targeted both CD4 and DCN. In
CHAPTER 4. ALZHEIMER’S DISEASE NETWORK ANALYSIS 94
Figure 4.4. MicroRNA incorporated integrated Alzheimer’s disease mechanism.
The 37 genes/proteins found in common in all 12 enriched KEGG pathways are
regulated by 22 microRNAs. Genes/proteins implicated in AD pathology are high-
lighted in green/red and the genes/proteins of potential interest are highlighted in
blue/orange (See Table 4.1.) for details.
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conclusion, by incorporating microRNAs into the integrated network, we were able
to suggest some critical nodes to regulate Alzheimer’s disease causing and/or ag-
gravating genes. Using network techniques we could offer both narrow and specific
range of entities through which the network could be modulated. Thus, we propose
17 microRNAs (miR-101-1, miR-107, miR-124-1, miR-135a1, miR-142, miR-146a,
miR-155, miR-15a, miR-181a1, miR-184, miR-19a, miR-221, miR-298, miR-302a,
miR-328, miR-520B and miR-7-1) in addition to the known AD-related five as po-
tential therapeutic targets in Alzheimer’s disease. Most of these novel microRNAs
are not yet experimentally verified but one may expect that after such verification a
sizable part of them will be found of therapeutic interest.
4.4.4 Alzheimer’s disease microRNA regulatory network
Besides finding the microRNAs that could regulate the critical nodes such as APP,
BACE1, CD4, DCN, IL8 and PSEN1, we searched to uncover additional regulatory
mechanisms of Alzheimer’s disease genes. For this we used all the 214 significantly
differentially expressed AD genes and constructed a shortest-path network with only
microRNA interactions found in Pathway Studio’s ResNet 9.0 database. This SPNW
revealed that 67 miRNAs regulate many of the 214 AD SDEGs. Utilizing these 67
miRNAs and 214 SDEGs, we then constructed a direct miRNA-mRNA targets inter-
action network shown in Figure 4.5.
In addition to miRNAs regulation, the network also incorporated regulation by
ten transcription factors like BCL6, LMO4, HEY2 and SMAD3 which were not like
the very generic TFs reported earlier. Thus, like in other complex diseases, coopera-
tive two-level gene expression regulatory mechanisms occur in Alzheimer’s disease
pathogenesis via miRNAs and transcriptional factors.
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Figure 4.5. Alzheimer’s disease miRNA regulatory network.The genes/proteins
and miRNAs implicated in AD pathology are highlighted in green and the genes/pro-
teins of potential interest are highlighted in blue. Genes/proteins that code for tran-
scription factors (TFs) are highlighted in yellow.
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On further examination of microRNA regulatory network (Figure 4.5), miR-148a
was the node with the highest degree (hub), closeness and betweenness centrality
scores. It regulates gene expression of ten genes including CDK5R1 whose expres-
sion is needed for proper CDK5 activity, as a part of the AD molecular mechanism
discussed above. MicroRNA quantitative biochemical study has reported altered
expression of miR-148a along with other microRNAs in hippocampus and medial
frontal gyrus regions of human AD brain samples (Cogswell et al., 2008). In ad-
dition, our network analysis revealed that expression of CDK5R1 gene could also
be regulated by five microRNAs (miR-103, miR-148a, miR-15a, miR-183, and miR-
27b), of which regulation via miR-103 along with miR-107 has already been exper-
imentally established (Moncini et al., 2011).
Additional microRNA regulation of some of the genes of interest in Alzheimer’s
disease was uncovered in the microRNA regulatory network. It includes modulation
of CAB39 gene expression by six microRNAs (miR-103-1, miR-155, miR-16-1, miR-
19b1, miR-203 and miR-23b), PCDH8 by four microRNAs (miR-200a/b, miR-218-1
and miR-96), CSF1R by three microRNAs (miR-155, miR-22 and miR-34a), GAB1
by three microRNAs (miR-17, and miR-29b1/c), CAMK4 by miR-507 and HEY2 by
miR-153-1, which would require experimental validation. Finally, we found that
miR-148a, miR-155 and miR-153 seem to target many of the critical genes, as well
as genes of interest, in Alzheimer’s disease.
4.5 Summary
Online Mendelian Inheritance in Man (OMIM) database search for Alzheimer’s dis-
ease revealed many genes such as A2M, ACE, APOE, APP, NOS3, PSEN1, PSEN2 and
SORL1 implicated in the disease mechanism. However, none of these genes except
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PSEN1 were included in our “seed genes” since these genes were not strongly dif-
ferentially expressed, and also their log-fold change was minimal (ranged from -0.3
to +0.1). We consider the lowered gene expression intensity in the post-mortem
brain samples compared to a functioning brain as attributing factor to this gene set
low variability. But it is valuable to note that APP and NOS3 along with other well-
known AD genes like AR, BACE1, STAT1 etc., although not significantly changed
were later included as one of the many connecting genes/proteins in our shortest-
path network and thus became critical nodes in the closest network environment
of the known significantly changed Alzheimer’s genes. These findings reflect upon
our ideas that it is beneficial to utilize network techniques to study complex systems
like neurodegenerative diseases where even in the absence of an appropriate study
medium (a fully functional brain) we could recreate some of missing links/nodes
that are valuable to understand the underlying system mechanism.
It should be mentioned that our detailed network analysis was unable to confirm
the AD role of APOJ, TIMP3 and IRAK1 genes reported by Dunckley et al. 2006.
These genes were not statistically significant after the normalization we performed
on their dataset, and they did not emerge in any way in the networks we constructed
on the basis of well-established AD genes. Identification of PSEN1, a well-known
familial Alzheimer’s disease gene as an important node in both direct-interaction
and shortest-path network is critical in number of ways. First, PSEN1 was found
to be significantly differentially expressed gene (p-value < 0.01) in the microarray
datasets. Secondly, it directly interacts with many already known AD genes such
as APP, CDH1, CDK5R1, CREB1, JUN, SP1 and STAT3. It is also among the top
33 nodes with degree ≥ 8, and top 26 nodes with higher accessibility (closeness
centrality index) to all other nodes in the compact shortest-path network, emerging
thus with a major role in the molecular mechanism of Alzheimer disease.
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Our network analysis provided sufficient arguments in favor of CAMK4 and GAB1
as novel candidate genes for Alzheimer’s disease based on their direct network inter-
actions with already known AD genes. With somewhat less confidence we propose
also CSF1R gene, which despite being a second-level neighbor, has demonstrated
important role in neuronal survival after injury and degeneration. All three genes
are significantly differentially expressed in the post-mortem AD samples we used and
they could have critical role as neuroprotective agents. From shortest-path network
assessment, being first-level interacting partners with three or more already known
AD-related genes we conclude that connecting genes/proteins added by the Pathway
Studio software such as ESRRA, MDM2, NRF1, PTK2B, SRC and SRF could also be
of potential interest in Alzheimer’s disease domain. Among the above listed genes,
MDM2 and SRC were directly connected with at least ten or more previously known
AD genes (!). Additionally, one may consider including to the list of Alzheimer’s
genes five more from the connecting genes in the shortest-path network (CHRM3,
CR2, HEY2, IL3 and NOX4) via their guilt-by-associations to one or two already
known AD genes. The ARRB1 and SPHK2 connecting genes, which are second-level
interacting partners with previously implicated AD genes, may also be viewed of
interest via their role as modulators in amyloid-β production (Takasugi et al., 2011;
Wolfe, 2013).
Apart from directly interacting with a large number of known AD-related genes/pro-
teins as shown in the guilt-by-association list above, MDM2 and SRC are among the
top 25 hub nodes (with degree > 10), among the top 25 nodes with higher acces-
sibility to all other nodes (as measured by closeness centrality network descriptor)
and among the top 25 traffic influential nodes in the network (as measured by the
betweenness centrality index). All this may be considered as evidence for a potential
important systems biology role of these genes/proteins in the integral mechanism
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of Alzheimer’s disease.
In addition to identifying novel individual genes, proceeding from our integrated
Alzheimer’s disease mechanism network, we propose three disease initiating routes
via extra-cellular ligands like CD4, DCN and IL8. These genes directly interact with
many known AD genes including APP, BACE1 and PSEN1 and influence AD patho-
genesis mechanism. Since this network was well-connected with almost 80% of
genes promoting neurodegeneration process, we were unable to propose any ther-
apeutic targets or mechanisms using this network. However, by incorporating mi-
croRNA regulations to this network, we identified 17 microRNAs (miR-101-1, miR-
107, miR-124-1, miR-135a1, miR-142, miR-146a, miR-155, miR-15a, miR-181a1,
miR-184, miR-19a, miR-221, miR-298, miR-302a, miR-328, miR-520B and miR-7-
1) in addition to the known five AD-related miRNAs as potential therapeutic targets
in Alzheimer’s disease. More generally, we propose a scheme of complex multi-level
regulations taking place between the critical players of AD, such as APP, BACE1,
and PSEN1, and other disease causing/alleviating gene/protein entities. In order
to maintain continued homeostasis, a delicate balance should be sustained between
the genes, and microRNA regulation could play an important role in this scenario.
Perhaps, a well-designed cellular automata simulation would help to shed some light
on this delicate but life-determining balance.
The genes discussed in the summary were also shown by gene ontology analysis
to be key players in numerous specific biological mechanisms like neuroprotection
against amyloid-beta accumulation, formation of neurofibrillary tangles, synapses,
cognitive deficits, mental retardation, memory loss and attenuating APP accumu-
lation, many of which are known to be modulated in the underlying Alzheimer’s
pathophysiology and potential compensatory responses.
Chapter 5
Huntington’s Disease Network Analysis
5.1 Introduction
Unlike the Parkinson’s and Alzheimer’s disease network analysis, we found and used
only one post-mortem human brain tissue sample dataset namely, GSE3790 for
Huntington’s disease (HD). However, this dataset had a larger number of samples
(44 HD and 36 controls) than the used PD and AD samples. Hodges et al. published
this dataset in 2006. One of the major conclusions of this study was that the dif-
ferential gene expression in HD brains showed distinct regional pattern similar to
an already known pattern of neuronal loss. The greatest number and magnitude of
differentially expressed genes/proteins were detected in the caudate nucleus, fol-
lowed by motor cortex, then in cerebellum tissue types. Our statistical analysis with
renormalized data revealed a similar gene expression difference in these tissue sam-
ples.
The original authors had performed gene set enrichment analysis using DAVID
tools to identify biological processes and pathways significantly affected in HD. In
this study, we expanded upon their research work by subjecting the differentially
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CHAPTER 5. HUNTINGTON’S DISEASE NETWORK ANALYSIS 102
expressed genes to various network techniques to explore the underlying cellular
mechanisms and molecular players of Huntington’s disease. We initiated our HD
network analysis using 531 “seed genes” (see Chapter 2 for details).
5.2 Huntington’s disease direct interaction (DI)
network
Compared to Parkinson’s and Alzheimer’s number of seed genes, for Huntington’s
disease we had a larger number of seed genes to deal with. Working with a larger
gene set is beneficial in a couple of ways. On one side one is having a broader
view of the network neighborhood of any gene of interest along with all its complex
interactions. On the other side, at times one could also shrink the network size
in order to have a closer look on the proximity of those nodes that are important.
Figure 5.1 shows the primary direct interaction (DI) network of the 531 Huntington’s
disease “seed genes”. 224 of these genes directly interact with each other and the
network included such types of interactions like regulation, physical binding, co-
expression, promoter binding, protein modification, molecular transport and direct
regulation.
After exhausted literature review, we found in the direct interaction network 23
genes that have already been associated to Huntington’s disease (more details on
which are given in Chapter 1). Another eleven genes (CNTNAP1, CX3CL1, DPYSL5,
FDFT1, FGFR1, FKBP5, PPARA, PRDX2, PRDX6, RCAN2 and ZNF148) were identi-
fied as being of potential interest in Huntington’s disease pathogenesis due to their
specific molecular functions as detailed below. More details on how we conducted
our literature search and gene classification are given in Chapter 2. We constructed
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Figure 5.1. Huntington’s disease direct interaction network. The 23 genes/pro-
teins implicated in HD pathology are highlighted in green and the eleven genes/pro-
teins of potential interest for that disease are highlighted in blue.
a compact direct interaction network using these 34 genes/proteins to understand
whether and how they interact with each other, and to validate the eleven genes of
interest by their guilt-by-association. The network shown in Figure 5.2 clearly re-
veals that except FKBP5 and DPYSL5, all other genes/proteins of potential interest
are connected to the HD-known ones.
5.2.1 Molecular functions of some of the proposed candidate
genes
The intrinsic biological functions of the proposed candidate genes seem promis-
ing for a neuroprotective mechanism in Huntington’s disease realm. For instance,
fractalkine (CX3CL1) is a known Parkinson’s disease gene where it exhibited neuro-
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Figure 5.2. Huntington’s disease compact direct interaction network. The 23
genes/proteins implicated in HD pathology are highlighted in green and the eleven
genes/proteins of potential interest for that disease are highlighted in blue.
protective role against microglia activation as well as reduced motor coordination
impairment (see Chapter 1 for details). Being a known neuroprotective agent for a
similar neurodegeneration disease with movement disorder, it may have a potential
therapeutic role in Huntington’s disease domain too. As mentioned earlier, FGFs
were proposed to improve the motor performance and to extend the lifespan in HD
mouse model study. Being a receptor for fibroblast growth factors, FGFR1 could up-
regulate FGF’s beneficial activities in the cell. Studies have found that PPAR-gamma
together with PGC-1α (a transcriptional co-activator) are required for the regulation
of mitochondrial biogenesis. PPAR-γ agonists are thought to be neuroprotective in
ALS and HD (Xiang et al., 2011). Similarly, PPAR-alpha could be another means for
a neuroprotective pathway in HD.
Currently, there is no cure available for HD patients. In a mouse model of HD
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study, zinc finger proteins were designed in such a way that these proteins were able
to recognize and bind with CAG repeats in DNA, specifically. The study reported that
there was considerable reduction of the mutant huntingtin gene expression at both
protein and mRNA levels (95% and 78% reduction, respectively) (Garriga-Canut
et al., 2012). Many zinc finger proteins including ZBTB10, ZFP36L1 and ZNF148
were found significantly differentially expressed in the microarray dataset used in
this study. These zinc finger proteins could emerge as a promising new gene therapy
tool for Huntington’s disease which could be extended and tested in human HD
patients.
5.2.2 Network attributes of some of the proposed candidate genes
The genes such as CX3CL1, FGFR1, PPARA and zinc fingers including seven others
are recommended as novel candidate genes for HD due to their biological/cellu-
lar functions. Additionally, from network perspective (see Figure 5.2), many of
these candidate genes are direct interacting partners with already HD-associated
genes. For example, CX3CL1 and PPARA interacts with four already known-HD
genes namely, BCL2, CLU, FGF2 and GAPDH and BCL2, CNR1, EGFR and GAPDH,
respectively. In addition, CX3CL1 and PPARA directly interact with each other. The
modulation of these previously known-HD genes have been shown beneficial in re-
ducing the disease pathogenesis. Similarly, ZNF148 directly interacts with three
known-HD genes BCL2, CASP6 and IRS2.
Besides being first-level interacting partners with already implicated-HD genes,
the novel candidate gene PPARA is one of the top 10 nodes with highest connectivity
(node degree ≥ 20) as well as betweenness (traffic-influential) centrality scores. In
addition, it is one of the top 20 nodes with highest closeness (accessible to other
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nodes) centrality measures in the network. Their innate physiological roles along
with their vital network attributes, increases the chance of the eleven candidate
genes to be involved in the HD pathology, which would require further investiga-
tion, particularly for FKBP5 and DPYSL5, which remained unconnected in the direct
interaction network.
5.3 Huntington’s disease shortest-path network (SPNW)
Different from the previous direct interaction network type, shortest-path network
help us to identify indirect protein-protein interactions that take place through inter-
mediary nodes in the absence of direct relationship. With this in mind, we attempted
to build the shortest-path network using only those seed genes which had at least
25 neighbors in Pathway Studio ResNet 9.0 database (refer Chapter 2). 258 out of
531 seed genes met this cut-off criteria and the resulted shortest-path network in-
cluded 208 Pathway Studio software-added connecting genes. Following our study
methodology, we categorized these connecting genes into two groups. The genes
that were already implicated in Huntington’s disease belong to the known-HD genes
group and those genes which could be of potential interest in HD due to their cellu-
lar functions were grouped separately. Table 5.1 shows the different categories and
the number of genes in each.
We constructed a compact shortest-path network (CSPNW), using the 85 genes
from Table 5.1 along with few additional connecting genes that were needed to have
a unified well-connected network. The average node degree of this compact shortest-
path network was 7.10. In this CSPNW, many of the known-HD genes such as AKT1,
AR, BCL2, INSR and SP1 were among the top 25 nodes with node degree ≥ 10, as
well as the top 25 with highest closeness (network monitors) and betweeness (traffic
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Table 5.1. Summary of the genes of interest and genes already known in Hunting-
ton’s disease.
Different categories
Number of
genes
Node color in figure
Genes of interest from SDEGs 14 blue
Known HD genes from SDEGs 24 green
Genes of interest in SPNW connecting nodes 24 orange
Known HD genes in SPNW connecting nodes 23 red
influential) centrality measures. Figure 5.3 illustrates the interactions between the
known and the genes of interest in the HD compact SPNW.
Even though PRNP gene/protein was not statistically differentially expressed
in our microarray dataset, it was valuable to note that it emerged as connecting
gene/protein in the shortest-path network. PRNP (prion protein) is a glycoprotein
that tends to aggregate into rod-like structures causing neuronal cell death. Prion
proteins have been associated with many neurodegenerative disorders including
Huntington’s, Creutzfeldt-Jakob diseases in human, and “mad cow” disease in cat-
tle (Imran and Mahmood, 2011; Moore et al., 2001). We found that PRNP was of
importance for network topology as one of the top 15 nodes with highest visibility
(closeness) and most influence (betweeness) in the compact shortest-path network.
5.3.1 Guilt-by-association analysis
In the next few paragraphs, we summarize the innate molecular characteristics of
various genes that could be of potential interest in HD pathogenesis, in addition to
their “guilt-by-association” relationship to some of the already implicated HD genes.
Table 5.2 lists our proposed Huntington’s disease candidate genes along with the
number of known-HD genes to which they directly interact with (see Figure 5.3).
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Figure 5.3. Huntington’s disease compact shortest path network.The genes/pro-
teins implicated in HD pathology are highlighted in green and red. The genes/pro-
teins of potential interest are highlighted in blue and orange. (see Table 5.1. for
gene highlighting details).
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Table 5.2. Genes of interest for Huntington’s Disease identified by guilt-by-
association with the known HD-related genes.
Genes of Interest
Interacts with
no. of known-
HD genes
EGR1 13
CEBPA 9
CDK1 8
FOXO1, HSP90AA1 7
PRKCZ 6
E2F1, STAT5A 5
SRF 4
ERBB2, FGFR1, IL2, INSR, LRP1, PRKCB, TNF, ZNF148 3
CX3CL1, GNAQ, PPARA 2
ATXN7, CNTNAP1, DCLK1, DPYSL2, PRDX2, PRDX6, THRA,
ZFP36L1 1
From the compact shortest-path network, we found that EGR1 (early growth re-
sponse 1) was first-level interacting partner to 13 (!) previously known-HD genes
(AKT1, AR, BCL2, CLU, CTNNB1, CYCS, FGF2, MAOB, MMP9, SOD1, SP1, TGFB1
and TP53). BIM (BCL2-like 11 apoptosis facilitator) plays an important role in
neuronal apoptosis, a hallmark feature of many neurological diseases including
Alzheimer’s and Parkinson’s. Previous research study had demonstrated that EGR1
directly transactivate BIM gene expression to promote neuronal apoptosis. EGR1/BIM
pathway has been suggested as a pro-apoptotic mechanism in neurological diseases.
Mithramycin A, a U.S. Food and Drug Administration clinically approved drug has
been studied to improve motor symptoms and extend life span in a mouse model
of Huntington’s disease. Mithramycin A was suspected to exploit the EGR1/BIM
pathway to promote neuroprotective mechanism in HD models and thus could be
a promising drug for the treatment for the same (Ferrante et al., 2004; Xie et al.,
2011).
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Our next HD candidate gene is CEBPA (CCAAT/enhancer binding protein, al-
pha). It has been shown to bind to the promoter and modulate the expression of
the gene encoding for leptin, a protein that plays an important role in body weight
homeostasis. Leptin receptors are found in various brain regions such as the hip-
pocampus and cerebral cortex, and have known roles in neural development and
neuroendocrine functions. Studies have indicated that leptin could be neuropro-
tective and thus enhance neuronal survival (Tang, 2008). CEBPA, the promoter of
leptin gene could also play a critical role in this neuroprotective mechanism. In the
compact shortest-path network, CEBPA was the first-level interacting partners with
nine known-HD genes.
Another recommendation for HD candidate gene is CDK1 (cyclin-dependent ki-
nase 1).The abnormal activation of CDK1 is likely to be involved in the neuronal cell
loss in neurodegenerative diseases including Alzheimer’s disease and HIV (Castedo
et al., 2002). Earlier, CDK5 was suspected to contribute to the deleterious protein
accumulation in Alzheimer’s disease (Iijima et al., 2000; Crews and Masliah, 2010;
Mateo et al., 2009). In the compact SP network, CDK1 directly interacts with eight
known-HD genes. CDK1 is a part of the kinase family that is actively contributing to
the neurodegeneration process in similar disease conditions; it could have potential
role in HD neurodegeneration mechanism too.
Thus, through their intrinsic molecular functions and their pivotal neighboring
positions with many already implicated HD genes in the compact shortest-path net-
work, we propose those genes listed in Table 5.2 as novel candidate genes for Hunt-
ington’s disease. Undeniably, these candidate genes should be further investigated
for their molecular role in HD. However, we expect many of these novel genes to sur-
pass the experimental verification due to their “guilt-by-association” with previously
established Huntington’s disease genes.
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5.3.2 Molecular functions and network attributes of some of the
critical connecting genes
Apart from novel connecting genes, it is valuable to note that genes like EGFR,
ESR1, HSBP1 and MAPT were also included in the compact SP network as connect-
ing genes. They are previously known contributors as well as therapeutic agents in
neurodegenerative disorders. Hyperphosphorylated tau (MAPT) is the major com-
ponent of the neurofibrillary tangles, one of the hallmarks of neurodegenerative
diseases (Jellinger, 2009; Pittman et al., 2006; Lei et al., 2010; Crews and Masliah,
2010). Similarly, huntingtin gene, the mutant in HD was suggested to be indirectly
associated with EGFR, thus deregulating the downstream actions of EGFR leading to
cell death (Liu et al., 1997). Considering the treatment measures, HSBP1 and ESR1
are suggested to offer such mechanisms. In general, heat shock proteins (HSBP1)
are evaluated as therapeutic targets in mitigating or preventing protein aggregate
formations (Mymrikov et al., 2011). One of the major conclusions of an animal HD
model study was that the female sex hormone, estrogen (ESR1) could be a target for
neuroprotective therapy aiming at postponing the onset and reducing the severity
of HD. A similar pattern of late onset was also shown in a human HD study (Bode
et al., 2008; Roos et al., 1991). Moreover, these four connecting genes were among
the top 25 nodes with highest connectivity (degree> 10) as well as one of the top 25
nodes with highest visibility as measured by the closeness centrality scores. Except
HSBP1, the other three genes were also among the top 25 nodes with highest acces-
sibility to other nodes in the network as determined by the betweenness centrality
in the compact SP network.
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5.3.3 DAVID enrichment analysis
Continuing with our network analysis, we subjected the genes in the compact shortest-
path network to DAVID analysis to identify various enriched biological processes and
pathways in Huntington’s disease. Table 5.3 lists some of the Gene Ontology cate-
gories/subcategories related to nervous system and functions that were statistically
significantly enriched in HD (with Benjamini-Hochberg multiple correction). DAVID
analysis uncovered biological processes involving in oxidative stress, reactive oxygen
species, deregulation in inflammatory response, steroid hormone receptor signaling,
lipid binding and insulin receptor signaling pathways to be significantly affected in
Huntington’s disease, some of which were mentioned above. Other neurodegen-
erative signaling pathway including Alzheimer’s and ALS were also considerably
affected in Huntington’s disease which reinforce our view for similar underlying
molecular pattern in all these diseases. In the next section, we will provide detailed
information about our proposed model for Huntington’s disease mechanism based
on the various biological pathways that were affected in this disease.
5.4 Integrated Huntington’s disease mechanism
In addition to various biological processes, DAVID analysis also recommended sev-
eral KEGG pathways to be significantly (p-values < 0.05 with Benjamini-Hochberg
multiple correction) affected in Huntington’s disease of which we selected ten path-
ways for further evaluation. These pathways were selected (listed in Table 5.4) on
the basis of previous implications in Huntington’s disease research work. Either
the entire pathway or many important players of the pathways were found dereg-
ulated in HD pathogenesis (Bae et al., 2005; Godin et al., 2010; Reis et al., 2011;
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Andreassen et al., 2002; Phan et al., 2009; Lalic´ et al., 2008; Moreira Sousa et al.,
2013; Apostol et al., 2006).
5.4.1 KEGG analysis
Enriched KEGG pathways belong to endocrine system, cell communication, cell
growth and death, signal transduction, neurodegenerative diseases, and endocrine
and metabolic diseases classification. We used the ten pathways (see Table 5.4) to
search for any underlying molecular mechanism that could either cause or mitigate
Huntington’s disease pathology. To accomplish this task, we constructed an inte-
grated HD mechanism network using the 41 genes found in common in all the ten
enriched KEGG pathways (see Figure 5.4).
We then performed a Huntington’s disease literature search to classify these 41
genes into two groups namely, genes that aid in the neuronal survival or cause loss.
23 out of 41 were implicated in neuronal loss and the remaining 18 genes were re-
lated to neuronal survival. This classification is depicted in Figure 5.4 where genes
are highlighted in purple and yellow, respectively. Similar to our previous integrated
neurodegenerative disease mechanism networks shown in Chapters 3 and 4, we
found a pattern of three extra-cellular ligands (FGF2, TNF, and TGFB1) initiating
various downstream signaling cascades in the integrated Huntington’s disease mech-
anism network as well. As explained earlier, FGF2s are pursed as promising drug
targets for its neuroprotective and neuroproliferative roles. TNF (tumor necrosis
factor) and TGFB1 (transforming growth factor, beta 1) belong to inflammatory
cytokine family which is involved in the regulation of a wide variety of biologi-
cal processes including cell proliferation, differentiation, adhesion, apoptosis, lipid
metabolism, and coagulation. Neuroinflammation has been implicated in a many
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Figure 5.4. Integrated Huntington’s disease mechanism. The 41 genes/proteins
are found in common in all 10 enriched KEGG pathways. Genes/proteins implicated
in HD pathology are highlighted in green/red and the genes/proteins of potential
interest are highlighted in blue/orange (See Table 5.1. for details).
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neurological disorders including Huntington’s disease. In general, cytokines are re-
quired for normal functioning of cells. However, the formation of protein aggregates
inside the cell triggers inflammatory mechanism which leads to increased cytokine
activities thereby causing chronic cell stress (Battaglia et al., 2010; Möller, 2010). A
delicate balance has to be maintained in order to sustain homeostasis within cell. On
examining the integrated network, we propose that the hemostasis in Huntington’s
disease environment could be restored by regulating the three extra-cellular ligands
FGF2, TGFB1 and TNF thereby controlling their downstream signaling cascades of
various target genes expression. On the other hand, even though the integrated HD
mechanism network size was relatively small, due to the high interconnectedness of
all the nodes it was difficult to suggest a pathway or two to implement our proposed
neuronal restoration in Huntington’s disease regulated via the three ligands.
5.4.2 Existing treatment options
Once again we went back to HD research literature looking for some molecular
mechanisms and/or therapeutic pathways that are currently being utilized in this
field. A recent review article by Zuccato et al. in 2010 described the past achieve-
ments, the current status along with suspected disease mechanisms and therapeutic
measures available in Huntington’s disease realm. Several research works suggest
few important players in HD whose regulation could promote neurogenesis. Under
normal physiological conditions, HTT interacts with many genes/proteins includ-
ing BDNF, MTOR and REST to promote the survival of striatal neurons, the ones
that are subjected to cell death in Huntington’s disease. Interaction between BDNF
(brain-derived neurotrophic factor) and HTT is important for the survival of stri-
atal neurons as well as promoting synapse formation. In addition, HTT bind and
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sequester mechanistic target of rapamycin (MTOR) inside the cytoplasm inhibiting
MTOR’s downstream regulation. In general, MTORs are negative regulators of au-
tophagy. Autophagy is an essential, homeostatic process by which cells break down
their own components. They are the debris clearance machineries in the cell that
is required to protect against infections, autoimmune and inflammatory diseases
(Levine et al., 2011). Likewise, REST (RE1-silencing transcription factor) and HTT
interaction is also important in HD pathogenesis. HTT binds with REST to maintain
low levels of REST gene expression inside the cytoplasm thereby not affecting the
transcription of BDNF gene.
In Huntington’s disease, mutation in HTT causes protein aggregation formations
which were not properly cleared from the cell thus disrupting the normal function-
ing of the stratial neurons. Due to transcription suppression by REST, BDNF level
was found reduced in neurodegenerative diseases including Alzheimer’s, Parkin-
son’s and Huntington’s disease (Zuccato and Cattaneo, 2007; Zuccato et al., 2001).
Mutant HTTs were found inducing neuronal death via distinct but complementary
pathways including deregulation of apoptosis and/or autophagy, altered transcrip-
tion, metabolism and cellular stress responses. Currently one of the therapeutic
measures suggested in Huntington’s disease domain is by clearing the HTT protein
aggregates from the cell through the induction of autophagy by the MTOR inhibitor
rapamycin. Another indicated treatment is through increasing the beneficial BDNF
gene expression (Zuccato et al., 2010). Animal HD model studies have shown that
the use of rapamycin (MTOR inhibitor) improved striatal neuron survival and motor
performance. However, due to deleterious side effects of rapamycin, it was not rec-
ommended for use as an exclusive drug in HD treatment. A combinatorial strategy
with rapamycin or other drugs promoting autophagy has been suggested as relevant
treatment for HD and other related diseases (Ravikumar et al., 2004).
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Following these HD literature suggested treatment ideas, we modified our inte-
grated Huntington’s disease mechanism network to include only those nodes (13
genes: AKT1, BCL2, GAPDH, EGFR, FGF2, FGFR1, INSR, MTOR, PPARGC1A, REST,
SP1, TGFB1 and TNF) that might play a critical role in both inhibiting MTOR and
improving BDNF gene expression. BDNF was added to the reduced network, as was
done with HTT. The resulted enhanced integrated HD mechanism network is shown
in Figure 5.5.
5.4.3 Proposed treatment options
From this enhanced network we propose two pathways through which homeostasis
in HD could be restored by initiating the downstream signaling cascade of various
target genes expression via primarily through TGFB1, one of the three extra-cellular
ligands. Our first proposal includes a two-step process of MTOR inhibition. Step
1: TGFB1 activates PPARGC1A gene expression in the nucleus, which in turn in-
creases GAPDH gene/protein activity. Step 2: Up-regulation of GAPDH inhibits
MTOR gene expression activity. Once MTOR is inhibited, autophagy mechanism
could be boosted up in the cell. As soon as autophagy process is reestablished, HTT
protein aggregates will be effectively cleared from the cell thus leading to neuronal
survival.
Our second restoration pathway recommendation is via both FGF2 and TGFB1
ligand activation of EGFR receptors thereby initiating several downstream target
genes expression. Among those upregulated genes, AKT1 (v-akt murine thymoma
viral oncogene homolog 1) is a vital downstream target for EGFR and has been
shown to be a critical mediator of neuronal survival. AKT1 has been suggested to be
a promising therapeutic target to promote cell survival (Dudek, 1997). Apart from
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Figure 5.5. Enhanced integrated Huntington’s disease mechanism.The 15
genes/proteins that were suggested to play major role in HD treatment. Genes/pro-
teins implicated in HD pathology are highlighted in green/red and the genes/pro-
teins of potential interest are highlighted in blue/orange (See Table 5.1. for details).
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AKT1, EGFR interacts with SP1 (Sp1 transcription factor) which is involved in many
cellular processes, including cell differentiation, cell growth, apoptosis, immune re-
sponses, response to DNA damage, and chromatin remodeling. SP1 fine-tunes the
transcription of many genes including BCL2 and REST. BDNF transcription could
be increased via maintaining tight regulation between REST and SP1. In addition,
SP1 could also up-regulate BCL2 gene expression, promoting anti-apoptosis. Thus,
eventually striatal neurons could be protected by promoting BDNF activity, as well
as by reducing the apoptotic process in the cell. Additionally, EGFR also promote
GAPDH gene expression eventually aiding in neuronal survival as detailed in our
earlier pathway proposal.
From network analysis stand-point, the two proposed homeostasis restoration
pathways show promising measures towards treatment plans in Huntington’s dis-
ease. As a first step towards translating our proposed therapeutic networks into real
world applications, such complex multi-player interconnected pathways could be
evaluated using advanced dynamic modeling tools such as cellular automata (Er-
mentrout and Edelstein-Keshet, 1993).
5.5 Huntington’s diseasemicroRNA regulatory network
MicroRNAs perform important role in delivering post-transcriptional regulation of
gene expression. In order to identify the microRNAs and their potential targets
in Huntington’s disease domain, we constructed a microRNA regulatory network
(MRN) using the 514 “seed genes”.
Before to proceed with the MRN construction, we first identified the microRNAs
that could target our seed genes. This was accomplished using the shortest-path
network option in Pathway Studio software where we subjected all the 514 HD “seed
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genes” to only microRNA interactions type. We found 132 microRNAs to target our
HD genes. In order to obtain the microRNA-target gene interactions, we constructed
a direct interaction network using the 132 microRNAs and the 514 “seed genes”.
[Note: MicroRNA regulatory network figure is not included in this text due to its
bigger size.]
5.5.1 Critical microRNA regulation in HD
The average node degree of the microRNA regulatory network was 4.3. Being the
node with highest degree in the network, miR-9 was observed to target 35 genes (!).
In addition, miR-9 was the node with highest closeness and betweeness centrality
scores. Finding it in our microRNA regulatory network was exciting for a couple of
reasons. First, miR-9 was previously known in Huntington’s disease mechanism, as
well as found to target REST (RE1-silencing transcription factor), one of the impor-
tant players of HD pathogenesis. Secondly, miR-9 regulation has already been identi-
fied and found reduced in both Alzheimer’s and Huntington’s disease brains (Lukiw,
2007; Packer et al., 2008; Zuccato and Cattaneo, 2007; Zuccato et al., 2001), pro-
viding thus another evidence for the conjectured unified underlined mechanism of
the neurodegenerative diseases. Apart from miR-9 regulation, the network included
miR-132 and miR-29a/b1 miRNAs, both already associated with HD pathogenesis
(Junn and Mouradian, 2012; Lau and de Strooper, 2010).
The next top five microRNAs found in the regulatory network were miR-124,
miR-135a, miR-141, miR-182 and miR-19a. All these microRNAs were among the
top 25 nodes with highest degree (node degree ≥ 12), and top 25 nodes with high-
est closeness and betweeness centrality scores. miR-124 is one of the most abun-
dantly expressed miRNAs in the nervous system, being widely expressed in neurons
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in the brain, retina, and spinal cord. It has been implicated in the modulation of
neurite outgrowth, as well as cytoskeleton formation (Yu et al., 2008). There have
been no indications so far for involvement in neurodegenerative processes of miR-
135a, known to target genes involved in blood pressure regulation (Sõber et al.,
2010). Similarly, miR-141 and miR-182 were known to be involved only in DNA
methylation and cancer metastasis, respectively (Segura et al., 2009; Vrba et al.,
2010). miR-19 and miR-21 have been found to target PTEN, a gene/protein found
localized in the neurofibrillary tangles (NFTs) and senile plaques in Alzheimer’s dis-
ease brains (Pezzolesi et al., 2008; Sonoda et al., 2010). MicroRNA regulatory net-
work also uncovered that many of these top regulating microRNAs modulate several
known-HD genes such as CNR1, FOXP1, GAPDH, and IRS2. Reiterating the ResNet
9.0 database’s current status of microRNA-target interaction identifications, further
experimental verification is recommended.
5.5.2 Highly targeted genes of interest in HD
Table 5.5. Genes of interest determined from Huntington’s disease microRNA reg-
ulatory network
Genes of Interest Targeted by no. of miRNAs
DOCK7, ZBTB10 7
DPYSL5, ZNF148 6
DCLK1, OSBPL11, RCAN2, ZFP36L1 5
CNTNAP1 4
FGFR1, FKBP5 2
CX3CL1, FDFT1 1
Table 5.5 shows the genes of interest in the HD microRNA regulatory network
and how many microRNAs are targeting each gene. In this network, DOCK7 (dedica-
tor of cytokinesis 7) was the gene with the highest number of microRNA regulations,
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being regulated by seven members of miR-181 and miR-30 families. DOCK7 gene
encodes for guanine nucleotide exchange factor (GEF) protein that plays a major
role in axon formation and neuronal polarization. In general, GEFs are critical me-
diators of Rho GTPase activation by stimulating the exchange of GDP for GTP. Under
normal physiological conditions, Rho GTPases act as molecular switches in intracel-
lular signaling pathways and have many downstream targets. Mutations in GEFs
and deregulated Rho GTPase signaling have been implicated in ALS, a debilitating
motor neuron disease caused by neuronal degeneration. Based on its molecular
function and its association with similar neurodegeneration disease, DOCK7 could
be of potential interest in Huntington’s disease mechanism as well.
Moving on with other genes of interest in the microRNA regulatory network, zinc
finger proteins (ZBTB10, ZNF148, and ZFP36L1) were highly targeted by multiple
microRNAs including miR-20a and miR-29b1, known microRNAs in Alzheimer’s and
Huntington’s disease, respectively (Sonntag, 2010). As reported in the previous
section, zinc finger proteins are demonstrated to be a promising new gene therapy
tool for Huntington’s disease. Such a therapy could be enhanced by these microRNA
regulations.
Additional to microRNA regulation, the network also included 43 genes that
code for transcription factors. These significantly differentially expressed TFs indi-
cate a possible integrated gene expression regulation mechanism in Huntington’s
disease. Like we noticed for the other two neurodegenerative disorders, there is a
likelihood of dual-level gene expression regulation also occurring in HD paradigm.
Thus, Huntington’s disease is becoming another complex disease system that in-
volves highly interconnected molecular players and multi-level regulation.
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5.6 Summary
As in our analysis on Alzheimer’s disease some of the well-known Huntington disease
genes like HTT, HDL3, JPH3 and PRNP have not been significantly expressed in the
post-mortem microarrays, and were not included in our “seed gene” list. While this
may be an unavoidable consequence of the overall decrease in the level of expression
in the post-mortem probes, one of the major advantages of our network analysis
is to offer additional ways for identifying such important genes as critical nodes in
network topology. Thus, the PRNP gene emerged in our shortest path network as one
of the many connecting genes/proteins, and in the compact version of this network
as one of the top 15 critical nodes with highest visibility (closeness centrality) and
most influence on the interaction traffic (betweenness centrality).
From our network analysis, we identified seven novel genes of importance for
the Huntington disease: CNTNAP1, CX3CL1, FGFR1, PPARA, PRDX2, RCAN2 and
ZNF148 based on their direct interaction with many already known-HD genes, as
well as on their intrinsic molecular functions mostly in neuroprotective roles. All
these seven genes were among the 514 “seed genes” that were significantly differ-
entially expressed in HD postmortem samples. Next, via their “guilt-by associations”
to many known-HD genes from shortest-path network, we concluded that 15 connect-
ing genes/proteins added by the Pathway Studio software, such as CDK1, CEBPA,
E2F1, EGR1, ERBB2, FOXO1, HSP90AA1, IL2, INSR, LRP1, PRKCB, PRKCZ, SRF,
STAT5A and TNF, could also be of potential interest in Huntington’s disease domain.
These genes were first-level partners with three or more previously implicated HD
genes. Especially, EGR1 was found interacting directly with thirteen (!) known-HD
genes in the compact shortest-path network. One may also consider including to
the list of potential Huntington’s genes also those, which interact in that network
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with two or one known HD genes, such as ATXN7, DCLK1, DPYSL2, GNAQ, PRDX2,
PRDX6, THRA and ZFP36L1.
Besides their “guilt-by-associations” with many previously implicated Hunting-
ton’s genes, the connecting genes/proteins CDK1, CEBPA, E2F1, EGR1 and INSR
were among the top 25 nodes with highest degree (≥ 12), highest visibility and
highest traffic influence in the compact shortest-path network, as assessed by their
closeness and betweenness centrality scores. Identifying these critical network mea-
sures may be considered as an evidence for a potentially important systems bio-
logical role of these five genes/proteins in the integral mechanism of Huntington’s
disease.
DAVID gene set enrichment analysis revealed that many of these candidate genes
were involved in neuron and glial cell development, projection and differentiation
process as well as regulation of synaptic transmission and response to oxidative
stress mechanism. Deregulation of these biological processes was attributed to the
dysfunction of many of the known-HD genes in addition to HTT gene mutation.
Due to their critical role in the biological pathways that were significantly affected
in Huntington’s disease, as well as being directly associated with many known-HD
genes, increases the probability that these proposed candidate genes could play a
major part in the HD pathogenesis.
Through our microRNA regulatory network, we suggest that microRNAs could
be potential regulators and drug targets in HD. The following twelve microRNAs
namely, miR-101-1, miR-124-1, miR-128-1, miR-135A1, miR-141, miR-153-1, miR-
15A, miR-16-1, miR-182, miR-19A, miR-27A and miR-96 could be of potential in-
terest in HD. These microRNAs were regulating many known and genes of interest
in HD. Like Parkinson and Alzheimer diseases, there is a possibility of dual-level
gene regulation by both microRNAs and transcription factors in Huntington’s dis-
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ease mechanism as well. Like Parkinson and Alzheimer diseases, there is a possi-
bility of dual-level gene regulation by both microRNAs and transcription factors in
Huntington’s disease mechanism as well.
From the integrated network assessment, we propose a couple of potential treat-
ment plans for Huntington’s disease initiated via the extra-cellular ligands TGFB,
FGF2 and TNF. Restoring the homeostasis in Huntington’s disease seems possible;
one such plan is to up-regulate the innate autophagy process by inhibiting MTOR ac-
tivity within the cell. Another, treatment plan is to promote striatal neuron survival
via increasing BDNF gene expression.
Chapter 6
Towards unified underlying
mechanisms of NDDs
6.1 Introduction
There is growing evidence that deregulation of several biological processes such
as oxidative stress, inflammation, mitochondrial dysfunction, free radical forma-
tion, ubiquitin-proteosomal system and others contribute to Neurodegenerative dis-
orders (NDDs) including Parkinson’s (PD), Alzheimer’s (AD), Huntington’s (HD),
Amyotrophic lateral sclerosis (ALS), Progressive supranuclear palsy (PSP) etc. Ge-
netic and environmental factors, protein misfoldings and abnormal protein aggre-
gations were some of the common hallmark characteristics of such diseases. Over
many years, affected individuals display cognitive, motor and emotional distur-
bances with increasing disability ultimately leading to death (Schon and Manfredi,
2003; Jellinger, 2009; Akiyama et al., 2000; Chiti and Dobson, 2006; Möller, 2010;
Di Monte et al., 2002; Gil and Rego, 2008; Mattson, 2000; Zuccato et al., 2010;
Emerit et al., 2004; Liu et al., 2011; Jellinger, 2010).
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With this background, using network biology tools we wanted to identify the
molecular players and underlying mechanisms in three universal and debilitating
neurodegenerative disorders namely, Parkinson’s, Alzheimer’s and Huntington’s dis-
eases. In earlier chapters, we identified and explained such critical molecular play-
ers, mechanisms and integrated approaches for possible disease initiators as well
as potential therapeutic techniques for each of these diseases. Following our mod-
est success, we further conducted similar network-based analysis to uncover crucial
molecular partakers and biological processes that are common in all three disease
conditions. Based on this we propose a unified underlying mechanism which in-
cludes several possible disease initiating as well as potential treatment scenarios
common for Parkinson’s, Alzheimer’s and Huntington’s neurodegenerative disor-
ders.
By overlapping the significantly differentially expressed genes from the PD, AD
and HD microarray datasets, 22 “seed genes” (ADAM23, AHNAK, ATP2B2, ATP6V0E1,
BCL6, CALD1, CAPRIN1, DCLK1, GLT1D1, ITSN1, MCL1, MSI2, NTRK3, PLCB1,
PREPL, RASGRP1, REPS2, SCAMP1, SSBP3, STXBP1, SYT1 and ZMAT3) were found
in common in all disease conditions. Ten (ATP2B2, ITSN1, MCL1, NTRK3, PLCB1,
RASGRP1, REPS2, SCAMP1, STXBP1 and SYT1) out of 22 overlapping genes were
previously known to be related in one or the other neurodegnerative disorders under
study. Among the remaining twelve overlapping genes, four genes AHNAK, BCL6,
CALD1 and DCLK1 could be of potential interest in NDDs. More information about
these novel candidate genes are given in the following sections. Utilizing the 22
seed genes, various types of biological networks were constructed using Pathway
Studio software.
CHAPTER 6. TOWARDS UNIFIED UNDERLYING MECHANISMS OF NDDS 130
6.2 Shortest-path network of neurodegeneration
mechanism based on seed genes found
in common in all three NDDs
In general, shortest-path (SP) network are used to uncover indirect relationships be-
tween any pair of genes. By doing so, many intermediary genes (connecting genes)
were revealed and their intrinsic molecular functions as well as their possible as-
sociations with neurodegeneration processes were identified. In this manner, the
shortest-path network of 22 “seed genes” grew bigger by incorporating 30 more
software-added genes. To construct the SP network, protein modification, promoter
binding and direct regulation types of interactions were used. A direct interaction
network with the 22 seed genes was constructed but it only revealed interactions
between two pairs of seed genes. Figure 6.1 illustrates the shortest-path network of
neurodegeneration mechanism.
Both the seed and the connecting genes were examined in OMIM, NCBI’s PubMed
and databases and Google website to confirm whether these genes were already or
not implicated in any of the NDDs pathogenesis. MalaCards, the human maladies
and their annotations database (available at http://www.malacards.org/) was
also cross-referenced for such previous disease associations (Rappaport et al., 2013).
If not, the intrinsic molecular functions of the genes were investigated to categorize
them as genes of potential interest in NDDs mechanisms. The genes are highlighted
in red or green if they were previously implicated in the neurodegenerative disease
mechanism. If the genes are of potential interest in NDDs then they are highlighted
in orange or blue in the network figures shown in this chapter.
The 22 “seed genes” used to identify and explore the common unified underlying
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Figure 6.1. Shortest path network of neurodegeneration mechanism. The
genes/proteins implicated in NDDs are highlighted in green and red. The genes/pro-
teins of potential interest are highlighted in blue.
mechanisms in NDDs were chosen purely based on the overlapping and yet signifi-
cantly differentially expressed genes in all three disease conditions. This set of “seed
genes” included few already known NDDs genes like ATP2B2, ITSN1, MCL1, NTRK3
and SYT1 while some well-known NDDs genes like APP, HTT, PSEN1 and SNCA etc.,
were among the non-completely overlapping ones. However, the SP and other net-
works (explained below) incorporated many noteworthy genes like BNDF, CREBBP,
CDK5, EGFR, MBP, NGF, PTEN and SP1 etc. as connecting genes/proteins. Emer-
gence of such important nodes as connectors in a network primarily based on the
inter-relationships is excellent example for network-based systems biology research
work. Network-based approaches could be vital in studying a system as a whole
even if it is missing some critical components. It can be used to recreate some of
the missing pieces from the components at hand. For example, from the 22 “seed
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genes” with limited associations to neurodegeneration process emerged a shortest-
path network with 45 genes of which 28 genes were previously implicated in NDDs
(see Figure 6.1).
6.2.1 Molecular functions and network attributes of some of the
critical conecting genes
In the next few lines, we explain the molecular functions of some of the known
NDDs genes, including those that reemerged in our shortest-path network, and their
suspected role in neurodegeneration process. Abnormal CDK5 activity has been sus-
pected to contribute to the aberrant accumulation of hyperphosphorylated tau pro-
teins in AD brains (Mateo et al., 2009). In addition to functioning as ’housekeeping’
transcription factor, when deregulated SP1 has been shown to promote neurode-
generation process in multiple ways. It is a positive regulator of APP (amyloid-beta
precursor protein) gene expression as well as of genes like tau, BACE1 and CASP3.
All these factors initiate the characteristic features of any NNDs such as the pro-
tein misfoldings, abnormal accumulations and eventual neuronal loss (Citron et al.,
2008). Another hallmark trait in NDDs is the presence of neurofibrillary tangles
(NFTs). PTEN is one of the main components of such tangles in the brain (Sonoda
et al., 2010).
The shortest-path and other networks constructed for this study not only in-
cluded many disease related genes, it also featured some of the genes that aid
in neuronal survival mechanisms. For instance, epidermal growth factor receptor
(EGFR) is a potential target to treat amyloid-beta accumulation (Wang et al., 2012).
Nerve growth factors (NGF) promote neuroprotection as well as nerve repair process
(Sofroniew et al., 2001). Another growth factor namely, brain-derived neurotrophic
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factor (BDNF) was explored as promising gene therapy tool for Alzheimer’s and
Huntington’s disease (Zuccato et al., 2001; Tapia-Arancibia et al., 2008). Along
with having significant molecular functions in neurodegeneration and protection
processes, many of these genes occupy critical positions in the shortest-path net-
work. Genes like CASP3, CDK1, CDK5, EGFR and SP1 were the top five nodes with
highest connectivity (degree ≥ 9), visibility and traffic-influential as measured by
the closeness and betweenness centrality scores. These attributes increase the sig-
nificance of the genes in a network. Higher connectivity means the node is more
central and critical for the proper functioning of the network. With higher visibility,
a node could be a better monitor of the information flow, and with higher between-
ness centrality score it could influence the outcome of network processes. Thus,
based on these vital network parameters and relevant molecular functions some of
the genes in the shortest-path network could be potential important players common
to the three NDDs under study.
6.3 Combined common regulator and common target
network of neurodegeneration mechanism based
on seed genes found in common in all three NDDs
Implied by the name, using the common regulator (CR) and common target (CT)
network one can identify the regulators and targets found in common for a given set
of genes. Finding such nodes in a network is important since they can be promising
drug targets. Next to shortest-path network, the CR and CT network constructions
are popular options offered by the Pathway Studio software. We constructed the
CR and CT networks individually using the 22 “seed genes” found in common in
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all three disease conditions. Protein modification, promoter binding and microRNA
regulatory interaction types were used. Next we merged the two networks to build
one combined common regulators/targets network (see Figure 6.2).
In this combined network, genes like BCL6, ITSN1, MCL1, NTRK3 and RASGRP1
were the top five common regulators with out-degree (outgoing connections from
the node) ≥ 10 as well as genes like BCL6, CALD1, MCL1, PLCB1 and SYT1 were
the top five common targets with in-degree (incoming connections to the node) ≥
10. In addition to their high network connectivity, BCL6 and MCL1 were the top two
nodes with highest closeness and betweenness centrality scores. These high quan-
titative scores make BCL6 and MCL1 critical molecular players in all three studied
neurodegenerative disorders - Parkinson’s, Alzheimer’s and Huntington’s disease.
MCL1 (myeloid cell leukemia sequence 1) is an anti-apoptotic protein of the
BCL-2 family. In general, it enhances the survival of the cell by inhibiting apoptosis.
Promoting BCL-2 function has been proposed to treat neurodegenerative as well
as neurological disorders like stroke. The neuroprotective functions of BCL-2 are
mediated by activation of ERK/PI3K and CREB pathways. Valproate, the anticon-
vulsant and mood stabilizer medication has been explored as a potential treatment
technique for NDDs where it was suspected to up-regulate BCL-2 (B-cell CLL/lym-
phoma 6) and promote BCL-2-related neuronal protective and neurotrophic effects
(Creson et al., 2009; Shacka and Roth, 2005). BCL6 is a transcription repressor
which is frequently translocated and hypermutated in diffuse large-cell lymphoma
(DLCL), and may contribute to the DLCL pathogenesis (Hans et al., 2004). How-
ever, the BCL6 association with neurodegenerative disorders is unclear. Based on its
multiple significant network attributes it would be noteworthy to explore in detail
the BCL6 role in NDDs.
The shortest-path and the combined CR and CT networks revealed novel genes
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Figure 6.2. Combined common regulator and common target network of neu-
rodegeneration mechanism. The genes/proteins implicated in NDDs are high-
lighted in green and red. The genes/proteins of potential interest are highlighted
in blue and orange. Genes/proteins contributing to the disease pathogenesis are
highlighted in purple and those in neuronal survival are in yellow.
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of potential interest in neurodegenerative disorders based on their innate molecu-
lar functions and their importance for network topology. A more general analysis
of the role of these candidate genes will be discussed in the next section within
the framework of our modest attempt to explain the unified underlying molecular
mechanisms in NDDs
6.4 Integrated neurodegeneration mechanism network
based on the seed genes found in common in all
NDDs.
The integrated neurodegeneration mechanism network was designed as an amalga-
mation of shortest-path, common regulators and common targets networks of 22
“seed genes” found in common in all Parkinson’s, Alzheimer’s and Huntington’s dis-
ease. By combining the connecting genes/proteins from the shortest-path network,
the 22 “seed genes” grew bigger into a 46 node network (Figure 6.1) which further
increased in size as a 114 node integrated network (Figure 6.3) by incorporating the
common regulators and common targets (Figure 6.2).
In the integrated network, MCL1 and BCL6 continue to be significant unifying
players in neurodegeneration mechanism as one of the top five nodes with highest
connectivity, closeness and betweenness centrality scores. Including these two genes
there were 13 nodes higher connectivity node with degree > 10. In biological net-
works, such hubs are important since these nodes tend to be critical and conserved.
In the constructed 114-gene network more than 60% of the genes like ATM, ATR,
BDNF, CREB1, CREBP, EGFR, MAPK1, NGF, PTEN, SNAP25, SYN1 and TGFB1 etc.
were previously implicated in NDDs either as disease contributing or as neuroprotec-
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tive agents. The intrinsic molecular functions of all 114 genes were cross-referenced
in OMIM, MalaCards, PubMed databases aided with Google search for their possible
associations in neurodegenerative disorders. Based on this, the genes were classi-
fied either as disease aggravators (highlighted in purple) or as helpers in neuronal
survival process (highlighted in yellow) (see Figure 6.3).
6.4.1 Guilt-by-association analysis
As mentioned earlier, the integrated network included some potential genes of in-
terest in NDDs. The criteria used to select such genes are as follows. As determined
by being neighbors of the known NDDs genes, CALD1 has the highest number of 15
(!) nearest neighbors in the integrated neurodegeneration mechanism network (see
Figure 6.3) all of which known to be involved in one or another NDD under study
(CAMK2G, CASP3, CDK1, EDN1, F2, MAPK1, MAPK3, MAPK8, PRKCA, PRKCD,
PTEN, PTK2, RAF1, STAT3 and SYN1). The guilt-by-association property makes
CALD1 prime NDD candidate gene. CALD1 (caldesmon 1) gene encodes calmodulin-
and actin-binding protein. Calcium together with calmodulin increases the activ-
ity of calmodulin binding proteins (CaBPs). One such CaBP is BACE1, the enzyme
which is essential for the generation of beta-amyloid (Cole and Vassar, 2007). Many
research studies point out that the increase in calcium and calmodulin leads to the
abnormal protein accumulations in the brain, the key feature of NDDs. Calmodulin
antagonists are explored as potential drug targets in Alzheimer’s disease (O’Day
and Myre, 2004). All this reinforces the prognosis made for CALD1 as an important
NDD-related gene.
Our second choice for candidate gene is AHNAK (nucleoprotein). It neighbors
with nine already known-NDDs genes (AKT1, CAPN2, CASP3, CD8A, GZMB, MAPK1,
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Figure 6.3. Integrated network of neurodegeneration mechanism. The
genes/proteins implicated in NDDs are highlighted in green and red. The genes/pro-
teins of potential interest are highlighted in blue and orange. Genes/proteins con-
tributing to the disease pathogenesis are highlighted in purple and those in neuronal
survival are in yellow.
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NGF, PLCG1 and RAF1). S100B (S100 calcium binding protein B) is suspected to
play a role in neurodegeneration by recruiting pro-inflammatory molecules which
ultimately cause neuronal apoptosis (Rothermundt et al., 2003). AHNAK is a ma-
jor and most specific calcium-dependent S100B target protein. The S100B/AHNAK
interaction is supposed to participate in the S100B-mediated regulation of cellular
calcium homeostasis (Salim et al., 2009). As mentioned earlier, disruption of cal-
cium homeostasis is one of the crucial steps in neurodegeneration process. Thus,
AHNAK could likely be involved in such deregulation activity promoting neuronal
loss.
Another recommendation for candidate gene is DCLK1 which directly interacts
with five known NDD-genes (CAPN2, CREBBP, MAPK1, MBP and SYN1). DCLK1
(doublecortin-like kinase 1) is highly expressed in the hippocampus and in the cor-
tices. Le Hellard et al. in 2009 have shown that up-regulation of DCLK1 by BDNF
(brain-derived neurotrophic factor) could be associated with increased synaptic for-
mation and general cognitive abilities. DCLK1 could be pursued as a potential drug
target to enhance the memory formation and cognition.
Intrinsic molecular functions relevant to neurodegeneration process, as well as
their associations with many previously known NDDs-genes, increases the chances
of ANHAK, CALD1 and DCLK1 to be potential genes of interest in Parkinson’s, Alzheimer’s
and Huntington’s disease.
6.4.2 MicroRNA regulation in NDDs
The integrated network also incorporated regulatory interactions of 19 microRNAs.
It included four miRNAs namely, miR-153, miR-34c, miR-7 and let-7, previously im-
plicated in NDDs. They target APP and SNCA, the two well-known promoters of
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neurodegeneration in Alzheimer’s and Parkinson’s disease (Miñones Moyano et al.,
2011; Junn and Mouradian, 2012). Apart from these four known miRNAs ten others
namely, miR-128-1, miR-135A1, miR-137, miR-15A, miR-16-1, miR-17, miR-19A,
miR-27A, miR-30B and miR-32, were repeatedly identified in this integrated net-
work as well as in the microRNA regulatory networks that we constructed for each
disease conditions individually (see sections 3.5, 4.4 and 5.5). Based on this recur-
ring pattern, these ten microRNAs could have potential role in NDDs, which requires
further validation. Besides microRNAs, regulation by transcription factors (TFs) was
also noticed in the integrated network. Twelve TFs regulates the expression of many
genes in this network. Except BCL6 all other TFs CREB1, CREBBP, ELK1, FOS, JUN,
MYC, SMAD3, STAT1, STAT3, SP1 and SOX4 were previously known in NDDs. The
transcription factor regulation is an integral part of NDDs mechanisms which we
also observed in the individual PD, AD and HD regulatory network-based analysis.
Again, the possibility of dual-level TF/miRNA regulation in each of these neurode-
generative disorders is reinforced here.
6.4.3 DAVID enrichment analysis
Apart from identifying individual molecular players in NDDs, DAVID analysis was
utilized to evaluate the biological processes and pathways enriched in the integrated
network 114-genes set. Table 6.1 shows the identified statistically significantly en-
riched (Benjamini-Hochberg multiple correction) Gene Ontology (GO) categories
and pathways related to brain and nervous system.
Biological processes like aging, memory or learning, neuron development and
differentiation, synaptic vesicle trafficking and endocytosis and vasculature devel-
opment etc. were some of the highly affected common mechanisms in the neu-
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rodegenerative disorders. The deregulation of such biological processes was also
revealed in the each of the individual disease enrichment analysis. In addition, en-
riched KEGG pathways also resulted from DAVID analysis. Table 6.2 presents all
the 31 significantly enriched (with Benjamini-Hochberg multiple correction) KEGG
pathways in NDDs.
The enriched KEGG pathways belonged to signal transduction, cell communi-
cation, nervous system, immune system, endocrine system, cell motility, develop-
ment, endocrine and metabolic diseases, neurodegenerative diseases and carbohy-
drate metabolism categories. It is remarkable to notice that other progressive and
chronic neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and
Prion diseases, although not directly included in our three NDDs project, were also
significantly enriched. Prion disease is characterized by the abnormal prion protein
misfoldings in the brain and ALS is caused by the degeneration and death of motor
neurons. Similarly, it was valuable to detect Type I and Type II diabetes mellitus to
be enriched in the NDDs gene set. Impaired glucose metabolism has been associated
with the abnormal protein aggregate formation and vice versa. In addition, cogni-
tive dysfunction and the incidence of dementia were related with impaired glucose
metabolism (Umegaki, 2012; Ristow, 2004).
As mentioned in the earlier chapters, many of the enriched KEGG pathways
like long-term potentiation, axon guidance, calcium signaling pathway, gap and
tight junction and neurotrophin signaling pathway etc. were also significantly af-
fected in Parkinson’s, Alzheimer’s and Huntington’s diseases when analyzed sep-
arately. Unlike the individual disease-based DAVID analysis, we observed in our
PD/AD/HD integrated network analysis several more KEGG pathways like inositol
phosphate metabolism, phosphatidylinositol signaling system, JAK-STAT signaling
pathway, leukocyte transendothelial migration, long-term depression, GnRH signal-
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Figure 6.4. Four-set Venn diagram illustration of the overlap of enriched KEGG
pathways found in Parkinson’s, Alzheimer’s, Huntington’s and unified NDDs
resulted from DAVID analysis. Courtesy: VENNY
ing pathway, type I diabetes mellitus and Prion diseases to be significantly affected.
Deregulation of these pathways in NDDs has been claimed in the literature previ-
ously. Figure 6.4 and Table 6.3 illustrates the overlap of 34 enriched KEGG pathways
that resulted from the DAVID analysis of the individual disease conditions as well as
the unified NDDs.
Observing these kinds of common molecular players and biological processes
is noteworthy suggesting that there is a unified underlying molecular mechanism
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Table 6.3. Enriched KEGG pathways found in Parkinson’s, Alzheimer’s, Hunting-
ton’s and unified NDDs resulted from DAVID analysis
KEGG pathways Enriched in disease conditions
hsa04010:MAPK signaling pathway PD, HD, unified NDDs
hsa04012:ErbB signaling pathway PD, AD, HD, unified NDDs
hsa04020:Calcium signaling pathway AD, unified NDDs
hsa04062:Chemokine signaling pathway PD, AD, unified NDDs
hsa04115:p53 signaling pathway PD, HD, unified NDDs
hsa04310:Wnt signaling pathway PD, unified NDDs
hsa04350:TGF-beta signaling pathway AD, unified NDDs
hsa04360:Axon guidance PD, unified NDDs
hsa04370:VEGF signaling pathway PD, unified NDDs
hsa04510:Focal adhesion PD, unified NDDs
hsa04520:Adherens junction PD, AD, HD, unified NDDs
hsa04530:Tight junction PD, unified NDDs
hsa04540:Gap junction PD, unified NDDs
hsa04620:Toll-like receptor signaling pathway PD, unified NDDs
hsa04650:Natural killer cell mediated cytotoxicity AD, unified NDDs
hsa04660:T cell receptor signaling pathway AD, unified NDDs
hsa04662:B cell receptor signaling pathway AD, unified NDDs
hsa04720:Long-term potentiation AD, unified NDDs
hsa04722:Neurotrophin signaling pathway PD, AD, unified NDDs
hsa04810:Regulation of actin cytoskeleton PD, unified NDDs
hsa04910:Insulin signaling pathway HD, unified NDDs
hsa04930:Type II diabetes mellitus HD, unified NDDs
hsa05014:Amyotrophic lateral sclerosis (ALS) PD, AD, HD, unified NDDs
hsa00562:Inositol phosphate metabolism unified NDDs
hsa04070:Phosphatidylinositol signaling system unified NDDs
hsa04630:Jak-STAT signaling pathway unified NDDs
hsa04670:Leukocyte transendothelial migration unified NDDs
hsa04730:Long-term depression unified NDDs
hsa04912:GnRH signaling pathway unified NDDs
hsa04920:Adipocytokine signaling pathway HD
hsa04940:Type I diabetes mellitus unified NDDs
hsa05010:Alzheimer’s disease PD, AD, HD
hsa05016:Huntington’s disease HD
hsa05020:Prion diseases unified NDDs
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across several NDDs. Based on this common phenomena and further analysis of the
integrated mechanism network, we propose several possible ways of neurodegen-
eration initiation, as well as neuroprotection mechanisms common for Parkinson’s,
Alzheimer’s and Huntington’s disease. First, we will describe some possible disease
induction routes. The integrated network shown in Figure 6.3, includes 11 extra-
cellular ligands and 15 membrane bound proteins and receptors. Some of these
entities such as BDNF, EGFR, INS and TGFB1 were also detected in the individual
integrated Parkinson’s, Alzheimer’s and Huntington’s disease networks (see section
3.4, 4.4 and 5.4).
6.4.4 Proposed neurodegeneration initiation routes
Reiterating the insulin deregulation in neurodegeneration hypothesis, we suggest
that INS could be a major disease initiation origin. The extra-cellular ligand INS
(insulin) interacts directly with many genes present not only in the membrane but
also in the cytoplasm and nucleus. Chronic hyperinsulinaemia and insulin resis-
tance, or reduced insulin effectiveness, is suggested to exert a negative influence
on memory and cognitive functions in AD patients (Umegaki, 2012; Ristow, 2004).
This could be realized by the INS interactions with phospholipase (PLD2) and synap-
totagmins (SYT1) as shown in our network. In general, phospholipases are a class of
enzymes that hydrolyzes phospholipids into fatty acids and other lipid substances.
Prolonged stimulation of phospholipase along with the accumulation of reactive
oxygen species (ROS) could contribute to both acute (brain injuries) and chronic
neurodegeneration diseases like Alzheimer’s. Recently in an AD mouse study, it has
been suggested that reduction of phospholipase could mitigate cognitive deficits
(Servitja et al., 2002; Farooqui et al., 1997; Sanchez-Mejia et al., 2008). Synapto-
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tagmins function as calcium sensors in the regulation of neurotransmitter release
and other hormonal secretion. They are one of the key players in the rapid exo-
cytosis and endocytosis of synaptic vesicles (SV). During synapse formation, SYT1
acts as calcium sensor and triggers the SV release (Chapman, 2008). Disruption
of calcium homeostasis could be detrimental to the calcium-dependent synaptotag-
min activities which could have adverse effects in SV trafficking and fusion, thus
contributing to neurodegeneration (Glavan et al., 2009). Another study has ex-
plained the role of synaptotagmin in Ca2+ mediated insulin exocytosis (Gauthier
and Wollheim, 2008). In addition, the integrated network also revealed direct in-
hibitory interaction between INS and BCL6. As mentioned earlier, the role of BCL6
is unclear and further experimental validation is required to explore whether any
neurodegeneration occurs as a result of such interactions between INS and BCL6.
In general, many research work supports that deregulation of insulin potentially
predisposes for the development of neurodegeneration (Schubert et al., 2004; Craft
and Watson, 2004).
Another proposed route for disease induction is via a different extra-cellular lig-
and namely, F2 (coagulation factor II (thrombin)). Animal studies have demon-
strated that thrombin is neurotoxic to the dopaminergic neurons and induces mi-
croglial activity, which contributes to neuronal loss. At physiological concentra-
tions, thrombin enhances the survival of neurons and astrocytes that were exposed
to cellular injury. However, at higher concentrations thrombin promotes neuron
degeneration. Caspase-3 mediates the neurotoxic apoptotic action of thrombin in
motor neurons (Choi et al., 2003; Lee et al., 2006). In the integrated network, F2 di-
rectly interacts with many genes including phospholipase D2 which was mentioned
in the foregoing as a calmodulin- and actin-binding protein potentially involved in
the neurodegeneration pathogenesis. The CASP3 and PTEN are the major down-
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stream targets of CALD1. PTEN is already implicated in Alzheimer’s disease where
it is associated with the hyperphosphorylated tau protein formations, a hallmark
feature of NDDs (Kerr et al., 2006).
Third possible route for neurodegeneration process is through the FAS ligand
namely, FASLG. Interaction of FAS and its receptor is critical in triggering apop-
tosis. In general, FAS is required to maintain the immune suppressed status in
brain. But when up-regulated, it is suspected to promote neuronal cell death and in-
flammation in a variety of neurological disorders including Multiple sclerosis (MS),
Prion diseases, PSPs etc. Studies have suggested that FAS-mediated signaling might
contribute to immune-mediated oligodendrocyte injury and demyelination in MS
(D’Souza et al., 1996; Choi and Benveniste, 2004). The integrated network reveals
FAS interactions with phospholipase B1 and other downstream targets which in-
creases the possibility of FAS-mediated neuronal loss in NDDs.
In addition to the above discussion, it should be noted that many T-cell molecules
like CD8a, CD28, CD44 and CD69 were identified in the extra-cellular space of the
integrated network, as well as in the cell membrane. Increasing biochemical research
evidence suggests that receptors of the innate immune response could act as sensors
that induce or amplify inflammation in NDDs like ALS, MS etc. (Glass et al., 2010).
Neuroinflammation is one of the key features that accelerate neurodegeneration
process and these T-cells could mediate such mechanism in NDDs.
6.4.5 Proposed therapeutic measures
Based on the integrated network (see Figure 6.3), until now we proposed many
neurodegeneration initiation routes. Below we focus on similar kinds of analysis
and proposals for neuroprotective mechanisms. Several growth factors, including
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BDNF, EGF, NGF as well as colony stimulating factor, endothelin and TGFB1, were
observed in the integrated network. Many of the above listed extra-cellular ligands
have been pursued as neuroprotective measures in NDDs. Up-regulation of brain-
derived neurotrophic factor (BDNF) has been widely explored as neuroprotective
mechanism in NDDs including Alzheimer’s and Huntington’s disease (Ferrer et al.,
2000; Zuccato et al., 2001; Tapia-Arancibia et al., 2008). Nerve growth factor (NGF)
mediates memory formation, learning and other higher cognitive abilities in addi-
tion to assisting with neuronal development and repair process. NGF cell therapy
has shown cognitive improvement in patients with Alzheimer’s disease (Sofroniew
et al., 2001; Chao et al., 2006). Another growth factor namely, epidermal growth
factor (EGF) has neuromodulatory role in the central nervous system. EGF also
stimulates neuronal growth, increases dopamine uptake and enhances the survival
of dopaminergic neurons. Recently, it has been shown that EGF promotes neurogen-
esis in age-related neurological disorders. Its survival activities are realized through
the activation of its receptor EGFR which is also identified in our integrated network
as one of the many connecting genes/proteins (Jin et al., 2003; Wong and Guillaud,
2004). Reduced TGF-β signaling in neurons resulted in age-mediated neurodegen-
eration. Up-regulation of TGFB1 signaling has been proposed as a therapeutic mea-
sure in mitigating the amyloid-formation in Alzheimer’s disease. In the integrated
network such neuroprotective mechanism of TFGB1 could be enhanced by its in-
teraction with BDNF, EGFR and other downstream targets (Krieglstein et al., 2002;
Tesseur et al., 2006).
Besides the genes, microRNA regulation could also be exercised to promote neu-
rogenesis as well as suppress the harmful gene expressions. Among the ten microR-
NAs proposed earlier, the following microRNAs miR-128-1, miR-135A1, miR-17,
miR-19A, miR-27A, miR-30B and miR-32 could have a potential role in suppressing
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the activity of some of the neurodegeneration promoting genes like CALD1, PLCB1
and SYT1. Similarly, epigenetic regulation of miR-137, miR-15A and miR-16-1 ex-
pressions (e.g., by hypermethylation) could be beneficial for the normal functioning
of pro-survival genes like MCL1 and DCLK1.
Analyzing the integrated neurodegeneration mechanism network, it was evident
that there are many complex interactions occurring between diseases promoting as
well as protecting agents. Many of the genes in the network are essential for the
general functioning of the cell including metabolism, growth, cytoskeletal organiza-
tion, cell cycle control and transcriptional regulation etc. A delicate balance between
these entities has to be established and maintained for the cell to survive. Identify-
ing disease initiation and protective routes is vital in restoring cellular homeostasis
and helps in identifying potential drug targets. Proceeding from similar underly-
ing pathophysiological conditions and researching their integrated network, seems
promising approach to reveal such disease initiating and neuroprotective mecha-
nisms that are common for Parkinson’s, Alzheimer’s and Huntington’s disease.
6.5 Summary
Motivation to undertake this research work is the growing evidence of deregulation
of many biological processes that were found in common in several neurodegener-
ative disorders. Using network-based systems biology approach we set out to in-
vestigate the critical molecular players and underlying mechanisms in Parkinson’s,
Alzheimer’s and Huntington’s disease. After initial success with such network-based
approaches in individual disease realm, we extended our inquiry for key players and
mechanisms that could be common in all three NDDs. The unified network-based
analysis was initiated using the overlapping 22 significantly differentially expressed
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genes found in all three NDDs microarray datasets. Using the 22 “seed genes”,
several networks including shortest path, common targets and common regulators
were constructed and merged to form one big integrated network which is used to
examine the critical molecular partakers and biological processes that are common
in all three NDDs. Four of the 22 seed genes remained unconnected in our net-
works. From the rest 18 ten (ATP2B2, ITSN1, MCL1, NTRK3, PLCB1, RASGRP1,
REPS2, SCAMP1, STXBP1 and SYT1) were previously known to be modulated in
NDDs, while the other eight (ADAM23, AHNAK, BCL6, CALD1, CAPRIN1, DCLK1,
SSBP3 and ZMAT3) are reported for the first time in this function.
The shortest path network incorporated many previously known-NDDs genes like
BNDF, CREBBP, CDK5, EGFR, MBP, NGF, PTEN and SP1 etc. as connecting genes/pro-
teins. Many of these known genes were highly connected nodes which suggest that
these genes could be critical in the neurodegeneration mechanism. MCL1 and BCL6
were the most highly connected common regulators as well as common targets in
the gene set used for the study. Finding such critical nodes is significant since they
can be promising drug targets in NDDs. On examining the integrated network it was
evident that there is complex inter-connection existing between disease promoting
and protective genes. It was difficult to have a line of separation between these
two types of agents. Via their guilt by associations with several well-known NDDs
genes, we propose AHNAK, CALD1 and DCLK1 as novel candidate genes common
for Parkinson’s, Alzheimer’s and Huntington’s disease. Apart from being neighbors
with previously implicated disease genes, these three candidate genes have innate
molecular functions relevant to neurodegeneration and protection mechanism. Dis-
ruption of CALD1 and AHNAK could increase neurodegeneration and the subsequent
neuronal loss whereas DCLK1 could be pursued as potential drug target to enhance
the memory formation and cognition.
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Besides genes, many microRNAs-target interactions were also detected in the
integrated network. Other than few known microRNAs, we identified ten novel mi-
croRNAs namely, miR-128-1, miR-135A1, miR-137, miR-15A, miR-16-1, miR-17,
miR-19A, miR-27A, miR-30B and miR-32 which occurred repeatedly in individual
and integrated networks of NDDs. Further experimental validation of these microR-
NAs could shed more light on the regulatory mechanisms in NDDs. Detection of
transcription factors in the integrated network reveals the possibility of dual-level
regulation in NDDs thereby adding more complexity to the disease mechanism.
DAVID analysis uncovered many biological processes like aging, memory or learn-
ing, neuron development and differentiation, synaptic vesicle trafficking and endo-
cytosis and vasculature development etc. including KEGG pathways like long-term
potentiation, axon guidance, calcium signaling pathway, gap and tight junction, neu-
rotrophin signaling pathway, ALS, AD and Prion diseases to be significantly affected
in all three NDDs under study.
In addition, we propose several disease initiating and neuroprotecting routes
that are common for Parkinson’s, Alzheimer’s and Huntington’s disease. In the in-
tegrated network, extra-cellular ligands like INS, F2 and FASLG could have a major
role in initiating the vicious cycle of inducing abnormal protein accumulation which
in turn promotes neurodegeneration and eventual neuronal loss. This mechanism
is mediated by the ligands and membrane receptors and is followed by disruption
of the normal activity of their downstream targets. Similarly, we propose several
more routes for neuroprotective mechanisms that could have a universal role in the
three neurodegenerative disorders. Up-regulation of BDNF, EGF, NGF, TGFB1 along
with EGFR could promote neurogenesis and restore homeostasis. In conclusion,
our systems biology study reveals important details of neurodegenerative disorders
as polygenic and highly complex in nature. Finding and maintaining the delicate
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balance between NDD promoters and protectors is essential for restoring the home-
ostasis.
In conclusion, using network-based system biology techniques we have identi-
fied many critical molecular players as well as deregulation of various biological
processes that were common in Parkinson’s, Alzheimer’s and Huntington’s neurode-
generative diseases. Based on these findings, we have proposed a unified integrated
neurodegeneration mechanism network with several possible routes for disease ini-
tiation and neuroprotection processes verifying thus the basic hypothesis of this re-
search project.
Chapter 7
Conclusions and future directions
7.1 Major findings
Major findings of our research work are listed below. Table 7.1 summarizes the main
results from Chapters 3-5 and lists the novel candidate genes, novel microRNAs as
well as the proposed routes for disease initiation and/or neuroprotective modula-
tion in Parkinson’s, Alzheimer’s and Huntington’s disease. Table 7.2 lists the major
findings of the unified Neurodegenerative disorders (NDDs) network-based analy-
sis. The reported seed genes are common for the three studied NDDs, while the new
genes, miRNAs, biological processes, pathways and routes for disease initiation or
potential disease suppression are obtained from the network analysis of the unified
mechanism of neurodegenerative disorders proposed in Chapter 6.
7.2 Future directions
Network-based approaches are powerful and beneficial tools to study complex sys-
tems like neurodegenerative disorders. By constructing and analyzing relevant net-
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Table 7.2. Major findings of unified network-based analysis of Neurodegenerative
disorder’s (NDDs).
Categories Counts Findings
Common “seed genes” 22
ADAM23, AHNAK, ATP2B2, ATP6V0E1, BCL6,
CALD1, CAPRIN1, DCLK1, GLT1D1, ITSN1,
MCL1, MSI2, NTRK3, PLCB1, PREPL, RASGRP1,
REPS2, SCAMP1, SSBP3, STXBP1, SYT1, ZMAT3
Previously known NNDs
genes 10
ATP2B2, ITSN1, MCL1, NTRK3, PLCB1,
RASGRP1, REPS2, SCAMP1, STXBP1, SYT1
Novel candidate genes 5 ADAM23, AHNAK, BCL6, CALD1, DCLK1
Novel microRNAs 10
miR-128-1, miR-135A1, miR-137, miR-15A,
miR-16-1, miR-17, miR-19A, miR-27A, miR-30B,
miR-32
Novel therapeutic targets 2 BCL6, MCL1
Major common biological
processes 7
Aging, memory or learning, neuron development
and differentiation, synaptic vesicle trafficking
and endocytosis, vasculature development
NDD common KEGG
pathways 34
Adipocytokine, B-cell receptor, calcium,
chemokine, ErbB, GnRH, Insulin, Jak-STAT,
MAPK, neurotrophin, p53, T-cell receptor,
Toll-like receptor, TGF-beta, VEGF, Wnt signaling
pathways, axon guidance, focal adhesion,
adherens, tight and gap juntions, natural killer
cell mediated cytotoxicity, regulation of actin
cytoskeleton, inositol phosphate metabolism,
phosphatidylinositol signaling system, leukocyte
transendothelial migration, long-term
depression/potentiation, type I/II diabetes
mellitus, ALS, AD, HD, Prion diseases a
ELDDIN routesb 11
ADAM23, BDNF, CD84, CSF1, EDN1, EGF, F2,
FASLG, INS, NGF, TGFB1
Major disease initators 3 F2, FASLG, INS
Major neuroprotective
mediators 5
BDNF, EGF, EGFR, NGF, TGFβ1
For full details see Figure 6.3.
aALS - Amyotrophic lateral sclerosis; AD - Alzheimer’s disease; HD - Huntington’s disease
bExtra-cellular Ligand Downstream Disease Initiating/Neuroprotecting
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works one could arrive at a broader view of the whole system. The structure of
the network is critical for its functioning and reveals the key players and molecular
pathways involved, along with the underlying mechanisms of the system.
In the past, guilt-by-association techniques and shortest-path network-based anal-
ysis have played a vital role in predicting protein-protein interactions in yeast as
well as identifying novel genes that modulate longevity in Saccharomyces cerevisiae
(Schwikowski et al., 2000; Managbanag et al., 2008). Especially such network-
based candidate genes predictions have been successfully validated by experimen-
talists there by contributing important advancement in aging-related research realm.
Based on such network approach, we have only exposed the tip of the iceberg
of the complex neurodegenerative mechanism. There are too many critical play-
ers with intertwined as well as delicate interactions among them. This opens new
prospects for integrative studies of neurodegenerative diseases. Using network-
based analysis, we have narrowed down the search for critical molecular players for
each of the three neurodegenerative disorders under study, as well as novel common
key players in this disease realm. Moving forward, both for the individual disease
conditions and the unified approach, we could further refine our proposed candidate
genes selections based on additional network attributes like eigenvector centrality
scores, cliques etc. (Koschützki and Schreiber, 2008; Ozgür et al., 2008). Future
research along these lines may include a broad collaboration with experimentalists
to test some of the candidate genes and NDDs mechanisms proposed in our project
with good chances for funded studies.
On computational side, the work done in this project may be considerably ex-
panded to include more advanced and accurate biochemical assays like exon arrays,
RNA-seq etc., as well as integrated network analysis of larger amount and broader
types of experimental datasets. We believe such development could expand and
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fine-tune our current findings thus contributing for the better understanding and
treatment of these dangerous diseases. Apart from this, integrating diverse data
types like proteomic data with gene expression data, one could have better under-
standing of the underlying complex molecular characteristics of the neurodegen-
eration mechanisms. This integrated approach will permit us to identify genes at
the transcription level along with post-transcriptional regulations that are crucial
during the neurodegeneration process which would otherwise be not apparent by
examining either mRNA or protein expression alone (Ideker et al., 2001; Grant and
Blackstock, 2001; Tian et al., 2004).
In addition, some of our proposed candidate genes and their critical functioning
in neurodegeneration process could be tested in appropriate animal models. Often
aging increases the risk for neurodegeneration in human which may not be directly
studied using animal models. However, many genetically engineered animals have
been instrumental in studying such complex diseases like NDDs (Phillips et al., 2009;
Jucker, 2010; Langui et al., 2007). Utilizing these animal models, we believe at
least a handful of our candidate genes could be further evaluated for potential drug
targets for neurodegenerative disorders. Age factor in human neurodegeneration
process could be studied in time-series experiments by including animals at different
chronological age.
In recent years, cerebrospinal fluids and blood samples have been investigated
for early disease detection, as well as for biomarker validation. Doecke et al. (2012)
have identified a panel of 18 blood-based biomarkers for Alzheimer’s disease where
the presence of genes/proteins related to inflammation and especially insulin-like
and epidermal growth factors had increased the sensitivity of the assay. From our
network-based gene expression analysis, we also found genes/proteins related to
inflammation (like interleukins) and EGFR, INS as well as genes/proteins related
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to wound healing and aging to be highly enriched in Parkinson’s, Alzheimer’s and
Huntington’s disease conditions. Similarly, Molochnikov et al. (2012) identified
seven blood-based protein biomarkers for Parkinson’s disease, such as p19 S-phase
kinase-associated protein 1A (SKP1), huntingtin interacting protein-2 (RNF2) and
heat shock 70-kDa protein 8 (HSPA8). In future we anticipate that such network-
based analysis will be vital in discovering better biomarkers from blood-based gene
expression datasets. The blood-samples analysis will also be extended to study the
protein-protein interaction networks that evolve over a time period.
Many prospective multi-disciplinary research opportunities could thus be opened
in near future by our network-based analysis of neurodegenerative disorders for fur-
ther refining our novel candidate genes collections and validating some of proposed
disease initiating and neuroprotective mechanisms.
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Appendix A
Statistical analysis of microarray dataset
A.1 R Program code
Below is the R program source code for statistical analysis of microarray dataset.
#R Code for Statistical Analysis of microarray dataset. This includes
#1. Pre-processing --- Density Histogram and boxplot, NUSE and RLE
#2. Normalization --- RMA normalization
#3. Post-processing --- ArrayQualityMetrix, Linear Model with eBayes.
MA plot and Clusters from the eBayes data.Valcano plot and Heat Map
from the toptable results
source("http://bioconductor.org/biocLite.R")
biocLite("hgu133a.db")
biocLite("hgu133acdf")
biocLite("gplots")
library(affy); library(limma); library(gcrma);
library(arrayQualityMetrics);library(hgu133acdf);
library(gplots);library(affyPLM);library(genefilter);
library(hgu133a.db);library(annotate);
#STEP 1: PRE-PROCESSING
#Read the CEL data
pd <- read.AnnotatedDataFrame("NBD_PD_TargetFile.txt")
data<-ReadAffy(filenames=rownames(pData(pd)),phenoData=pd)
187
APPENDIX A. STATISTICAL ANALYSIS OF MICROARRAY DATASET 188
#Quality assessment plots
hist(data)
boxplot(data)
Pset <- fitPLM(data)
NUSE(Pset)
RLE(Pset)
RNAdeg <- AffyRNAdeg(data)
plotAffyRNAdeg(RNAdeg,transform="shift.scale",log.it=F)
#STEP 2: PROCESSING/NORMALIZING
#Normalize the data
eset_rma <- rma(data)
#To run array Quality Metrics after normalization
arrayQualityMetrics(expressionset = eset_rma, outdir="QA_NBD_PD_Norm",
force = FALSE, intgroup = fac)
#Analysis - Do a linear model of the expression dataset described by
diagnosis (Control and case)
design <- model.matrix(~diagnosis,pData(eset_rma))
fit <- lmFit(eset_rma, design)
efit <- eBayes(fit)
#STEP 3: POST-PROCESSING
#MA Plot
M <- efit$coefficients[,2]
A <- efit$Amean
ma.plot(A,M,plot.method="normal")
#Clustering of different samples
eset_cluster <- exprs(eset_rma)
distance <- dist(t(eset_cluster),method="maximum")
clusters <- hclust(distance)
plot(clusters,main="Cluster dendrogram of normalized dataset")
#Volcano plot
plot(results$logFC,-log10(results$P.Value),pch=16,cex=0.1,
xlab="Log Fold-Changes",
ylab="-log10 P-Values",
main='Volcano Plot of normalized NBD_PD dataset')
abline(h = 2, v=c(0.5,-0.5))
t <- is.element(results$ID,results$ID[results$adj.P.Val<0.05])
points(results$logFC[t],-log10(results$P.Value[t]),pch=16,col='red',cex=0.1)
t <- is.element(results$ID,results$ID[results$adj.P.Val<0.05][1:25])
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points(results$logFC[t],-log10(results$P.Value[t]),pch=7,col='black')
legend("topright",
c('SDEGs (BH p-value<0.05)','Top 25 SDEGs (BH p-value<0.05)','Other'),
pch=c(16,7,16),col=c('red','black','black'),cex=1)
#Heatmap of the arrays using the significant genes
topgenes = results[results[, "adj.P.Val"] < 0.00001, ]
m = exprs(eset_rma[topgenes[, "ID"], ])
par(mfrow=c(1,1))
colnames(m) = pData(pd)$Diagnosis
rownames(m) = topgenes$Symbol
colours = c("Red", "Blue")
col = colours[diagnosis]
heatmap.2(m, ColSideColors = col, margin = c(5,
8),scale="none",cexRow=0.5,col=redgreen(75),
key=FALSE,symkey=FALSE,density.info="none",trace="none",
dendrogram="both",
main = "Top SDGEs (p value <0.00001)",
xlab="<-- Samples -->", ylab="<-- Genes -->")
A.2 Microarray data processing plots/graphs
Following are the various plots/graphs drawn during the statistical analysis of a
microarray dataset.
 Pre-normalization: Histogram 
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 Pre-normalization: Boxplot 
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 Pre-normalization: Normalized Unscaled Standard Error (NUSE) plot 
 
 
 
 
 
 
 
 
 
 
APPENDIX A. STATISTICAL ANALYSIS OF MICROARRAY DATASET 192
 Pre-normalization: Relative Log Expression (RLE) plot
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 Pre-processing: RNA degradation plot 
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 Post-processing: Histogram of p-and q-values 
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 Post-processing: Histogram of p-and q-values 
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 Post-processing: Histogram of p-and q-values 
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 Post-processing: Histogram of p-and q-values 
 
 
 
APPENDIX A. STATISTICAL ANALYSIS OF MICROARRAY DATASET 198
 Post-processing: MA plot 
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 Post-processing: Clustering 
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 Post-processing: Volcano plot 
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 Post-processing: Heatmap 
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A.3 Sample arrayQualityMetrics report
Next few pages contains the arrayQualityMetrics report for a microarray dataset used
in this study.
GSE8397QA Norm Report
Section 1: Between array comparison
Distances between arrays
Principal Component Analysis
Section 2: Array intensity distributions
Boxplots
Density plots
Section 3: Variance mean dependence
Standard deviation versus rank of the mean
Section 4: Individual array quality
MA plots
Browser compatibility
This report uses recent features of HTML 5 which have not yet been implemented by all browsers. Thus, unfortunately,
browser compatibility currently needs to be considered:
Firefox 4 - tested, works well,
Chrome 10 - tested, works well,
Safari 5 - the interactive (SVG) plots will be missing, since this browser does not support the embedding of the <svg>
tag in HTML.
+ Array metadata and outlier detection overview
Section 1: Between array comparison
- Figure 1: Distances between arrays.
APPENDIX A. STATISTICAL ANALYSIS OF MICROARRAY DATASET 204
Figure 1 (PDF file) shows a false color heatmap of the distances between arrays. The color scale is chosen to cover the
range of distances encountered in the dataset. Patterns in this plot can indicate clustering of the arrays either because of
intended biological or unintended experimental factors (batch effects). The distance dab between two arrays a and b is
computed as the mean absolute difference (L1-distance) between the data of the arrays (using the data from all probes
without filtering). In formula, dab = mean | Mai - Mbi |, where Mai is the value of the i-th probe on the a-th array. Outlier
detection was performed by looking for arrays for which the sum of the distances to all other arrays, Sa = Σb dab was
exceptionally large. No such arrays were detected.
- Figure 2: Outlier detection for Distances between arrays.
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Figure 2 (PDF file) shows a bar chart of the sum of distances to other arrays Sa, the outlier detection criterion from the
previous figure. The bars are shown in the original order of the arrays. Based on the distribution of the values across all
arrays, a threshold of 18.8 was determined, which is indicated by the vertical line. None of the arrays exceeded the threshold
and was considered an outlier.
- Figure 3: Principal Component Analysis.
array
sampleNames
Target
Name
TissueType
Age
ScanDate
Figure 3 (PDF file) shows a scatterplot of the arrays along the first two principal components. You can use this plot to explore
if the arrays cluster, and whether this is according to an intended experimental factor, or according to unintended causes such
as batch effects. Move the mouse over the points to see the sample names.
Principal component analysis is a dimension reduction and visualisation technique that is here used to project the multivariate
data vector of each array into a two-dimensional plot, such that the spatial arrangement of the points in the plot reflects the
overall data (dis)similarity between the arrays.
Section 2: Array intensity distributions
- Figure 4: Boxplots.
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Figure 4 (PDF file) shows boxplots representing summaries of the signal intensity distributions of the arrays. Each box
corresponds to one array. Typically, one expects the boxes to have similar positions and widths. If the distribution of an array
is very different from the others, this may indicate an experimental problem. Outlier detection was performed by computing the
Kolmogorov-Smirnov statistic Ka between each array's distribution and the distribution of the pooled data.
- Figure 5: Outlier detection for Boxplots.
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Figure 5 (PDF file) shows a bar chart of the Kolmogorov-Smirnov statistic Ka, the outlier detection criterion from the previous
figure. The bars are shown in the original order of the arrays. Based on the distribution of the values across all arrays, a
threshold of 0.0274 was determined, which is indicated by the vertical line. 2 arrays exceeded the threshold and were
considered outliers.
- Figure 6: Density plots.
array
sampleNames
Target
Name
TissueType
Age
ScanDate
Figure 6 (PDF file) shows density estimates (smoothed histograms) of the data. Typically, the distributions of the arrays
should have similar shapes and ranges. Arrays whose distributions are very different from the others should be considered for
possible problems. Various features of the distributions can be indicative of quality related phenomena. For instance, high
levels of background will shift an array's distribution to the right. Lack of signal diminishes its right right tail. A bulge at the
upper end of the intensity range often indicates signal saturation.
Section 3: Variance mean dependence
- Figure 7: Standard deviation versus rank of the mean.
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Figure 7 (PDF file) shows a density plot of the standard deviation of the intensities across arrays on the y-axis versus the
rank of their mean on the x-axis. The red dots, connected by lines, show the running median of the standard deviation. After
normalisation and transformation to a logarithm(-like) scale, one typically expects the red line to be approximately horizontal,
that is, show no substantial trend. In some cases, a hump on the right hand of the x-axis can be observed and is symptomatic
of a saturation of the intensities.
Section 4: Individual array quality
- Figure 8: MA plots.
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Figure 8 (PDF file) shows MA plots. M and A are defined as:
M = log2(I1) - log2(I2)
A = 1/2 (log2(I1)+log2(I2)),
where I1 is the intensity of the array studied, and I2 is the intensity of a "pseudo"-array that consists of the median across
arrays. Typically, we expect the mass of the distribution in an MA plot to be concentrated along the M = 0 axis, and there
should be no trend in M as a function of A. If there is a trend in the lower range of A, this often indicates that the arrays have
different background intensities; this may be addressed by background correction. A trend in the upper range of A can indicate
saturation of the measurements; in mild cases, this may be addressed by non-linear normalisation (e.g. quantile
normalisation).
Outlier detection was performed by computing Hoeffding's statistic Da on the joint distribution of A and M for each array.
Shown are the 4 arrays with the highest value of Da (top row), and the 4 arrays with the lowest value (bottom row). The value
of Da is shown in the panel headings. 0 arrays had Da>0.15 and were marked as outliers. For more information on Hoeffing's
D-statistic, please see the manual page of the function hoeffd in the Hmisc package.
- Figure 9: Outlier detection for MA plots.
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Figure 9 (PDF file) shows a bar chart of the Hoeffding's statistic Da, the outlier detection criterion from the previous figure.
The bars are shown in the original order of the arrays. A threshold of 0.15 was used, which is indicated by the vertical line.
None of the arrays exceeded the threshold and was considered an outlier.
This report has been created with arrayQualityMetrics 3.10.0 under R version 2.14.0 (2011-10-31).
(Page generated on Sat Nov 17 16:43:33 2012 by hwriter  )
APPENDIX A. STATISTICAL ANALYSIS OF MICROARRAY DATASET 211
Appendix B
Find “seed genes”
Four-set Venn diagram illustrations of the overlap of significantly differentially ex-
pressed genes in various microarray datasets used in the study. The key to the Venn
diagram is also included at the end. Courtesy: Oliveros, J.C. (2007) VENNY. An
interactive tool for comparing lists with Venn Diagrams. http://bioinfogp.cnb.
csic.es/tools/venny/index.html.
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Figure B.1. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE20295 HG-U133A gene expression dataset for Parkinson’s disease. Cour-
tesy: VENNY
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Figure B.2. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE28146 HG-U133 Plus 2.0 gene expression dataset for Alzheimer’s disease.
Courtesy: VENNY
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Figure B.3. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE3970A HG-U133A gene expression dataset for Huntington’s disease. Cour-
tesy: VENNY
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Figure B.4. Four-set Venn diagram illustration of the overlap of SDEGs in
GSE3970B HG-U133B gene expression dataset for Huntington’s disease. Cour-
tesy: VENNY
